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ABSTRACT
Current federal heart transplant policy is based on several
unproven assumptions about the relation between experience and
mortality for this procedure. To test these assumptions, I
studied a data set containing information from the Registry
of the International Society for Heart Transplantation and
from a personally collected supplementary survey that provided
additional patient, donor and center characteristics. The data
set included 2,005 patients who underwent heart
transplantation between 1984-1986 at one of 70 centers
participating in the Registry.
This study's major conclusions are that: 1) Heart
transplant centers acquire incremental experience while
performing their first several transplants, and this enables
them to reduce the risk of death in subsequent patients. This
learning curve is most apparent in patients who have the
highest mortality risk to begin with. 2) Heart transplant
mortality is not related to transplant volume, transplant
rate, or the year of transplantation. 3) In new heart
transplant centers, prior transplant experience among
cardiologists and/or transplant coordinators is associated
with lower mortality.
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GLOSSARY
Comorbid Conditions-Any patient attribute that worsens
prognosis following heart transplantation. Examples include
female gender, pulmonary disease and diabetes. Patients
having multiple coexisting comorbid conditions are said to
have a high burden of premorbid illness.
Cumulative Experience-Skill and/or knowledge that accrues
through successive repetitions of a procedure.
High Risk Patient-One who, by virtue of an excessive burden
of premorbid illness, has a relatively high likelihood of
death following heart transplantation.
Intertransplant Interval-A measure of the rate at which
centers perform heart transplantation. It is calculated by
dividing the number of days between the first and the most
recent transplant by the total number of transplants
performed.
Ischemic Time-The elapsed time between the moment surgeons
clamp the donor aorta during harvesting and the moment the
recipient aorta is unclamped after the aortic anastomosis
is completed. Prolonged ischemic times can damage the donor
heart.
Low Risk Patient-A transplant recipient who has few or no
comorbid conditions, and who therefore has a relatively
high likelihood of survival following heart
transplantation.
Learning Curve-A description of the observation that initial
repetitions of a procedure are associated with
incrementally improved outcomes.
Left Ventricular Ejection Fraction-The percentage of blood
ejected from the left ventricle (the heart's main pumping
chamber) during each cardiac contraction. Normal values
exceed 55%. Values less than 20% indicate severe heart
failure.
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GLOSSARY (ctd.)
Premorbid Burden of Illness-The accumulated risk of death
secondary to the presence of one or more comorbid
conditions.
Preoperative Mechanical Support-The use of intraaortic balloon
pumps, left ventricular assist devices or total artificial
hearts to augment heart function and maintain adequate
circulation to vital organs. These devices are reserved for
patients with very severe heart failure.
Transplant Volume-The total number of heart transplants
performed at one center.
Transplant Rate-The number of heart transplants completed per
unit time. Usually measured as the intertransplant
interval.
Triple Drug Immunosuppressive Therapy-A treatment protocol
for the prophylaxis of cardiac transplant rejection. It
consists of Cyclosporine, Azathioprine (Imuran) and
Prednisone.
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INTRODUCTION:
WHY SHOULD WE STUDY THE RELATION
BETWEEN EXPERIENCE AND OUTCOME
FOR HEART TRANSPLANTATION?
SUMMARY:
This introduction provides the rationale for a study of
the relation between experience and outcome in heart
transplantation.
KEY POINTS:
- In the 1980s, the number of centers offering heart
transplant services proliferated at an explosive rate.
This growth followed the introduction of cyclosporine
and a series of favorable coverage decisions.
- This technology's proliferation has been characterized
by a lack of concordance between the need for services,
as defined by local population density, and the avail-
ability of these services.
- In addition, there is striking variation in the number
of transplants performed per center.
- The federal government has recently attempted to
regulate the proliferation of heart transplantation in
order to equalize access to it and to maximize results
from the scarce donor organ supply.
- Unfortunately, federal regulators have so far been
unable to develop a single strategy that maximizes both
goals.
- A major obstacle to the development of optimal federal
heart transplant policy has been the absence of empiric
data showing a relation between experience with the
procedure and survival following it.
- Optimal federal policy cannot be formulated until this
relation is studied and characterized.
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Among recent medical innovations, heart transplantation
remains one of the most highly visible and captivating. The
first United States heart transplant was performed in 1967,
and it attracted intense public interest. In the next two
years, clinicians performed nearly 100 more heart transplants,
but clinical and lay interest rapidly waned when it became
clear that clinicians could not successfully prevent or treat
rejection of the transplanted organ. Few heart transplants
were performed over the next decade.
Widespread enthusiasm resurfaced in 1980 when a new immuno-
suppressive drug, cyclosporine, became available on an
experimental basis. Cyclosporine quickly proved to be far more
effective than first generation immunosuppressive agents in
preventing rejection. It also caused fewer infectious
complications. Cyclosporine was released for routine clinical
use in 1984. By that time, investigators had already begun to
report that a regimen combining small doses of cyclosporine
with two other immunosuppressive agents (so called "triple
drug therapy") was more effective in preventing rejection and
infection than a regimen consisting solely of cyclosporine in
high doses.
As a result of these advances in immunosuppressive
management, survival following heart transplantation increased
dramatically. By the mid 1980s, most centers reported one-year
survival rates above 80% (1-4). This compared favorably with
80-90% six-month mortality rates among eligible patients for
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whom a donor heart did not become available (1,2). In
addition, investigators reported that transplant recipients
experienced marked improvements in functional capacity: 81%
of eligible patients were bedridden at their pre-transplant
evaluation, and yet 88% of the recipients had no physical
limitations following transplantation (5). These results
convinced physicians that heart transplantation was reasonable
therapy for patients with advanced, isolated congestive heart
failure.
With the clinical efficacy of heart transplantation no
longer in doubt, the mid-1980s witnessed a rapid expansion in
third party coverage for heart transplantation. Most Blue
Cross/Blue Shield programs chose to cover this procedure by
1986. At least 25 Medicaid programs, dozens of HMOs and most
commercial insurers also followed suit in this period.
The number of heart transplant centers increased
dramatically in response to these favorable reimbursement
conditions. In 1982, only 8 US centers had performed this
operation. By 1986, 75 centers had done so. The General
Accounting Office now estimates there are approximately 130
such centers in this country (6).
The proliferation of heart transplant centers has been
remarkable because of its rate and also because of the uneven
geographic distribution of these centers. For example,
presently there are 27 heart transplant centers within 300
miles of Chicago, and 31 centers within the same radius of
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Indianapolis (2). However, there are only 12 programs on the
entire west coast. Texas has 9 heart transplant centers,
whereas 8 states have none. Eight of the nation's fifty
largest metropolitan areas have no heart transplant centers
(2).
An additional feature of this technology's diffusion has
been remarkable variation in the number of transplants
performed per center. In 1985 for example, ten centers
performed 70% of all US heart transplants, although 60 centers
performed at least one (1).
That year the number of transplants performed per center
varied from 91, at the University of Pittsburgh, to one, at
many centers. These variations in procedure volume continue
today. They are due to variations in referral patterns,
institutional commitment, population density and the
geographic proximity of other centers.
Nevertheless, despite rapid public and clinical acceptance
of the procedure and the rapid proliferation of facilities
capable of performing it, the number of transplants performed
annually equals no more than one-half the number of patients
who could benefit from the procedure (4). The disappointing
reality is that the number of donor organs is essentially
fixed, despite numerous attempts to increase it, at about
2,300 per year (1).
These features of heart transplantation-its rapid ascension
to the status of accepted medical practice, the lack of
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concordance between the need for services and their geographic
availability, the vast differences in procedure volume across
centers, and the profound lack of donor organs-create an
unquestioned need for federal regulatory intervention. The two
imperatives for policymakers are to equalize access to the
service, and to assure that it is offered only by centers
capable of providing care of the highest quality.
Regulators are concerned about equalizing access to all
medical services, but their interest is particularly acute
for heart transplantation. This is because the procedure is
life-saving, there is no alternative to it for patients with
end-stage heart failure, and because the service is
constrained by the donor organ supply.
Regulators and clinicians have long recognized that access
to heart transplantation depends critically on the distance
between the patient's home and the nearest transplant center.
It is simply too difficult to manage the intricacies of
patient care over long distances. For example in the pre-
operative period, potential recipients often require prolonged
hospitalization and intensive care at the transplant center.
If the patient lives far from the center, family members find
it difficult to accompany them. Patients frequently find such
separation intolerable and refuse to be considered as
transplant candidates.
In addition, transplant centers must occasionally require
that outpatients wait for their transplants near the center.
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This places an enormous financial burden on patients: they
must pay out of pocket for temporary accommodations because
these expenses are not covered by third parties. It places an
equally large burden on family members: they must forego work
or school in order to care for their loved ones.
Similar geographic barriers exist in the post-operative
period. Most physicians are unfamiliar with the medications
and protocols used to manage transplant recipients. And yet,
routine post-transplant care requires very intensive follow-
up with physicians who are familiar with the above protocols.
Again, the necessity to receive care at the transplant center
creates potentially insolvable difficulties for certain
patients.
Regulators are also acutely concerned that heart
transplants are performed in high quality centers. The
rationale for regulatory intervention in the quality arena is
straightforward. First, the donor organ supply is fixed.
Second, investigators have demonstrated dramatic graft and
patient survival differences across kidney transplant centers
(see chapter 5), and most believe similar differences exist
in heart transplantation. The regulatory imperative therefore
becomes to maximize public benefits from the scarce resource.
Ideally, heart transplant policy would simultaneously
equalize access and assure that transplants were performed
only in high quality facilities. Unfortunately, regulators
have so far been unable to develop a single policy that
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maximizes both goals. This has created a major controversy
among policymakers, and led to the deployment of an array of
policies which lack consistency.
Consider on one hand a policy that establishes very low
barriers for centers wishing to initiate transplant programs.
This policy would hasten the proliferation of new centers and
hence improve access1.
This policy would simultaneously reduce the number of
transplants performed per center, because the number of donor
organs is fixed. Reductions in the number of transplants
performed per center decelerate the learning process at each
institution and create disincentives for centers to accumulate
transplant expertise on site. In addition, it might increase
inappropriate competition for organs or recipients, either via
the manipulation of patient selection criteria or through
less-than-rigorous application of patient "listing" criteria.
On the other hand, consider a policy that sets rigorous
criteria for the designation of transplant centers2. This
policy would assure that transplant services are provided by
capable centers and would hence maximize outcomes from the
limited donor supply. Unfortunately, this policy would
simultaneously prevent many potential centers from offering
1 The United Network of Organ Sharing (UNOS), which
operates the nation's transplantation network (see below), has
designed its transplant policy with this in mind.
2 Medicare designed its transplant coverage policy with
this in mind.
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transplant services, inhibit further proliferation of the
technology, and hence impede access to the procedure.
To complicate matters further, regulators (wishing to
designate centers on the basis of quality) face the imposing
task of developing criteria that effectively distinguish the
best facilities. No regulatory agency has perfected this art
to date. There are two major approaches to the formulation of
criteria for designation: one is to base criteria on proven
success; the other is to base criteria on the presence of
center characteristics that are thought to be predictive of
future success.
Regulators would certainly find it appealing to designate
centers on the basis of hard patient outcome data.
Unfortunately, there are several problems with this approach.
First, it is statistically difficult to isolate the "bad
apples" when both the number of cases performed by a center
and the probability of an adverse event are low, as is the
case in heart transplantation3. Second, for new or rapidly
evolving medical technologies such as heart transplantation,
existing data are often unavailable or outdated. Third,
isolated outcome-based designation criteria would create
incentives for centers to select only low risk patients and
this might inappropriately favor certain groups.
I discuss this further in chapter 5.
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EXPERIENCE AS A CRITERION FOR THE DESIGNATION OF TRANSPLANT
CENTERS
In the case of heart transplantation, even data regarding the
proxies for future success is sparse. As a result, Medicare
designation criteria are based on the best judgement of
clinician advisors (3,4). The outputs of this process have
been designation criteria that include, prominently,
specifications for procedure volume.
These specifications are supported by a large body of
research demonstrating that centers characterized by high
procedure volumes are associated with relatively low mortality
rates from those procedures4 . The mechanism linking high
procedure volumes to improved outcomes is thought to include
the creation of incentives for high volume centers to invest
in capital and to attract teams of experts who can pool their
skills on behalf of patients.
Unfortunately, it is far from clear that the above studies
are applicable to the case of heart transplantation. Consider
for example that the above volume-outcome studies have focused
on procedures for which volumes are relatively fixed over
time. As a result it is not possible to determine from this
literature whether outcomes in one period reflect procedure
volume in that period or procedure volume in some earlier
period. This is critically important to the study of heart
4 This literature is reviewed in detail in chapter 5.
15
transplantation, because most new heart transplant centers are
characterized by rapidly increasing procedure volumes over
time.
Beyond this, it is not clear that the presumed mechanism
linking high volumes to improved outcomes is relevant for
heart transplantation. First of all, centers require little
or no capital investment in order to initiate a heart
transplant program, because heart transplant programs use the
same facilities as preexisting open-heart surgery programs.
Second, providers are aware that public scrutiny inevitably
surrounds the initiation and continued operations of a
transplant program, so they virtually always make strong
efforts to assemble the appropriate expertise before they
attempt their first transplant5.
Perhaps most important from a conceptual standpoint is that
procedure volume is a rather static descriptor for
institutional experience: it does not appear to capture the
dynamic, accelerated learning that was taking place in US
transplant centers at the time federal transplant policy was
formulated (between 1984-86). During this period, many centers
attempted the procedure for first time. It was a period of
active experimentation: individuals varied their approach,
practiced manipulative and cognitive skills, and integrated
current experiences with those of the past and those of
5 Obviously regulations may be useful to the extent that
this does not occur in all cases.
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colleagues. Another descriptor of experience-the learning
curve-appears to better capture these events.
Regulators wishing to use experience as a criterion for the
designation of transplant centers face other challenging
questions as well. Should prior transplant experience be a
requirement for physicians wishing to initiate programs at
new centers? If so, what constitutes adequate transplant
experience? Should experience be vested in the transplant
surgeon, the cardiologist or the coordinator? Finally, is
there any benefit in shunting particularly ill recipients to
the most experienced centers?
UNITED STATES HEART TRANSPLANT POLICY
Federal heart transplant policy has attempted to balance
the access and quality issues and to answer the above
questions as well. A brief summary of current heart transplant
policy follows:
In 1984, Congress passed the National Organ Transplant Act
(P.L. 98-507) in response to increasing public concern about
access and equity. The act directed the Secretary of Health
and Human Services to establish:
1- A Task Force on Organ Transplantation, which was
charged to review medical, ethical, economic and social
issues associated with organ procurement and
transplantation (2), and
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2- The Organ Procurement and Transplantation Network
(OPTN), which matches donor organs with potential
recipients (6)6
THE TASK FORCE AND MEDICARE POLICY
The Task Force's April, 1986 report emphasized both the
costs and outcomes from transplant technology. It recommended
that Medicare cover the procedure, and "that transplant
centers be designated by an explicit, formal process using
well-defined, published criteria (3)". Its rationale was "to
prevent transplantation from being jeopardized by the
uncontrolled diffusion of transplantation technology into
unqualified institutions." The Task Force also reasoned that
transplant center designation would result in "a more orderly,
systematic process for the expansion of quality transplant
centers...cost-effective organ transplantation...(and it
would) minimize inappropriate competition for donor organs and
transplant recipients (3).
The Task Force suggested that 13 criteria be used in the
center designation process, including one stating that centers
should have an "established, ongoing (4)" heart transplant
6 It also prohibited individuals from purchasing or
distributing donor organs, and authorized grants to stimulate
growth of the existing organ procurement network. A
substantial part of federal transplant policy focuses on organ
procurement and distribution. This document will not cover
this subject in detail. See references 2,3 and 5 for further
information.
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program in which one year survival was 70%.
The Task Force's most controversial criterion was that
centers should complete a minimum annual volume of 12
transplants per year. The volume criterion was controversial
because no one had studied the volume-outcome relation in
heart transplantation, and no one could demonstrate this
relation in extrarenal transplantation (7-9). The Task Force
felt such a recommendation was prudent given that significant
volume-outcome relations had been demonstrated in the vast
majority of surgical procedures for which data was available
(to be discussed in chapter 5) and it did suggest the volume
criterion could be waived for centers which might be desirable
because of geographic location or pediatric specialization
(2).
In the fall of 1986, the Health Care Financing
Administration finally announced its Medicare heart transplant
coverage policy (10). The policy generally follows the spirit
of the Task Force recommendations. It includes criteria for
patient selection and management, institutional commitment,
facility plans, maintenance of data, organ procurement, and
laboratory services. Medicare also requires that centers have
performed at least 12 transplants per year in the two years
prior to certification, plus an additional 12 transplants
before this (a total of at least 36 transplants). It requires
reasonable proof that the center will continue to perform at
least 12 transplants per year. Finally, there are minimally
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acceptable one- and two-year survival rates: 73% and 65%,
respectively.
Medicare criteria do differ from Task Force recommendations
in that they do not allow exceptions for geographic
considerations (2). This has resulted in an uneven
distribution of the 31 so-far approved centers. For example,
there are five designated centers within 300 miles of
Philadelphia, Chicago and St. Louis, whereas eligible patients
living in Seattle or Miami have to travel nearly 700 miles
(and, in the latter case, pass by a dozen programs on the way)
to reach a designated center (2).
In conclusion, Medicare heart transplant coverage policy
was implemented in late 1986. It is a precedent-setting
federal attempt to limit the diffusion of and control federal
outlays for the heart transplant procedure, and to assure high
success rates by designating centers at which the service is
covered. The policy has clearly not been effective in limiting
diffusion because it was implemented after the period in which
this technology diffused most rapidly (2). Its rationale for
assuring high success rates was logical given existing volume-
outcome literature for other procedures, but it was not based
on empiric findings in heart transplantation.
THE OPTN AND THE UNITED NETWORK FOR ORGAN SHARING
In 1986, the Department of Health and Human Services
awarded contracts to the United Network for Organ Sharing
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(UNOS) to operate the transplantation network and to maintain
a registry7 of organ transplants (6). UNOS was further
empowered by the Omnibus Budget Reconciliation Act of 1986 (PL
99-509) which "required hospitals performing heart transplants
to be members of, and abide by the rules of, the
Transplantation Network (6)".
In establishing its membership criteria, UNOS did not adopt
the Task Force recommendations regarding transplant volume and
other structural characteristics of the transplant center. In
fact, UNOS criteria do not require prior institutional
experience as a requisite for initial membership. Instead,
"UNOS criteria for membership are based primarily on the
experience of the transplant team (6)". 8 UNOS criteria are
still undergoing modification, but in principle, they require
each transplant center to have:
1- A transplant surgeon having a minimum one year formal
training and one year experience at a transplant program
meeting UNOS membership criteria. Alternatively, the
surgeon may qualify by virtue of having 3 years
Recently, UNOS reached an agreement with the
International Society for Heart Transplantation such that the
latter's Registry (the one used for this study) will serve
this purpose.
8 However, UNOS does intend to review programs that
perform less than 12 transplants per year and programs that
do not meet Medicare survival guidelines.
21
experience at a UNOS-sanctioned transplant program.9 In
addition, the surgeon must be board certified by the
American Board of Thoracic Surgery.
2- A transplant "physician" having a minimum one year
formal training in transplantation medicine or two years
documented experience at a UNOS-sanctioned transplant
program. The physician must be board certified or board
eligible in cardiovascular disease.
Thus, UNOS promulgated personnel-based criteria in order
to stimulate the establishment of new transplant programs in
underserved areas and hence to improve access to the
procedure. In contrast to the Medicare criteria, UNOS criteria
do not include structural attributes of transplant centers.
In the context of donor shortages, UNOS also avoided volume
and survival criteria so as to eliminate incentives to perform
marginally necessary procedures. As of September 1988, 131
hospitals had registered with UNOS as heart transplant centers
(6).
OBJECTIVES OF THIS DISSERTATION
In conclusion, current federal heart transplant policy has
attempted to balance several apparently conflicting interests,
particularly the trade-off between strategies to equalize
access and those to maximize benefits from the scarce donor
9 Precise specifications for training and experience
remain to be defined.
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supply. Of great importance, existing policies have been
formulated in the absence of data that might have informed the
policymaking process. In particular, Medicare's strategy of
designating transplant centers assumes, without empiric
support, that high volume centers have better outcomes from
the procedure. This policy may well impede access to the
procedure for Medicare beneficiaries, and it exists despite
a nagging feeling that the volume proxy does not accurately
reflect the nature of experience with this new procedure.
In this dissertation, I intend to provide an empiric basis
for the study of current heart transplant policy and for its
refinement if necessary. In particular, I explore and
characterize the relation between experience and outcomes in
heart transplantation. To accomplish this, I analyze data from
the International Registry of Heart Transplantation and data
from a survey of transplant coordinators that I personally
conducted. Chapter 1 of this document summarizes the methods
used in this study. Chapters 2-8 summarize the study's primary
results. Chapter 9 discusses the results and their
implications for heart transplant policy.
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CHAPTER 1
METHODS
SUMMARY:
This chapter describes the data set used in this study,
the method by which data was collected, the study
population and the analytic techniques used during this
study.
KEY POINTS:
- The study includes more than 90% of the patients that
underwent orthotopic heart transplantation in the United
States between 1984-1986.
- The principal data sources for this study are the
Registry of the International Society for Heart
Transplantation, a personally administered supplemental
survey, and the 1986 American Hospital Guide.
CHARACTERISTICS OF THE DATA SET USED IN THIS STUDY
The data set for this study contains merged information
from three sources. These are: l)the Registry of the
International Society for Heart Transplantation, 2)a
personally administered supplemental survey, and 3)the 1986
American Hospital Association Guide. The salient features of
each source are as follows:
The Registry: The Registry is the most important source of
data for this study. In May, 1987, transplant centers were not
required to contribute data to the Registry. However,
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approximately 95% of all U.S. heart transplant centers did
voluntarily contribute the required information. Dr. Michael
Kaye was at the time solely responsible for maintaining and
updating the Registry's data files. He did so on an IBM AT
personal computer located at the University of Minnesota.
The process by which the Registry collected information was
as follows:
1) The Registry periodically mailed blank copies of its
standard patient information form to transplant coordin-
ators at each participating center.
2) Two to three times per year, transplant coordinators
(or occasionally, data managers) completed these forms
for every patient that had undergone heart transplan-
tation since the last update. They then forwarded the
information to the Registry.
3) Coordinators were also responsible for informing the
Registry about changes or additions to the information
contained in existing patient files. The most important
update was the date of death for any patient that had
died since the original data was entered into the
Registry. This follow-up information played a critical
role in determining the reliability of the Registry's
actuarial analyses, as the Registry assumed all patients
were alive unless it was specifically informed otherwise.
4) Dr. Kaye or his designee entered the information into
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the Registry files as it was received.
The Registry's standard information form (figure 1.1)
elicited details concerning gender, dates of birth, transplant
and death (if appropriate), cause of death, indications for
and type of transplant (orthotopic, heterotopic or
retransplant), as well as some facts about the relevant donor
and the immunosuppressive regimen used. Although most centers
submitted updated information 2-3 times per year, there was
considerable variation in the update frequency. The
approximate range of frequencies with which centers updated
Registry files was from once per month to once per year.
The Supplementary Data Form-After reviewing the literature
on the determinants of mortality following organ
transplantation, I felt that it would be preferable to augment
the Registry data base with additional information concerning
characteristics of the transplant centers, the recipients and
the donors. To do so, I designed a supplementary questionnaire
and mailed it to transplant coordinators.
Part I (figure 1.2) elicited details about the structural
characteristics of the transplant centers. Included were
questions regarding:
1 The Registry has modified this form on several
occasions since 1987, such that more patient, donor and
immunosuppressive information is available.
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- the presence of a preexisting kidney transplant program
(and hence local expertise in immunosuppressive management),
- the volume of open heart surgery procedures (the skills
for which might be transferrable to the heart transplant
procedure)
- the volume of cardiac catheterization (which is required
during routine pre- and post-transplant care)
- the clinician primarily responsible for managing immuno-
suppressive therapy (to compare the skills of surgeons and
cardiologists in this regard), and
- the presence of prior heart transplant experience among
key personnel (to test its effect on transplant mortality at
new centers).
Part II (figure 1.3) elicited details about each recipient
which were not available from the Registry data banks.
Included were questions regarding:
- the listing status at the time of transplant 2 (to assess
the relation between the severity of premorbid illness and
2 When a center has decided that a patient is an
acceptable candidate for heart transplantation, it contacts
the relevant organ procurement agency. This agency adds the
patient's name to its waiting list. Then, when a donor becomes
available, the agency and the transplant center use this list
to select the most appropriate candidate. The selection
process is influenced by several factors in addition to the
original date that the patient was placed on the list. The
most important of these factors is the transplant team's
assessment of each patient's severity of illness and
probability of death in the short term. Patients having the
worst prognosis (that is, having the highest listing status),
are given priority over others, even if the latter have been
waiting for longer periods.
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mortality following heart transplantation),
- the left ventricular ejection fraction (for the same
reason),
- the presence coexisting diseases that might impact long
term survival following heart transplantation.
I also used the American Hospital Association Guide (1986;
AHA Press; Chicago) to determine each transplant center's
admission rates and membership status in the Council of
Teaching Hospitals.
DATA COLLECTION
With consent from Dr. Michael Kaye, the Director of the
Registry of the International Society for Heart
Transplantation, I acquired an updated copy of the Registry's
patient care files on May 1, 1987. I used these files
throughout the study.
In September 1986, I mailed supplementary surveys to the
transplant coordinators of all centers that were participating
in the Registry. I included cover letters (figures 1.4-1.5)
emphasizing that the International Society For Heart
Transplantation supported the additional data collection. I
allowed 6 months for centers to respond. Three large, well
established centers could not respond to the survey, but they
permitted me to make a site visit in order to personally
collect the data. These centers were: Stanford University,
Presbyterian Hospital at the University of Pittsburgh, and
28
the University of Minnesota.
Once I had obtained the results of the supplementary survey
and an updated copy of the Registry files, I merged the data,
as follows. I first created data files for the supplementary
information on the VAX-VMS mainframe computer at the Whitaker
College of Health Sciences at Massachusetts Institute of
Technology. I then converted the Registry files into an ASC-
II file. After translating the file into a format compatible
with the VAX, I combined the two data sets on the basis of
common information on transplant center and the patient's
dates of birth, death and transplant. Figure 1.6 shows a
complete list of variables analyzed in this study.
STUDY POPULATION
The study population (figure 1.7) included patients that
underwent orthotopic heart transplantation between January 1,
1984 and December 31, 1986 at a United States transplant
center that contributed data to the Registry. In addition,
recipients had to be at least 10 years old, and their 90 day
mortality status had to be known. Retransplants and
heterotopic heart transplants were excluded from the study.
DATA ANALYSIS
I performed statistical analyses on the Vax using Version
5.0 of SAS (Cary, North Carolina). I used PROC LIFETEST for
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lifetable analysis and PROC CATMOD for logistic regression
analysis.
I followed certain guidelines and made several key assumptions
in analyzing the data. These were as follows:
1) To test the validity of Medicare guidelines for
transplant center certification and to be consistent with
previous published reports (6), I considered age to be a
dichotomous variable (50 vs. >50).
2) To test the hypothesis that preoperative mechanical
support is an important predictor of mortality post-
transplant, I combined patients who were classified as
"Listing Status Class I" and "Class II" into one category and
compared mortality in this group with patients who were
classified as "Listing status 9" 3 .
3) To test the relationship between transplant mortality
and the existence of any coexisting disease (see figure 1.3),
I generated a new variable, Comorbid Conditions, which
indicated the presence of any of the coexisting diseases
referred to in the supplementary survey.
4) The Indication for Transplantation (see figure 1.1) in
more than 90% of transplant recipients was either
cardiomyopathy or coronary artery disease. The remaining 13
indications account for less than 10% of the cases. Therefore,
to simplify the analysis of the relation between transplant
3 The precise specifications for each listing category
are described in figures 1.3 and 1.5.
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indication and mortality, I aggregated all patients with a
rare indication into one category.
5) I decided not to study donor organ location because only
3 coordinators responded to this question.
6) I grouped data regarding admissions, the volume of open
heart surgery and the volume of cardiac catheterization into
quartiles.
7) I grouped data regarding ischemic time into two
categories: less than two hours and greater than or equal to
two hours, as most coordinators reported the data as such.
8) Before I began to analyze data, I developed a list of 8
pretransplant attributes (including some from the patient,
donor, and center) that were likely to have an impact on
mortality following transplantation (figure 1.8). I chose
these risk factors on the basis of a literature review and
personal clinical experience. In subsequent analyses (see
chapter 2, figures 2.4-2.5), I used these "risk factors" to
calculate the overall burden of premorbid illness in the study
population, to assess its overall impact on mortality
following transplantation, and to determine whether the burden
of illness in an individual patient might modulate the
relation between center experience and mortality following
heart transplantation4
A more detailed discussion of these risk factors and
their role in this study appears in chapter 2.
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Figure 1.1
INTERNATIONAL HEART TRANSPLANTATION REGISTRY
PATIENT DATA:
Transplant Center Number Patient Number
Patient Chart Number Sex: Male Female
Age Death No Yes Date of Birth / / -
Date of Transplant//__ Date of Death / /__
Type of Transplant: Orthotopic Heterotopic H-L
Retranplantation No Yes Other
Comments
DONOR DATA:
Age
Cause of Death:
Motor Vehicle Accident Suicide
Cerebrovascular Accident Other
Locale-Donor Heart: In Hospital In Community_
Ischemic Time (hr)
INDICATIONS:
Remote
Cardiomyopathy
Congenital
Primary Pul Hypertension
Pulmonary Hypertension
Congestive Heart Failure
Valvular Disease
Endocardial Fibro
Emphysema
Other-
Coronary Artery Dis.
Graft Rejection
Rheumatic Heart Dis.
Myocarditis
Idiopathic
Carcinoma
Eisenmengers
Comments
IMMUNOSUPPRESSIVE REGIMEN:
Cyclosporine
Imuran
Other
CAUSE OF DEATH:
Acute Rejection
Infection
Cardiac Arrest
Pulmonary Embolism
Other
ATG
Prednisone
Comments
Chronic Rejection
Ventricular Failure
Myocardial Infarct
Carcinoma Type
Comments
COMMENTS
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MAJOR
OTHER
FIGURE 1.2
INTERNATIONAL HEART TRANSPLANT REGISTRY
SUPPLEMENTARY QUESTIONNAIRE
PART I: CENTER CHARACTERISTICS
1. Did your hospital have a kidney transplantation program in the
year your heart transplantation (HT) program was initiated?
YES NO
If not, has a kidney transplantation program since been
started?
YES (START UP YEAR) NO
2. Number of Coronary Bypass operations done at your hospital in:
Year of HT program's initiation?
1985?
3. Number of cardiac catheterizations done at your hospital in:
Year of HT program's initiation?
1985?
4. Your patient's immunosuppressive therapy is managed primarily
by:
Surgeons Cardiologists Immunologists
5. Did any team members have prior "Hands on" experience in the
management of HT patients when your HT program was initiated?
(Please state institution where the experience was obtained)
Surgeon
Cardiologist
Transplant Coordinator
Other
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FIGURE 1.3
PATIENT NUMBER
PATIENT CHART NUMBER
DATE OF BIRTH
DATE OF TRANSPLANTATION
DATE OF DEATH (IF APPROPRIATE)
PART II: DONOR CHARACTERISTICS
1. Donor Ischemic Time: minutes
2. Location of donor organ relative to your institution:
In-Hospital
In same community
Distant
PART III: PATIENT CHARACTERISTICS
1. Home address (city and state, only):
2. Date patient was officially listed for HT:
3. Date of hospital discharge following transplant:
4. Listing status at the time of transplant:
(Note: Class I: Awaiting transplant, out of hospital;
Class II: Hospitalized due to cardiac failure;
Class 9: Death imminent without transplant.)
5. Coexistent diseases at the time of transplant:
Diabetes
COPD
Primary Renal Dysfunction
Primary Liver Dysfunction
Other (specify)
6. Left Ventricular Ejection Fraction prior to transplant:
less than 12%
12-20%
more than 21%
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FIGURE 1.4
AND
W/OMEN' S
Dear Sir/Madam:
I am a cardiologist at the Brigham and Women's Hospital.
Recently, I received permission from the Registry of the
International Society for Heart Transplantation to examine their
data base for the purpose of analyzing the effects of coexistent
diseases, the severity of preexisting heart disease, and donor
characteristics on the outcome from heart transplantation, and the
extent (if any) to which these relations are modulated by
experience with the technique.
After a review of the Registry's available data, I believe it
is necessary to obtain some additional information about patients
having already undergone transplantation. Dr. Kaye has granted me
permission to contact you and encourage your cooperation in this
project, since this data would strengthen the Registry's data base
and allow additional informative data to be transmitted to the
transplant community. We realize that this request will be a
burden but feel that this information will prove valuable to you
and your patients.
Should you agree to cooperate in this study, I would prefer
to collect this data by mail. The plan is to mail you blank
supplementary questionnaires, similar to the sample enclosed with
this letter. I would ask that you complete them for as many
patients as possible and mail them back to me. I do recognize that
in some cases it will be impossible to collect data in this
fashion. In these situations, although my resources are limited,
it may be possible to make site visits and help collect the data.
You will note that the questionnaire has three parts. Part
one requests information regarding your center. Please be assured
that: no information regarding any specific center will be
published; all information in the Registry is considered in terms
of individual and institutional rights to privacy. Part two
requests information regarding donor characteristics. This
information is requested on the present Registry forms, but had not
been requested on older forms. Part three requests additional
information about recipient characteristics in the peri-transplant
period.
My plan is to wait approximately two weeks after this mailing
to allow you time to consider this request and review the sample
questionnaires. During this time, if you determine that you will
be unable to provide any of the information, or if you will require
a site visit, please contact me by phone: (617) 732-5696 beeper
#1520. If I have not heard from you in two weeks, I will send you
the proper number of questionnaires by mail, along with additional
instructions. Under Dr. Kaye's close supervision, I will perform
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initial data analysis here in Boston. Subsequently, all data will
be entered into the Registry's data banks.
We thank you in advance for your cooperation.
Sincerely,
Glenn Laffel, M.D.
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FIGURE 1.5
, S H I I A L . ,' ' , .. ,,
Dear
Thank you for agreeing to participate in my study, which will
be done in cooperation with the International Heart Transplant
Registry. We plan to analyze the effects of several patient,
donor, and center characteristics on the outcome from heart
transplantation, and the extent (if any) to which these relations
are modulated by experience with the technique.
Initial data analysis will be done in Boston, and will be
supervised by Michael Kaye, M.D., the director of the International
Heart Transplant Registry. Subsequently, all data will be
transferred to the Registry's data banks in Minneapolis. I want
to reemphasize our commitment to honoring institutional and
individual rights to privacy.
I have enclosed the questionnaires which will be used for data
collection. There is one form containing five questions regarding
your' center. Also, there are several copies of a second form
requesting information about each transplanted patient. These
forms contain routine biographical information from the Registry's
files, (patient number, chart number, date of birth, date of
transplant, date of death, if appropriate) which will allow you to
provide the requested information for each patient. The forms are
ordered according to the date of transplant.
One clarification on Part III, Question (4): A class 9
listing status refers to patients who are intubated, or who have
had a mechanical device inserted to maintain adequate cardiac
output (i.e., intraaortic balloon, left ventricular assist device,
biventricular assist device, "artificial heart," etc.). Class II
status includes patients who are receiving any form of in-hospital
medical therapy, including pressors, for the management of
congestive heart failure.
In completing the questionnaires, please include the "date of
death" for those patients who have passed away since you last
updated your Registry files. I have included some blank
questionnaires for your most recently transplanted patients, and
can supply more if required (alternatively, a xeroxed copy of one
of the blanks would suffice).
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]PLEASE NOTE: We also plan to study the use of different
protocols for the management of routine immunosuppressive therapy
and for acute rejection. Therefore, please include a brief summary
of (or a copy of) your present protocols for the management of
these issues.
Please return the completed questionnaires and protocols to
me in Boston, at the above address. I will be happy to assist you
in any way I can--don't hesitate to call! I can be reached at:
the Brigham, (617) 732-5696 beeper #1520, or home (617) 332-1426.
Once again, thank you for your time and cooperation.
Sincerely,
Glenn Laffel, M.D.
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Figure 1.6
DETERMINANTS OF SURVIVAL
FOLLOWING HEART TRANSPLANTATION
PATIENT CHARACTERISTICS
GENDER
FIELDS
MALE
FEMALE
AGE <50
>50
INDICATIONS FOR HT
PRETRANSPLANT REQUIREMENTS
FOR MECHANICAL CIRCULATORY
SUPPORT*
LEFT VENTRICULAR (LV)
EJECTION FRACTION*
COMORBID CONDITIONS*
CARDIOMYO PATH Y
CORONARY ARTERY DISEASE
OTHER
PRESENT
ABSENT
<11%
>11%
PRESENT
ABSENT
DONOR CHARACTERISTICS
ISCHtEMIC TIME* 0-120 MIN.
>120 MIN.
CHARACTERISTICS OF EXPERIENCE
PROGRAM DURATION
(see chapter 3)
CUMULATIVE EXPERIENCE
(see chapter 4)
TRANSPLANT VOLUME
(see chapter 5)
YEAR
1984-1986
TRANSPLANT
1,2,3..
CENTER
1-70
NUMBER
TRANSPLANT RATE
(see chapter 6)
MEAN INTERTRANSPLANT INTERVAL
#1-5, 6-10, 11-20
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Figure 1.6 (ctd.)
DETERMINANTS OF SURVIVAL
FOLLOWING HEART TRANSPLANTATION
CENTER CHARACTERISTICS FIELDS
CYCLOSPORINE USED
NOT USE[
TRIPLE DRUG THERAPY USED
NOT USE[
KIDNEY TRANSPLANT PROGRAM* PRESENT
ANNUAL VOLUME-CORONARY BYPASS*
ANNUAL VOLUME-CARDIAC CATH.*
IMMUNOSUPPRESSIVE MANAGEMENT*
PRIOR HT TRAINING-SURGEONS*
PRIOR HT TRAINING-CARDIOLOGISTS
PRIOR HT TRAINING-COORDINATORS*
TOTAL ADMISSIONS, 1986*
COUNCIL OF TEACHING HOSPITALS
AFFILIATION*
D
ABSENT
94-236
240-436
467-744
775-3700
180-900
900-1569
1600-2109
2169-6193
(first quartile)
(first quartile)
SURGEONS
INTERNISTS
YES
NO
YES
NO
YES
NO
9,376-17,687 (first quartile)
17,703-21,535
21,540-28,813
29,084-47,749
YES
NO
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* data available only through the supplemental survey
D
Figure 1.7
ENTRY CRITERIA
Transplanted Between 1/1/84-12/31/86
Orthotopic Transplant (retransplants and heterotopic
transplants excluded)
Age >10 Years
Performed In US
Center Contributes Data To ISHT Registry
90-Day Mortality Status Known
figure 1.8
PRIMARY RISK FACTORS
IN HEART TRANSPLANTATION
1. Age >50 Years
2. Preoperative Mechanical Support
3. Comorbidities Present
4. Rare Indication for Transplant 0
5. Ejection Fraction <11 %
6. Gender = Female
7. Ischemic Time >150 Minutes*
8. 3-Drug Immunosuppression Not Used
* Available from Supplemental Survey only
o All indications OTHER THAN cardiomyopathy
and coronary artery disease
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CHAPTER 2
TRADITIONAL DETERMINANTS OF MORTALITY
FOLLOWING HEART TRANSPLANTATION
SUMMARY:
This chapter reviews some general features of the data
set and then it reviews the results of univariate and
bivariate analyses relating heart transplant mortality
to several patient characteristics, the donor ischemic
time and the use of certain immunosuppressive regimens.
KEY POINTS:
- 80% of the Registry centers responded to the supple-
mentary survey.
- Heart transplant deaths in the first 90 days account
for 85% of the total first year deaths and 70% of the
total deaths in the first two years.
- For several reasons, 90-day mortality is used as the
outcome measure in this study.
- Univariate and bivariate analyses suggest that female
gender, preoperative mechanical support, left ventricular
ejection fractions less than 11%, comorbid conditions,
donor ischemic times greater than 2 hours, and non-use
of triple drug immunosuppressive therapy are all related
to heart transplant mortality.
Studies of the experience-outcome relation for any medical
procedure must first account for "traditional" determinants
of mortality such as age and coexisting disease. Surprisingly,
we know relatively little about these traditional determinants
following heart transplantation. In part this is because the
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technology is relatively young. For example, nearly half of
all United States heart transplants have been performed in the
last 3 years, and so long term follow-up is sparse.
It is also true that uncontrolled transplant center prolif-
eration has prevented all but a few programs from accumulating
series large enough to support research. To make matters
worse, transplant centers have tended to develop unique
treatment protocols and unique data collection instruments,
and this complicates attempts to compare results. In addition,
they have so far been unwilling to participate in multicenter
randomized trials. Furthermore, until recent legislation
mandated that centers contribute to the Registry of the
International Society for Heart Transplantation, the Registry
depended on voluntary participation.
Nevertheless, investigators have slowly begun to define
relations between these traditional determinants-usually
categorized into patient, donor and center attributes-and
mortality. In this chapter, I review my univariate and
bivariate analyses of these relations and compare these
findings with existing literature on the subject. This review
follows a discussion of some general features of my data set,
and a discussion of the mortality variable itself.
GENERAL FEATURES OF THE DATA SET
On May 1, 1987, 70 United States heart transplant centers
were contributing information about their recipients to the
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Registry of the International Society for Heart
Transplantation (figure 2.1). Between the years 1984 and 1986,
these centers performed a total of 2,005 heart transplants on
patients that met entry criteria for this study.
These centers exhibit striking heterogeneity with respect
to the total heart transplant volume per center during the
three year study period. The total number of heart transplants
performed per center ranges from 1 (one) to 207. These
transplant centers also exhibit striking heterogeneity with
respect to their 90-day mortality; center-specific death rates
range from 0% to 75% (figure 2.2).
Of great interest, a preliminary display of the relation
between center-specific procedure volume and mortality (figure
2.2) fails to reveal a strong correlation, as the Federal Task
Force on Organ Transplantation and others thought would be
present . This preliminary analysis does show considerably
more mortality rate variation among centers with low volumes,
but such increases could be attributed to chance alone when
center volume is small. Chapter 5 presents a detailed analysis
of this and other issues pertaining to the volume-outcome
relation in heart transplantation.
I was able to collect supplementary information from 56 of
the 70 US heart transplant centers (80%) that were
1 See the Introduction for a further discussion of the
Federal Task Force and its impact on Medicare heart transplant
policy.
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participating in the Registry. These 56 centers performed
1,711 (85%) transplants during the three year study period.
Among the 56 participating centers, some could not provide
supplementary information about certain patients. Other
centers could not answer particular questions (for any of
their patients) because they simply had not been collecting
the appropriate data. Nevertheless, the centers did manage to
provide complete supplemental information for a total of 1,123
transplant recipients.
Importantly, the characteristics of patients for whom
complete supplemental data is available do not differ
significantly from those for whom supplemental data is not
available (figure 2.3). Specifically, the two groups are
comparable with respect to mortality, the percentage of
patients aged less than 50 years, gender, and the indications
for transplant.
In the patients for whom complete supplementary information
is available, it is possible to tally the number of risk
factors2 present in each patient, and thus to assess the
overall burden of illness in the study population. The number
of risk factors present ranges from zero (in 72 patients) to
seven (in 1 patient), with a median of two (figure 2.4)3
2 For a discussion of risk factors, see chapter 1.
3 Appendix 1 (available on request) provides additional
details regarding the precise mix of risk factors in each
patient. This histogram is not meant to imply that the impact
of each risk factor is the same as that for each of the other
six, nor is it meant to imply that the effects of each risk
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Of great interest, heart transplant mortality increases
steadily as the number of risk factors increases. This
confirms clinical suspicions about the individual impact of
the risk factors4, but multivariate analyses are required to
precisely assess interactive or additive effects of these
variables.
NOTE: For the purposes of later analyses, I have in
certain places reaggregated the patient risk factor data
from seven categories into three categories (figure 2.5).
The first group includes patients that have either zero
or one risk factor: I define these patients as having a
"low burden of premorbid illness". The second group
includes patients that have exactly two risk factors-
defined as a "moderate burden of illness". The third
group includes patients that have more than two risk
factors. I define these patients as having a "high burden
of illness". The principal reason for reaggragating the
data in this way is to generate subgroups that have
factor are strictly additive to the effects of the others.
Multivariate analyses are required to explore each risk
factor's relative impact on mortality, its correlations with
other risk factors, and the interactive effects of all risk
factors on transplant mortality. Chapter 8 provides such an
analysis.
Note: Figure 2.12 displays univariate analyses of the
relations between these variables and transplant mortality.
Figure 2.13 shows bivariate analyses. These will be discussed
shortly.
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l)clearly different mortality risk following heart
transplantation and that 2)contain enough patients in
each group to permit meaningful, informative analyses.
As figure 2.5 shows, these three subgroups include
between 330-430 patients each, and their mortality rates
are in fact distinctly different5
MORTALITY FOLLOWING HEART TRANSPLANTATION
Mortality (%) following heart transplantation for all
patients in this study is as follows:
1 month: 10
2 months: 12
3 months: 14
12 months: 19
24 months: 25
36 months: 27
As expected, mortality rates are highest in the months
immediately following transplantation. Interestingly, the
mortality rate appears to be relatively constant between 3 and
24 months. This rate is well below that observed within the
first three months, and well above the rate observed beyond
The algorithm that I use to create these new
categories is to some extent arbitrary. It is possible for
example, that by virtue of their specific combination of risk
factors, some patients in the "moderate risk" category could
actually have a worse prognosis than some in the "high risk"
category.
Nevertheless, the above algorithm has the advantage of
being conceptually simple and consistent with clinical
intuition about the burden of illness. It certainly appears
to be as logical as any other approach that could be developed
to create large subsets of patients that are stratified
according to their risk of death.
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24 months (see the lifetable analysis in figure 2.6). Deaths
within the first 90 days account for 85% of the total deaths
at one year, and for 70% of the total deaths at two years.
When I stratify the data donor characteristics, by the year
of transplant, or by the use (or nonuse) of cyclosporine, I
find a similar pattern-in which mortality risk declines with
time (figures 2.7-2.11). Similar relations are demonstrable
for other univariate predictors, and this information is
available on request.
For this study, I have chosen mortality at 90 days to be
the independent variable. There are several reasons for this:
1) 90-day mortality appears to be predictive of 1- and
2-year mortality, as shown in figure 2.6.
2) By selecting a relatively "tight" follow-up period
(90 days), I maximize my ability to include data from
1986 transplants in my analyses. Had I selected mortality
at one year, I would have been unable to include patients
transplanted after May 1, 1986 (because I obtained the
final data tapes from the Registry on May 1, 1987). It
is certainly desirable to include as many 1986 transplant
recipients as possible, since nearly half the study's
heart transplants took place that year.
3) The 90-day endpoint covers the immediate post-
operative period and (roughly) the first two months
following hospital discharge. During this time, patients
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are most susceptible to infection and transplant rejec-
tion. It is also the time in which clinicians rapidly
taper immunosuppressive drugs towards chronic dosage
regimens. Therefore it is reasonable to postulate that
experience or learning would most likely have an effect
on mortality in these first 90 days. I choose the 90-day
endpoint in part to enhance the likelihood of detecting
a learning phenomenon.
RELATIONS BETWEEN HEART TRANSPLANT MORTALITY AND
PATIENT, DONOR AND IMMUNOSUPPRESSIVE THERAPY:
UNIVARIATE AND BIVARIATE ANALYSES
Univariate analyses from this study (figure 2.12) show that
the following attributes are associated with significantly
higher mortality following heart transplantation: female
gender, preoperative requirements for mechanical support, left
ventricular ejection fraction less than 11%, comorbid
conditions present, donor ischemic times greater than 120
minutes, and immunosuppressive management without triple drug
therapy. Similar analyses fail to demonstrate a significant
impact for the following variables: age, indication for
transplant, and cyclosporine use.
Of great interest, bivariate analyses (figure 2.13) suggest
that the above univariate predictors remain important in many
patient subsets. For example, mortality is 12% for males that
do not require preoperative mechanical support. It is 16% for
patients who are either female or who require such support.
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It is 31% for females requiring preoperative mechanical
support. Appendix 2, available on request, displays several
more two by two and three by two comparisons of this nature.
These bivariate analyses suggest that the above univariate
predictors have independent effects on transplant mortality,
although formal multivariate analyses are required to test
this assertion (see chapter 8).
A Review of the Literature-As I mentioned earlier in this
chapter, the medical literature comparing these traditional
determinants to mortality is surprisingly underdeveloped.
However in general, the results of the above analyses are
consistent with the available literature.
Among these traditional determinants, investigators have
most frequently studied patient AGE. Reports from individual
centers consistently show that carefully selected patients
aged greater than 50 or even 60 years experience a mortality
risk similar to that of younger patients (11-15). The results
of this are consistent with these earlier findings.
Of note, investigators have also studied the effects of
recipient age on other important outcomes from heart
transplantation. They have found that age does not appear to
have adverse effects on length of stay, renal function or the
number of rejection episodes following transplantation. One
study did note that patients aged greater than 55 years
experienced a higher incidence of steroid-induced diabetes
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(17% vs. 9%) and osteoporosis (13% vs. 3%), although these
conditions did not significantly affect functional status 6
Several investigators have suggested that the degree of
cardiac failure prior to heart transplantation may affect
mortality following the procedure. All eligible patients have
depressed cardiac function, but measures of cardiac function
do vary from patient to patient. For example, preoperative
left ventricular ejection fraction varied from 5% to 28%
(normal >55%) and left ventricular filling pressure varied
from 4mm Hg to 42mm Hg (normal <12mm Hg) in a recent series
(18). However until this study, no investigator had actually
studied the relations between such direct measures of native
heart function and mortality post-transplant. This study's
univariate analyses show in fact that patients having very
severely depressed left ventricular function (ejection
fraction less than 11%) are characterized by higher mortality
following heart transplantation7
On a related topic, several investigators have already
studied the relations between indirect measures of cardiac
performance, such as REQUIREMENTS FOR INOTROPIC SUPPORT or
MECHANICAL ASSIST DEVICES, and mortality. The results have
6 Our experience at Brigham and Women's Hospital
suggests that steroid-associated osteoporosis substantially
affects functional status. The effects of age on steroid-
associated osteoporosis requires further investigation.
7 However, as discussed in chapter 8, these findings are
not confirmed in multivariate analyses. Reasons for this are
discussed in chapter 8.
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been mixed (36,37). McBride's group for example, found that
patients requiring preoperative mechanical support had a 30-
day survival of 33% (2/6). 63% (12/19) of patients requiring
preoperative inotropic support survived 30 days. In contrast,
30-day survival in patients not requiring mechanical or
inotropic support was 97% (19). However, O'Connell's group
recently reported that small mortality differences notable at
one month disappeared completely by one year (20), and they
concluded that mortality following heart transplantation does
not depend on preoperative requirements for inotropic or
mechanical support.
The univariate and bivariate analyses of this study, in
which the follow-up period is 90 days, suggest that
preoperative mechanical support is an important predictor of
post-transplant mortality 8. All these studies must be
interpreted with caution, as the use of such support may
reflect resource availability or simply variation in practice
rather than differences in the severity of underlying cardiac
disease. Such discretionary utilization may underlie recent
reports of excellent results with mechanical assist devices
(36-37).
With respect to TRIPLE DRUG IMMUNOSUPPRESSIVE THERAPY, this
8 However, as with the case of left ventricular ejection
fraction, these findings are not supported in multivariate
analyses. These two instances represent the only important
discrepancies between the findings of univariate and bivariate
analyses and the findings of the multivariate analyses. I
discuss these issues in more detail in chapter 8.
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study's univariate and bivariate analyses support existing
studies (18-21) that consistently show survival benefits for
patients receiving this regimen. Earlier studies had
documented markedly reduced infection and rejection rates when
this regimen was used, and this undoubtedly underlies the
mortality benefits.
The relations between other patient characteristics and
transplant mortality have been studied less extensively. One
study found a higher rate of allograft rejection among
FEMALES, but no mortality differences between sexes (23).
However, the Registry of the International Society for Heart
Transplantation has reported higher mortality rates among
females (1). The univariate and bivariate analyses of this
study, using more recent data than the above, continue to show
that females have higher mortality rates.
Among donor characteristics, the ISCHEMIC TIME is the most
likely donor attribute to affect mortality following heart
transplantation. The ischemic time is defined as the time
elapsed between the moment surgeons clamp the donor aorta
during harvesting and the moment the recipient aorta is
unclamped after the aortic anastomosis is completed. It has
long since been known that ischemic times greater than 4-5
hours cause substantial ultrastructural damage and diminished
contractile function in the donor heart (27). Most transplant
surgeons will not accept a donor organ if they anticipate that
the ischemic time will exceed 5 hours.
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However, studies of the relation between donor ischemic
time and mortality have been somewhat inconclusive to date.
Two groups found no relation (28-29). However, the Registry
has recently reported that 30-day mortality is directly
related to ischemic time. It reports that the 30-day mortality
is 6% when the ischemic time is less than 2 hours, and 13%
when the ischemic time is 2-5 hours (1).
Univariate and bivariate analyses in the study, in which
the majority of donor ischemic time data is collected via the
supplementary survey (not the Registry), and in which the
follow-up period is 90 days, confirms earlier Registry
findings. They suggest that transplant mortality is lower in
patients having donor ischemic times less than 2 hours. Such
studies assume great importance in the context of the current
donor organ shortage, since the donor organ pool might be
expanded by as much as 5-10% if clinicians would accept organs
for which the anticipated ischemic time was 5-6 hours.
In chapters 8 and 9, I discuss further the relations
between transplant mortality and these traditional attributes
of patients and donors. It is worth mentioning at this time
that until this study, no investigator had studied the
relations between center characteristics (another
"traditional" determinant) and transplant mortality. I have
studied this in detail. I present the results of these
analyses in chapter 7.
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Figure 2.1
U.O. (HEART TRANSPLANT CNTERS
(circa April,
CENTER
Stanford University
Mayo Clinic
St. Louis University
Methodist Hospital (Indiana)
University of Pittsburgh
University of Arizona
Texas Heart Institute
University of Minnesota
Columbia Presbyterian
McGuire VA Medical Ctr.
John's Hopkins Hospital
Medical College of Virginia
University of Alabama:
UCLA School of Medicine
Loyola University
Georgia Heart Institute
Pacific Presbyterian Hosp.
Arizona Heart Institute
Brigham and Women's Hosp
Kansas University
Humana Hosp. Audobon
St. Luke's Hosp. (Milwaukee)
University of Wisconsin
Hartford Hospital
Temple University
Hershey Medical Center
SUNY Buffalo
Methodist Hospital (Baylor)
Jewish Hospital (Louisville)
Vanderbilt University
Tennessee Heart Institute
Henry Ford Hospital
St. Luke's Hospital (K.C.)
Utah Medical Center
Lutheran Hosp. (Fort Wayne)
Tampa General Hospital
University of Florida
Milwaukee County M.C.
Cleveland Clinic
St. Paul MC. (Dallas)
University of Michigan
University of Chicago
Talahassee Memorial Hosp.
Beth Isreal Hosp. (NJ.)
Mercy M.C. (owa)
Bishop Clarkson Hosp. (Ne.)
University of Iowa
Barnes Hospital
Loma Linda Hospital
Sharp Memorial Hosp (Ca.)
Hines VA Hosp. (II.)
St. Anthony Hosp. (Ok.)
University of Tennessee
Emory Clinic
University of Cincinnati
Massachusetts General Hosp.
University of Illinois
St. Francis Hospital (Ne.)
University of Washington
Baptist Medical Center (Ok.)
McGaw Medical Center (I_)
Indiana University
University of New Mexico
Oregon Health Sciences Univ.
Baptist Medical Center (Al.)
Seton Medical Center (Tx.)
St. Francis Hospital (Ks.)
Abbott Northwestern (Mn.)
St. Vincent Hospital (In.)
University of Miami (Fl.)
IN T IOHT RGISTRY
1987)
FIRST TOTAL SUPPLEMENTAL
rr IT(84-861 NFOR
1968 130 Yes
1981 0 No
1972 47 Yes
1982 46 Yes
1980 207 Yes
1979 67 Yes
1982 145 Yes
1978 65 Yes
1977 91 Yes
1977 99 No
1983 62 Yes
1968 60 Yes
1981 61 Yes
1984 30 Yes
1984 76 Yes
1984 13 Yes
1984 21 Yes
1984 4 No
1984 30 Yes
1984 18 Yes
1984 23 Yes
1984 21 Yes
1984 24 Yes
1984 18 Yes
1984 51 Yes
1984 38 Yes
1984 5 No
1984 40 -Yes
1984 23 No
1985 7 Yes
1985 12 Yes
1985 38 Yes
1985 10 Yes
1985 63 No
1985 15 Yes
1985 16 Yes
1985 14 Yes
1985 9 Yes
1984 38 Yes
1985 3 Yes
1984 30 Yes
1984 16 Yes
1985 16 Yes
1986 10 Yes
1985 9 Yes
1985 7 Yes
1985 8 Yes
1985 44 No
1985 10 Yes
1985 13 Yes
1986 8 Yes
1985 5 Yes
1985 6 Yes
1985 42 Yes
1985 32 Yes
1985 5 Yes
1985 4 Yes
1985 3 Yes
1985 5 Yes
1985 9 Yes
1985 2 Yes
1986 6 Yes
1986 6 Yes
1985 30 No
1986 0 No
1986 4 No
1986 3 No
1985 10 No
1986 8 No
1986 1 No
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figure 2.2
TOTAL NUMBER OF HEART TRANSPLANTS
vs. MORTALITY
(1984-1986)
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Each point represents actual data from a transplant center
participating in the Registry,
* Note: In this case and all subsequent figures, "Mortality"
refers to 90-day mortality. See pp 46-48.
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figure 2.3
RECIPIENT CHARACTERISTICS
Complete Data Complete Data
Available Not Available
Number 1,123 882
90 Day Mortality (%) 14 15
% Age <50 66 67
% Male 87 85
% Cardiomyopathy 57 56
% Coronary Artery Disease 37 38
% Cyclosporine Used 94 88
% "Triple Therapy" Used 51 46
% Transplanted in 84 18 17
% Transplanted in 85 38 31
% Transplanted in 86 44 52
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figure 2.4
RISK FACTORS PER PATIENT
(n=1 123)
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figure 2.5
THE BURDEN OF PREMORBID ILLNESS
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Figure 2.6
MORTALITY FOLLOWING HEART TRANSPLANTATION
All Patients
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MORTALITY FOLLOWING HEART TRANSPLANTATION
By Gender
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Figure 2.8
MORTALITY FOLLOWING HEART TRAN:.- LANTATION
By Mechanical Support
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figure 2.9
MORTALITY FOLLOWING HEART TRANSPLANTATION
By Use of Cyclosporine
Cyclosporine used
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figure 2.10
MORTALITY FOLLOWING HEART TRANSPLANTATION
By Year of Transplant
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figure 2. 11
MORTALITY FOLLOWING HEART TRANSPLANTATION
By Transplant Number
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Figure 2.12
MORTALITY FOLLOWING HEART TRANSPLANTATION
UNIVARIATE ANALYSIS
FIELD
M
F
Age < 50
>50
Indication CRDMPY.
C.A.D.
Other
Mechanical Support
Ejection Fraction
Comorbid Conditions
No
Yes
< 11%
>11%
No
Yes
lschemic Time < 120 min
> 120 min
Cyclosporine
Triple Drug Rx
No
Yes
No
Yes
MORTALITY
13
19
14
15
13
17
17
13
20
18
13
13
20
10
17
PATIENTS
1612
304
1288
699
1091
754
218
1301
334
417
940
1724
262
439
971
19
14
1862
206
18
12
1065
996
p < .05 *
p =NS
p =NS
p < .05
p < .05
p < .05
p < .05
p <.05
p < .05
* Note: "One-tailedI tests are used in this analysis.
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CHARACTERISTIC
Gender
liguro 2. 13
DETERMINANTS OF MORTALITY FOLLOWING
HEART TRANSPLANTATION
(2 x 2 Tables)
GENDER
Male Female
Mechanical No 12 16
Support Yes 16 31
GENDER
Male Female
Yes 13 18
3-Orug Rx
No 20 21
MECHANICAL SUPPORT
No Yes
Yes 10 13
3-Drug Rx
No 16 23
GENDER
Male Female
Comorbid No 13 17
Conditions Yes 18 24
MECHANICAL SUPPORT
No Yes
Comorbid No 12 16
Conditions Yes 18 26Yes 18 28
COMORBID CONDITIONS
No Yes
Yes 12 21
CRDMPY
No 15 17
GENDER
Male Female
Yes 12 16
CRDMPY
No 14 22
MECHANICAL SUPPORT
No Yes
Yes 11 15
CRDMPY
No 20 18
COMORBID CONDITIONS
No Yes
Comorbid Yes 10 18
Conditions N 17 21No 17 21
NOTE: Figures represent 90-day mortality in patients
having both characteristics as shown.
CARDI OMYOPATHY
Yes No
Yes 10 12
3-Drug Rx
No 16 19
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CHAPTER 3
YEAR OF TRANSPLANT AND MORTALITY
FOLLOWING HEART TRANSPLANTATION
SUMMARY:
This chapter explores the relation between year of
transplant and mortality following heart transplantation.
KEY POINTS:
- Between 1984 and 1986, clinicians altered their patient
selection practices to include more patients who were
older than age 50, who required preoperative mechanical
support, and who had indications for the procedure other
than cardiomyopathy.
-However, the overall burden of premorbid illness did
not change over these three years.
- In part, this was because transplant centers also
utilized triple drug immunosuppressive therapy with
increasing frequency during this period.
- There was a trend toward decreased mortality during
this period, but it did not reach statistical sig-
nificance.
- This trend is explained primarily by the increasing use
of triple drug immunosuppressive therapy and by a learn-
ing phenomenon at new centers.
The years 1984-1986 (the period of this study) can be
described as the "renaissance" era of heart transplantation.
These were the years during which the technology swept into
the public eye as a newly effective, life-saving and
enormously compelling symbol of high-tech medicine. It was a
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period of unprecedented growth and optimism as the overall
volume of procedures doubled annually and the number of
transplant centers increased from 32 to 70 (figure 3.1). The
vast increases in procedure volume generated an explosion of
new data about the procedure, and new journals, forums,
professional societies and conferences founded during this
period facilitated the dissemination of this information. And
of great significance, it was during this period that
clinicians adopted "triple drug immunosuppressive therapy" for
the prophylaxis of transplant rejection. Triple drug therapy
remains to this day the primary immunosuppressive strategy for
heart transplant recipients1
This growth in transplant volume was fueled a tendency to
relax patient selection criteria and to accept patients that
would have been excluded in the past2. Specifically, there
were significant increases in (figure 3.2):
- The number of transplant recipients who were older than
age 50: Between 1984 and 1986, there was an 800% growth
in this group, but "only" a 200% growth among transplant
recipients who were younger than age 50.
- The number of patients who required preoperative
mechanical support: This group grew three times faster
1 The events surrounding the maturation of heart
transplantation into a generally accepted medical practice are
summarized in the Introduction and in chapter 9.
2 And presumably by the increased availability of donor
organs.
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than the overall growth in transplant volume3.
- The number of recipients requiring transplantation for
indications other than cardiomyopathy (the "classic"
indication): This group grew twice as fast as the group
requiring transplantation for cardiomyopathy.
Interestingly, the overall burden of premorbid illness-
calculated according to the formula in chapter 2 (see figures
2.4-2.5)-did not change appreciably during this period. This
is illustrated in figure 3.3, where for example one sees that
the percentage of transplant recipients having a high burden
of illness remains essentially constant from 1984 to 1986.
The reason why overall burden of illness does not change
despite the above trends in patient selection is that the
"non-use" of triple drug therapy-another patient risk factor
(see figure 1.8)-decreases dramatically during the study
period (figure 3.4). By 1984, several groups had reported that
recipients treated with small doses of three immunosuppressive
agents-cyclosporine, prednisone and azathioprine-had fewer
and less fulminant episodes of cardiac rejection and fewer
side effects than patients treated with high dose cyclosporine
alone4. These reports triggered a massive, nationwide change
3 Growth in the number of transplant recipients
requiring preoperative mechanical support undoubtedly also
reflects the diffusion of (and improvements in) mechanical
support technology.
See Introduction and chapter 9 for details.
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in immunosuppressive protocols such that usage of triple drug
therapy nearly quadrupled from 15% in 1984 to 57% in 1986.
As patient selection practices and immunosuppressive
management strategies changed, overall mortality following
heart transplantation decreased from 18% in 1984 to 14% in
1985, to 13% in 1986 (figure 3.5). This trend approaches, but
does not quite achieve statistical significance (p=.06).
This strong trend certainly requires further investigation.
Specifically, three questions require further analysis:
1) What is the possibility that a very strong trend toward
reduced mortality between 1984-1986 does not achieve
statistical significance because it is masked by another
trend, in which clinicians tended to select sicker patients
in the later years of this study?
2) To what extent is the trend towards reduced mortality
explained by the increasing use of triple drug
immunosuppressive therapy during this period?
3) What is the possibility that a very strong trend toward
reduced mortality is hidden by the vast expansion in the
number of new, inexperienced transplant programs that began
during the study period?
I analyze these questions below.
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YEAR OF TRANSPLANT, PATIENT CHARACTERISTICS AND THE MANAGEMENT
OF IMMUNOSUPPRESSIVE THERAPY
Univariate analyses described earlier (figure 2.12) reveal
that several patient attributes confer survival benefits in
this study. For example, gender is a univariate predictor of
mortality following heart transplantation: males have
significantly lower mortality rates than females. Similar
survival benefits are demonstrated among patients not
requiring mechanical support and patients without comorbid
conditions.
The year of transplant does not affect these primary uni-
variate relationships. As shown in figures 3.6 and 3.7, the
expected relation is found in 11 of the 12 samples when the
data is stratified by year of transplant: males have lower
mortality in all three years, patients without comorbid
conditions have lower mortality in all three years, and so
forth. Five of these 12 comparisons reach statistical
significance (as shown). This pattern is very unlikely to have
occurred by chance (p<.005) , and it provides additional
support for the conclusion that the above patient
characteristics are indeed important predictors of transplant
mortality.
5 If these patient characteristics were not correlated
with transplant mortality, the chances of observing 11 of 12
events in this pattern are equal to 12/(1/2) ,or 12/4,096.
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GIVEN THAT the above patient characteristics are important
predictors of transplant mortality, it is now possible to test
the hypothesis that year of transplant is another important
predictor. IF THIS WERE THE CASE, one would expect to see
stepwise reductions in transplant mortality by year in each
of the patient subsets. However, this pattern is not seen: the
year of transplant has no consistent effect. For example, when
I stratify by gender, the trend towards a decline in mortality
between 1984-1986 is maintained in females, but it is less
apparent in males (figure 3.6). [Neither trend achieves
statistical significance (X 2(fees) =1.89; p=NS. X 2 ()=0 .73;
p=NS].
When I stratify by comorbid conditions, there is an in-
significant trend (X2(lot present)=0.65; p=NS), towards reduced
mortality in patients having no comorbidities, and no trend
at all in the group featuring the presence of comorbid
conditions (figure 3.6). Similarly, there are no clear
patterns in either subset when the data is stratified by the
presence or absence of preoperative mechanical support.
And interestingly, yet a different pattern is visible when
I stratify the mortality-by-year data by the use or non use
of triple drug immunosuppressive therapy (figure 3.7). A trend
toward declining mortality with time, consistent with the
overall trend in the data set, is apparent in patients who did
not receive triple drug therapy (however this trend does not
reach statistical significance, as shown). The opposite trend,
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towards higher mortality in later years, is seen for the
patients treated with triple drug therapy! Further analyses
of this sort (available on request) fail to reveal any
clearcut relation between year of transplant and mortality.
Taken together, these findings suggest that the above
patient characteristics and the decision to use triple drug
immunosuppressive have a greater impact on transplant
mortality than the year of transplant itself. And since
clinicians tended to select sicker patients over these three
years (older, more mechanical support, etc.), the data also
suggests that the choice of triple drug immunosuppressive
therapy has a powerful impact on transplant mortality-enough
perhaps to be responsible (at least in part) for the trend
towards reduced transplant mortality seen between the years
1984-1986. Further confirmation of this suspicion requires
multivariate analysis (see chapter 8)6
PROGRAM DURATION AND MORTALITY
In examining the trend towards reduced heart transplant
mortality between 1984-86, I must also account for the
considerable role played by the new transplant centers-those
that began operation during the study period. During this
6 A somewhat less plausible hypothesis to explain the
above findings is that clinicians did in fact learn to select
candidates who were more likely to survive the transplant
procedure, and that the cues they learned to use were not
detectable in the present study. This hypothesis cannot be
tested directly using this data set.
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period, the number of transplant centers increased from 32 to
70 (figure 3.1), and it is reasonable to suppose that this
influx of inexperienced centers could have an impact on
overall mortality following heart transplantation. If this
were true, then the trend towards reduced mortality over the
study period would assume greater significance.
Interestingly, centers beginning programs in 1984 and in
1985 tended to select patients with risk profiles similar to
their established counterparts (see figure 3.8-NOTE: THIS
FIGURE APPEARS ON THE SAME PAGE AS FIGURE 3.4)7. However,
centers beginning in 1986 selected significantly more high
risk patients than their established counterparts.
When I stratify transplant mortality by program duration
and the year of transplant, several interesting observations
emerge (figure 3.9). First, for each calendar year, centers
beginning programs in that year experienced higher mortality
rates than their established counterparts, as follows:
In this analysis, "new centers" began programs in the
calendar year shown. "Established centers" had begun
transplant operations before that calendar year.
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1984
TRANSPLANTS:
1985
TRANSPLANTS:
1986
TRANSPLANTS:
New center mortality 23% (n=56)
Established center mortality 14% (n=147)
z=1.53; p=NS
New center mortality 20% (n=66)
Established center mortality 14% (n=340)
z=1.26; p=NS
New center mortality 19% (n=24)
Established center mortality 14% (n=470)
z=0.64; p=NS
And when I reaggregate the above data, I find that
transplant mortality is significantly higher at new centers:
ALL
TRANSPLANTS: New center mortality 20% (n=146)
Established center mortality 14% (n=957)
z=2.13; p<.05
Second, the mortality difference between new and
established centers is particularly notable in patients having
a moderate or a high burden of illness. In such patients,
stepwise increments in program duration are correlated with
stepwise reductions in mortality (figure 3.9) in all three
years. This relation is not evident among patients having a
low burden of illness. Although none of these relations
reaches statistical significance by itself, the presence of
such a stepwise relation in six independent samples (1984-
moderate, 1984-high, 1985-moderate, 1985-high, 1986-moderate,
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1986-high) would be exceedingly unlikely to occur by chance.
To summarize the pertinent observations on program
duration:
1) New centers select patients with characteristics
similar to those chosen by the established centers8.
2) Regardless of the year of transplant, new centers are
associated with higher mortality rates.
3) Increases in program duration are associated with
mortality reductions in moderate and high risk patients.
The most logical explanation for these observations is that
new transplant centers are able to improve their performance
in the sickest patients as a result of having learned from
their own past experience with the transplant procedure.
Furthermore, at least some of the skills and/or knowledge that
centers obtain through repetitions of the transplant procedure
cannot be obtained vicariously (if it been possible for new
centers to learn by observing or reading about the practice
of other centers, then new centers should have demonstrated
mortality rates equal to their more established counterparts).
The results of these analyses suggest that the trend
towards reduced transplant mortality between 1984-1986 is
8 With the 1986 high risk exception mentioned above.
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mediated (at least in part) by increases in the use of triple
drug immunosuppressive therapy and by a learning phenomenon
that occurred at new transplant centers. The learning
phenomenon will be analyzed in chapter 4.
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figure 3.1
TRANSPLANT VOLUME
(1984- 1986)
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TRENDS IN PATIENT AND DONOR CHARACTERISTICS
AND IN IMMUNOSUPPRESSIVE MANAGEMENT
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TRENDS IN THE BURDEN OF ILLNESS
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Figure 3.5
MORTALITY FOLLOWING HEART TRANSPLANTATION
(1984- 1986)
X = 3.75;
p = .06 (NS)
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YEAR OF TRANSPLANT AND MORTALITY %
By Gender
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YEAR OF TRANSPLANT AND MORTALITY
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TRENDS IN THE USE OF TRIPLE DRUG THERAPY
(1984 - 1986)
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PREMORBID BURDEN OF ILLNESS AND MORTALITY
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CHAPTER 4
CUMULATIVE EXPERIENCE AND MORTALITY
FOLLOWING HEART TRANSPLANTATION
(the "Learning Curve")
SUMMARY:
This chapter investigates the hypothesis that knowledge
and skills acquired during initial repetitions of the
heart transplant procedure lead to decrements in
mortality risk.
KEY POINTS:
- Mortality following heart transplantation is highest
among the first several patients to receive the procedure
at any particular center.
- As centers repeat the procedure, they achieve better
results in moderate and high risk patients. This relation
is less well defined in low risk patients.
- The rate of decline in mortality risk and the number
of transplants over which mortality decrements can be
demonstrated vary by category of high (or moderate) risk
patient.
- Skills and knowledge obtained through the management
of low risk patients are applicable to the management of
moderate or high risk patients.
In chapter 3, the analysis of transplant program duration
revealed that mortality following heart transplantation is
significantly higher at new centers than it is at established
centers. The analysis also revealed that when transplant
programs are stratified by the number of years in which they
86
have performed the procedure, there are successive mortality
reductions for each additional year of experience (figure
3.9). These findings suggest that centers acquire knowledge
and/or skills by performing the heart transplant procedure and
that the centers can translate these experiences into improved
outcomes in future repetitions of the transplant procedure.
In other words, they "learn by doing".
When one considers the multiplicity and complexity of the
care processes required to provide heart transplant services,
one might reasonably expect learning curve phenomena to exist.
In this regard, it is interesting to note that current heart
transplant policy fails to account for this possibility1 . Of
course it is also true that to date no investigator has
attempted to demonstrate such phenomena in heart
transplantation, and in fact empirical studies documenting the
presence of learning curves in health care are quite rare.
In this chapter, I will provide an overview of learning
curve theory, review what limited literature exists on
learning curves in health care, and then present the results
of my study of learning curve phenomena in heart
transplantation.
AN OVERVIEW OF LEARNING CURVES
The learning curve was originally described as a
1 The Introduction and chapter 9 provide an overview of
heart transplant policy.
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logarithmic decline in labor costs as a function of cumulative
production experience. It was first observed in aircraft
production during wartime (40). Similar relations have been
described for the production of integrated circuits, high-
grade aluminum and benzene (40). More recently, learning
curves have been demonstrated in the acquisition of second
languages (41), and in the acquisition of cognitive and
manipulative skills by children (42,43).
Health care providers routinely refer to "learning curves"
in medicine. Most implicitly believe they exist for a very
broad range of clinical activities: from simple phlebotomy to
the interpretation of radiologic images, to the performance
of complex operations such as open heart surgery2. In
addition, professional organizations routinely require that
providers perform procedures while being supervised before
they can become certified to perform them independently3. In
the context of these beliefs and policies, it is striking to
find how little empiric support there is in the medical
literature that documents or characterizes in any way learning
curve phenomena in health care.
Fortunately the literature is relatively well developed for
one technology, and it happens that this technology is in some
... in the author's personal experience.
For a summary of practice guidelines and standards in
health care, see: Leape, L; Practice Guidelines and Standards;
An Overview; Quality Review Bulletin; (16)42-50; 1990.
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ways similar to heart transplantation. The technology is
Percutaneous Transluminal Coronary Angioplasty (PTCA). In
PTCA, cardiologists use balloon-tipped catheters to dilate
coronary arteries that have become narrowed due to
atherosclerosis. The similarities between PTCA and heart
transplantation are as follows: 1) they both gained acceptance
in the mid-1980s. 2) The number of centers offering both
services has exploded in recent years. 3) Rapidly improving
outcomes from these procedures could be reasonably attributed
to both increasing professional skill and associated
innovations in related fields (for PTCA, it was catheter
design; for heart transplantation, it was immunosuppressive
therapy). I will now review the literature on PTCA learning
curves and use it to introduce some general discussion points
about the learning curve phenomenon.
The first account of a PTCA learning curve appeared in
1984. In a study published in the American Journal of
Cardiology, Kelsey used results from the National Heart, Lung
and Blood Institute's PTCA registry to determine whether
learning curves were present for this procedure (44). He found
that cardiologists had 55% success rates during their first
50 cases and 77% success rates after case number 150. Kelsey
showed that improved results were secondary to improved
manipulative skills rather than the year in which the PTCA
was performed or the attributes of the lesions that were
dilated.
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In the period between 1982-1986, there were many important
breakthroughs in the design of dilation catheters and the
guidewires that were used to advance the catheters into proper
position. First, several companies introduced steerable
catheters which improved catheter maneuverability. Then they
introduced so called "low profile" catheters, which performed
the same functions as the older versions, but they offered
better torque control and they were much thinner, thus
enabling operators to advance these catheters beyond proximal
stenoses.
These advances changed the characteristics of the PTCA
learning curve (45-46). Cardiologists with no prior PTCA
experience began to report outstanding results as soon as they
began to use the new catheters. In one report, previously
untrained cardiologists successfully dilated 85% of the first
20 lesions they attempted (46). In another report,
cardiologists successfully dilated 94% of their first 100
lesions (47). This group noted their failures occurred
sporadically; there was no demonstrable learning curve! The
explanation for such results was that advances in catheter
design had reduced task complexity to the point where
excellent performance could be expected on the very first
attempt.
Factors That Influence Learning Curves-Thus in the case of
PTCA, innovation in a related area (catheter design) affected
the shape of the learning curve by markedly simplifying a
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previously complex task. Other factors may determine whether
learning curves will be present or mediate their shape. Task
complexity per se is one such factor. Activities requiring
complex cognitive or manipulative skills, or for whatever
reason generate a multitude of situations that operators must
handle, are likely to be associated with prolonged learning
phases. Those which are relatively simple will manifest a
steep learning curve or none at all.
Preexisting skills or knowledge in related areas are a
third factor that may modulate the shape of learning curves.
Individuals having skills which are transferable to the new
task are likely to master the new task more rapidly than those
without such skills. This observation provides the rationale
for requirements that new heart transplant centers have
preexisting open heart surgical programs (10). Skills and
teamwork mastered during routine open heart surgery are
certainly applicable to the heart transplant procedure, and
they allow individuals to focus learning efforts on its unique
aspects.
A fourth factor that can modulate the learning curve is the
RATE at which the relevant task is performed (40). If this
rate is low, individuals may not be able to practice newly
acquired skills intensively enough to master them, and there
may be extinction of these acquired skills. At the other
extreme, it is possible that very high performance rates may
impair the assimilation of new knowledge by providing
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insufficient time to internalize knowledge and skills.
Learning curves may also be modulated by a fifth factor,
the time period in which learning takes place. This was also
demonstrated in the PTCA example. Clinicians that began
performing PTCA after innovations in catheter design had
starkly different learning curves than those who began before.
The learning curves of late starters are also affected by
better teaching (from the pioneers) and better support
processes (again, fashioned by the pioneers)4
A sixth factor that can impact the presence and shape of
learning curves is the choice of measures used to detect it.
If investigators select an outcome measure that is relatively
insensitive, then they may not be able to detect a learning
curve phenomenon. For example, mortality rates associated with
PTCA have not dropped notably since PTCA was introduced, but
success rates and other more sensitive measures have shown
improvement.
A final point concerning the medical literature on learning
curves is that it is focused on individual, as opposed to
organizational performance. This literature has yet to
document, much less characterize learning curves at the
organizational level [although outside health care there is
evidence that learning curve phenomena can be observed at this
It would appear that innovations in related fields,
task complexity, preexisting skills, performance rate and
program start time could all modulate volume-outcome relations
as well, although these interactions have not been studied.
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level (40)].
This omission is important because the success of heart
transplant technology almost certainly depends on
organizational, not individual performance. And while few
would find it implausible that learning curves could exist for
heart transplantation, it remains a major challenge to isolate
and describe these phenomena given that new transplant centers
are also likely to exhibit variations in their patient
selection and patient care protocols, their transplant team
structure, and in the degree of institutional support for
their program.
LEARNING CURVES IN HEART TRANSPLANTATION:
THE RESULTS OF THIS STUDY
To investigate whether transplant centers accumulate
knowledge and/or skill during their initial repetitions of the
transplant procedure, and whether they can translate this into
reduced mortality in subsequent procedures, I:
1- Created a new data set consisting of centers that began
transplant programs in the years 1984-1986.
2- Grouped all patients in this data set according to their
"transplant number". For example, all the patients who
happened to be the first transplant recipient at their
respective centers were grouped (transplant number 1), as were
all patients who happened to be the second (transplant number
2), and so on.
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Figure 4.1 shows the relation between transplant number and
mortality for the first 50 transplants at these "new"
transplant centers. Mortality is consistently high in the
earliest phases of this sequence (approximately the first four
transplants). As the transplant number increases from number
four to approximately number 20, a somewhat lower steady state
mortality is reached, although sporadic peaks and valleys are
common. Beyond (about) transplant number 20, the sequence is
characterized by large variations in mortality from
observation to observation. When both parametric and non-
parametric statistical tests are applied to this sequence of
50 transplants5, a statistically significant trend toward
mortality reduction is not demonstrable.
Figure 4.2 shows the same relation, but it displays data
for the first 20 transplants only. This figure is meant to
highlight possible mortality reductions as centers accumulate
skills and/or knowledge from their initial experiences with
the procedure. Of great interest, there is a significant trend
toward reduced transplant mortality as transplant number
increases from one to 20 (see figure).
Therefore, one can demonstrate a significant trend for the
5 Parametric method: Chi-Square Test for the comparison
of more than two proportions in independent samples.
Non-parametric method: Spearman's Rank Correlation
Test to determine the degree of relationship between two
variables.
For further information see: Colton, T; Statistics In
Medicine; Little, Brown and Co.; Boston, Ma.; 1974; p174-9,
223-7.
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first 20 transplants, but the trend is no longer apparent when
the sequence is extended to 50 transplants. There are two
possible explanations for these findings (which are not
mutually exclusive). First, it is possible that centers
achieve the maximal benefits from learning relatively early
in their sequence of heart transplant procedures, and so
extending the sequence out to 50 transplants dilutes the
effect. Second, it is possible that sample sizes for the
higher transplant numbers are too small to allow a real
difference to be detected.
To explore these possibilities, I reaggregated the data
into larger groups by transplant number. For example, to
create figure 4.36, I combined individuals having transplant
numbers from 1-5 into one group, those with transplant numbers
from 6-10 into a second group, etc. In this figure, one can
see that mortality is highest in the first group (the earliest
transplants in the sequence). There is considerable variation
after this first group, but it is noteworthy that of the 10
observations in figure 4.3, the first 5 observations contain
4 of the highest mortality rates, and the last 5 observations
contain 4 of the lowest mortality rates. However, as shown,
this trend does not reach statistical significance.
Importantly, figure 4.3 also shows that even after
reaggregating the data as described, sample size becomes
6 In these figures, and all subsequent histograms in
this chapter, the mortality rate is shown + 1 standard error.
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relatively small as transplant number increases beyond about
number 30. Therefore, for a second analysis I grouped the data
into multiples of ten transplant numbers (figure 4.4). This
analysis again reveals that mortality is higher in the first
group (transplant numbers 1-10). It also shows that mortality
is lowest in the last group (transplant numbers 40-50).
Although this trend does not quite reach significance using
a non-parametric test, the chi-square analysis does suggest
this pattern is unlikely to have occurred by chance.
To pursue these findings further, I then reaggregate
transplant number into two groups (figure 4.5): the first
group consists of transplant numbers 1-5 and the second
consists of all transplant numbers greater than 5. Mortality
in the former group is 20%, and mortality in the latter group
is 12%. This difference is highly significant (p<.002). I
subsequently aggregate transplant number into different
groups, as follows:
Group A Group B
Transplant Number 1-10 >10
Mortality (%) 17.0 12.2
Sample Size 413 483
Z=2.13; p<.05
Transplant Number 1-15 >15
Mortality (%) 16.5 12.0
Sample Size 540 346
Z=1.83; p=NS
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Thus, the significant relation between transplant number
and mortality disappears after about the 10th transplant.
If one could attribute this relation to improvements in the
execution of patient care processes, then one would in fact
be describing a learning curve phenomenon in heart
transplantation. However, the above relations could also be
explained by changes in patient selection or in the use of
triple drug immunosuppressive therapy as transplant number
increases.
I investigate these possibilities by studying the relations
between transplant number and: 1) patient characteristics
shown by univariate analysis (figure 2.12) to be significant
predictors of mortality, b) immunosuppressive practices, and
c) the premorbid burden of illness. These relationships are
displayed in figures 4.6-4.8.
Transplant number is not related to any of the univariate
predictors of mortality (analyses available on request) [Of
peripheral interest however, transplant number is related to
recipient age-a patient characteristic not found to be a
strong predictor of transplant mortality (figure 4.6). The
relation is characterized by a tendency to select patients
older than age 50 years as transplant number increases].
Of greater importance, there is a modest positive
relationship between transplant number and the use of triple
drug immunosuppressive therapy (figure 4.7). However, this
relation is characterized by an increasing tendency to use
97
this more effective regimen as transplant number increases7
This effect enhances, rather than confounds, the central
observation that mortality is higher among patients with low
transplant numbers.
Equally important, the data does not indicate a tendency to
select patients with a low burden of illness as transplant
number increases (figure 4.8).
These observations essentially rule out the possibility
that the inverse relationship between transplant number and
mortality is due to underlying trends in patient selection or
in the management of immunosuppressive therapy. The remaining
hypothesis is that a learning curve exists in heart
transplantation:
Transplant centers are able to improve the execution of
their patient care processes as a result of their early
experiences with the procedure. These improvements trans-
late into reduced transplant mortality in subsequent
cases.
I use the word "modest" because the non-parametric
test for correlation reaches conventional standards for
statistical significance, while the chi-square test does not
suggest the relation is significant. This implies a very
consistent trend of very small magnitude, as can be seen in
figure 4.7.
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CHARACTERISTICS OF THE HEART TRANSPLANT LEARNING CURVE
Now that I have identified the heart transplant learning
curve, I proceed by characterizing it more fully. Several
questions come to mind in this respect, and I will answer each
of them.
What is the relation between the year in which transplant
programs are initiated and the learning curve? Interestingly,
the data shows significant learning curve phenomena for
transplant programs that began operations in 1984 and 1985
(figures 4.9-4.10), but nothing even remotely resembling a
learning curve in 1986 start-up centers (figure 4.11).
The learning curves for 1984 and 1985 have different
characteristics. The curve for 1984 shows strikingly and
consistently high mortality through the first 6 transplants
followed by a rather abrupt reduction in mortality which is
maintained throughout the remainder of the sequence. The
overall trend reaches statistical significance by parametric
tests but not by non-parametric tests (the latter presumably
because of the notable uniformity in the sequence beyond
transplant number 6).
In contrast, the curve for 1985 start-up centers (figure
4.10) is characterized by a gradual reduction in transplant
mortality which is more or less evident over the entire 20-
transplant sequence. This curve reaches significance at the
.05 level using the Chi-Square Test and the Spearman Rank
Correlation test (the latter presumably because the of the
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near perfect correspondence between transplant number and
"mortality rank" at both the beginning and the end of the 20-
transplant sequence).
For 1986 start-up centers, the relation between transplant
number and mortality is not at all reminiscent of a learning
curve (figure 4.11). When compared to the curves for 1984 and
1985 centers, the 1986 data is characterized by unexpectedly
high mortality in transplant numbers 8-10. The data set used
in this study includes relatively little information about
transplant recipients from centers that began programs in 1986
(see figure 2.1), and it would certainly be worthwhile to
reexplore this relation with more complete information
regarding 1986 start-up centers.
In the current data set however, a hint at the explanation
for this unexpected result comes from a previous analysis
(figure 3.4), which revealed that 1986 start-up centers
selected unusually high numbers of high risk patients to begin
with. Further exploration of this finding reveals the
following results:
MORTALITY IN 1986 START-UP TRANSPLANT CENTERS
TRANSPLANT # # PATIENTS # DEATHS DEATHS BY RISK GROUPS
High Mod. Low
1-5 33 2 2/19 0/3 0/11
6-10 17 8 6/14 1/1 1/2
11-15 4 1 1/2 0/2 0/0
TOTAL 54 11 9/35 1/6 1/13
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From this table, it is apparent that several factors
contribute to the unusually high mortality rates seen between
transplants 6-10 in these 1986 start-up centers. These factors
include 1) the selection of a disproportionately high number
of high risk patients between transplant numbers 6-10, 2)
unusually low mortality rates among high risk patients
transplanted between numbers 1-5, and 3) the apparently
coincidental deaths of one patient from both the moderate and
low risk groups that occurred in group of transplants from 6-
108. I can think of no clinically plausible explanation for
the concurrence of these events, but given the small numbers
of patients that underwent heart transplantation at 1986
start-up centers, I recommend further investigation of the
learning curve phenomenon using a more complete data set
before I would reject the possibility that a learning curve
could exist in 1986 start-up centers.
Is the learning curve demonstrable after the data is
stratified by important patient characteristics or immunosup-
pressive management protocols? The results suggest that
learning curve phenomena are demonstrable in moderate and high
risk patients (figures 4.16-18, 4.20, 4.22-23) but not in low
8 Another explanation-regarding the trend toward
treating transplant recipients with triple drug
immunosuppressive therapy-is discussed below.
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risk patients (figures 4.13-15, 4.19, 4.21).
For this analysis, I use three methods to stratify patients
according to risk: univariate predictors of mortality,
bivariate predictors, and the burden of illness classification
system (these three methods are described in chapter 2).
Figures 4.13 to 4.15 display the relation between cumulative
transplant experience and mortality in three categories of low
risk patients identified through univariate analysis (see
figure 2.12): these are males, patients receiving triple drug
immunosuppressive therapy, and patients having comorbid
conditions. In two of these three low risk groups, mortality
is slightly higher in the earliest transplant recipients, but
the mortality difference between these earliest recipients and
subsequent recipients is small. In the third case, mortality
is lower for transplant numbers 1-5 than it is for transplant
numbers 6-10. Both parametric and non-parametric tests suggest
there are no significant relations between transplant number
and mortality in these low risk groups. The results of similar
analyses involving other univariate predictors of low risk
also fail to reveal a learning curve phenomenon. These
analyses are available on request.
Figures 4.16 to 4.18 show the above relations for corres-
ponding categories of (univariate) high risk patients.
Learning curve phenomena are demonstrable in these three high
risk groups: mortality is highest among the earliest
transplant recipients and it declines subsequently. As noted
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in previous analyses, this family of learning curves displays
considerable variation in both the rate at which mortality
declines and the length of the transplant sequence over which
declines can be measured.
In the case of females (figure 4.16) there is a striking,
rapid decline in mortality over the first 8-10 transplants,
and this relation is highly significant. In the case of
patients not receiving triple drug therapy (figure 4.17) the
learning curve exhibits a more gradual decline, with evidence
for improvements almost through the completion of the 20-
transplant sequence. This relation also achieves statistical
significance using either parametric or non-parametric tests.
In the case of patients having comorbidities (figure 4.18) the
learning curve is difficult to appreciate over the 20-
transplant sequence, but the marked variation from transplant
to transplant suggests that sample sizes are to small to
detect a significant trend. Interestingly, when transplant
numbers are aggregated into groups of 5 in the accompanying
histogram, the learning curve phenomenon becomes apparent (and
achieves statistical significance using parametric tests).
The observation that a learning curve exists for patients
who do not receive triple drug immunosuppressive therapy, and
that it does not exist for patients who do, is very important.
Recall that in chapter 3, I noted that over the years 1984-
86, there was a significant trend toward the adaptation of
triple drug therapy. This trend provides another reasonable
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explanation for the failure to document a learning curve in
1986 start-up centers (figure 4.11) and further emphasizes the
need to restudy the 1986 learning curve issue using a more
complete data set (see previous discussion)9. And assuming
that the trend toward using triple drug therapy continued
beyond 198610 this finding also raises questions about the
applicability of these findings to current heart transplant
experience.
Figures 4.19 and 4.20 are examples of bivariate analyses.
The results of these analyses are consistent with the above
univariate analyses. Bivariate analyses generate, in a rough
sense, three strata of risk: patients can have neither, one,
or both of the "high risk" attributes. In the example shown,
the two high risk attributes are prolonged ischemic times and
preoperative mechanical support. Therefore in this analysis,
low risk patients have ischemic times less than 2 hours and
no need for preoperative mechanical support. There is no
apparent relation between cumulative experience and mortality
in these low risk patients (figure 4.19).
In the corresponding analysis for moderate risk patients
(those having exactly one of the two "high risk" attributes),
mortality declines as cumulative experience increases (figure
However, the explanation provided earlier in this
chapter appears sufficient to describe observations seen in
figure 4.11.
10 Based on personal experience, this is almost certainly
true. It would be easy to verify using updated Registry files.
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4.20). This relation is almost imperceptible in the original
20- transplant sequence, but when the data are aggregated into
groups of five, the trend is easy to detect and achieves
significance using both the Chi-Square test and the Spearman
Rank Correlation Test.
Unfortunately, only 43 patients qualify as "high risk" in
this bivariate analysis 1 . This extremely small sample size
does not permit one to detect a learning curve using the above
methods: there are, on average only slightly more than two
patients per transplant number.
The results of other bivariate analyses show similar
patterns: learning curves are generally not demonstrable in
low risk patients; a family of learning curves is demonstrable
in moderate risk patients; and small sample sizes prevent the
use of this methodology for high risk patients.
The sample size problem for high risk patients in bivariate
analyses can be overcome by using the premorbid burden of
illness classification system (developed in chapter 2) to
generate new risk classifications. When patients are
stratified according to their premorbid burden of illness, and
the above methodology is used to identify learning curves,
distinct patterns can be seen for each of the three strata.
In the low risk group (figure 4.21), there is no discernable
relation between cumulative experience and mortality. In the
11 This undoubtedly reflects clinical attempts to control
the overall mortality risk in transplant recipients.
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moderate risk group (figure 4.22), there is a steep drop in
mortality after the first 5 transplants, with no further
changes seen beyond this point. This learning curve reaches
statistical significance when the data are aggregated into
groups of five, as shown. In the high risk group (figure
4.23), there is a continuous and relatively gradual decline
in mortality over the first twenty transplants. This finding
is somewhat obscured by variation in mortality from transplant
number to transplant number due to small sample sizes, but
when the data are aggregated into groups of five, the learning
curve is easy to visualize. Once again I have demonstrated the
presence of learning curves in high and moderate risk
patients, and not in low risk patients.
Are the skills and/or knowledge obtained from the
management of low risk patients transferrable to high risk
patients? I have devised two tests for this question. Both
suggest that learning acquired while managing low risk
patients is applicable to, and can be used reduce mortality
in, high risk patients.
The two tests are based on the creation of a series of new
data sets. These sets consist of high risk patients only, with
careful attention to maintain their original transplant
sequence. To accomplish this, I use the methodology shown in
figure 4.24. The first of the two tests involves simply
displaying data from the newly created sets using the same
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format as in previous analyses throughout this chapter. By
examining the shapes of the learning curves generated in the
new data sets, I can infer whether learning from the
(currently excluded) low risk patients is transferrable to
high risk patients. If learning was transferrable, learning
curves in the new data sets would appear truncated when
compared to the curves in the original set. If learning was
not transferrable, the new learning curves would appear
similar to, or even more gradual in their slope than those in
the original data set.
The curves so generated from these new data sets (figure
4.25-4.27) in fact demonstrate that the first one or (at most)
two transplant procedures have higher mortality risk than
subsequent procedures. Beyond these very early procedures,
there appears to be no relation between transplant number and
mortality risk. As above, these truncated learning curves
suggest that knowledge and skills acquired during the
management of low risk patients is being successfully applied
to the patients high risk patients.
The second test is a somewhat stronger test of the
hypothesis that learning from low risk patients is
transferrable to the high risk population. For this test, I
used the following methodology:
1) I create subsets of high risk patients according to
their sequence in the new data set: for example, one subset
consists of all high risk patients who are first in the new
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sequence (so called "Hi" patients).
2) Then, I determine the place of each such patient in the
original sequence. Patients in all these subsets-homogenous
with respect to their position in the new data set-exhibit
striking heterogeneity with respect to their position in the
original data set12 . For example, among the subset of H1
patients having comorbidities (figure 4.25), the range of
their appearance in the original data set is from transplant
number 1 to transplant number 16 (this will be denoted as H 1 )
and H( 16) in analyses below).
3) Because of small sample size in each subset of high risk
patients, I then create 3 groups: those whose position in the
original sequence is from 1-5, those whose original position
is from 6-10, and those whose original position is >10. For
the H subgroup, the denotation for these groups is as
follows: H 1.5), H1(6 10), and Hl(>10)
4) I then determine mortality rates for each subgroup, as
shown presently:
12 The "original" data set is entire data set. It is the
one containing low and high risk patients.
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PATIENTS W/COMORBIDITIES
Transplant Number in Original Sequence
1-5
Deaths/Transplants Hi: 10/21
H2: 5/12
H3: 0/1
6-10
4/16
3/14
2/8
Transplant Number
1-5
Deaths/Transplants H1: 10/25
H2: 3/12
H3: 1/5
6-10
2/13
3/12
2/10
>10
1/4
0/6
3/14
Total (%)
15/41 (.37)
8/32 (.25)
5/23 (.22)
in Original Sequence
>10 Total (%)
0/1
0/9
2/8
12/39 (.31)
6/33 (.17)
5/23 (.22)
PATIENTS W/HIGH BURDEN OF ILLNESS
Transplant Number in Original Sequence
1-5
Deaths/Transplants H: 9/15
H2: 3/7
H3: 2/2
6-10
7/28
10/30
5/21
>10
1/5
3/8
3/17
Total (%)
17/48 (.35)
16/45 (.35)
10/40 (.25)
I performed similar analyses for the other 4
predictors of poor outcome (see figure 2.12)
univariate
and these
analyses are available on request.
The second test of the hypothesis that learning from low
risk patients is transferrable to high risk patients is
derived from this data.
Test 2: If learning was not transferrable, then one would
expect that mortality in H(1.5) would not be significantly
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FEMALES
different from mortality in H1(610) or Hl(>10). However, in the
above three examples, H1(15) mortality is greater than or equal
to the latter two subgroups. These differences do not reach
statistical significance in any of these three examples but
they warrant further investigation:
When the above two univariate analyses (comorbidities and
females) are combined with data from the remaining four
univariate analyses (mechanical support, ejection
fraction, ischemic time, and triple drug therapy; see
figure 2.12), it turns out that H1(1 5) mortality is
greater than H1(6.10) and H2(>10) mortality in 10 of the 12
cases. The probability that this observation could have
occurred given no transferrable learning is .01513 and
this strongly mitigates for rejecting this hypothesis
(and supporting the hypothesis that learning is
transferrable).
Similar analyses can be performed for the H2 and H3
subsets, and indeed for any subset beyond H3 (HX). However,
the number of patients in the HX(1. 5) category rapidly
diminishes to zero as X grows past numbers two or three. This
phenomenon substantially reduces the analytical power of this
13 The calculation for the chance of x successes in n
independent trials with z chance of success in each trial
(x=10, n=12, z=.5) is:
(1/ 2 ) [12!/10!(2) ]=66/2 =.015
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method. Nevertheless, for the H2 subset, the data shows that
H2(1 5) mortality exceeds that of H2(610) and H2(>10 ) in 9 of 12
opportunities. The probability that this could have occurred
in the absence of transferrable learning is .054. It is
therefore reasonably unlikely to have occurred by chance
alone.
In the H3 data set, H3(1. 5) exceeds the remaining two
categories in only 7 of the 12 cases. This event would occur
fully 20% of the time if indeed there were no differences
between the three groups, and there is hence no reason to
suspect transferrable learning has affected the H3 data set.
For data sets beyond H3, there is no clearcut benefit for any
of the three subsets (that is, HX(1.5), HX(6 10 ) and HX(>10) are
equally likely to exhibit the highest mortality rates).
This pattern of highly significant declines in mortality in
the H1 data set, declines of borderline significance for the
H2 data set, and no clear relation for data sets H3 and
beyond, is consistent with the earlier findings (figures 4.25-
27) and provides strong support for the hypothesis that
learning in low risk patients is transferrable to the high
risk patients.
In summary, it is possible to demonstrate learning curves
in heart transplantation. These learning curves manifest
themselves as progressive reductions in mortality with
increasing center-specific transplant experience. This
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phenomenon is readily apparent in moderate and high risk
patients, but it cannot be demonstrated in low risk patients.
The learning curve phenomenon is easy to appreciate in 1984
and 1985 centers, but is not present in 1986 centers. Although
this latter finding may be caused by small sample sizes, the
findings that:
1) learning curves are not present in patients treated with
triple drug immunosuppressive therapy, and
2) the increasing trend to use this therapy in 1986 and
beyond,
strongly warrant follow-up studies with complete, recent data.
Finally the experience of performing heart transplantation
in low risk patients appears to improve subsequent mortality
rates in high risk patients. The mechanisms and policy
implications of these important findings are reviewed in
chapter 9.
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RESEQUENCING TO ANALYZE HIGH RISK PATIENTS
(an illustration)
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CHAPTER 5
TRANSPLANT VOLUME AND MORTALITY
FOLLOWING HEART TRANSPLANTATION
(the "Volume-Outcome Relationship")
SUMMARY:
This chapter investigates the hypothesis that there is
a relation between the performance of large quantities
of heart transplant procedures and mortality following
heart transplantation.
KEY POINTS:
- There is no relation between heart transplant volume
and mortality.
The results of chapter 4 indicate there is a heart
transplant learning curve: transplant centers acquire skills
and/or knowledge as they perform their initial procedures, and
this experience allows them to improve performance in
subsequent procedures.
Recall however that the methods used to identify learning
curves lose their analytic power if they are applied to
procedures beyond the very earliest in the transplant
sequence. One is reminded for example, that the above methods
easily detected (in fact, rigorously demonstrated) a learning
curve when they were applied to an initial 20 transplant
sequence (figure 4.2). However, when these same methods were
applied to an extended sequence of 50 initial transplants from
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the same data set (figure 4.1), they were unable to detect the
phenomenon.
Beyond this, it is important to recognize that learning
curves are not the only way to conceive of experience: other
descriptors, or proxies, exist as well. One of the simplest
and most commonly used proxy for experience is volume, the
total number of repetitions of a function or task. Although
these two proxies reflect in many cases the same
manifestations of experience, there are some important
conceptual differences between them. Learning curves tend to
emphasize a dynamic process by which providers acquire skills
and/or knowledge: the provider learns with each repetition,
but the increment learned decreases as the level of
accumulated knowledge and/or skills grows. In this model,
incremental learning eventually decays to zero and a steady
state performance results.
The volume proxy in effect assumes the provider has already
achieved this steady state, and instead it tends to emphasize
scale: centers that have produced high volumes of certain
procedures (and that are likely to produce high volumes in the
future) can reorganize their care processes, hire or train
specialists and make capital investments that in combination
result in improved outcomes.
As one considers these conceptual differences, it is well
to remember that Federal heart transplant policy (as it
relates to experience) focuses on volume-not learning curves-
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as the proxy for experience. Federal heart transplant policy
focuses on volume for the compelling reason that the volume-
outcome phenomenon has been intensively studied and well
documented for many activities in health carel. Investigators
in this field have focused primarily on surgical procedure
volume and its relation to procedure-specific mortality. Most
of these investigators have demonstrated that "high volume"
centers are characterized by relatively low mortality rates
for the procedures in question (32-35).
However, no study has to date documented such a relation in
heart transplantation, or for that matter in any form of organ
transplantation. Obviously there is a need to document the
existence of such a relation in heart transplantation, and if
it does exist, to distinguish it in some way from the
previously documented learning curve phenomena. Therein lies
the goal of this chapter.
I will begin by briefly reviewing the "volume-outcome"
literature in health care, and then continue by analyzing my
data set to determine whether a volume-outcome relation exists
in heart transplantation. I conclude with some further
1 And, as mentioned in chapter 4, the medical literature
on learning curves is not nearly as well developed. I cannot
explain why the latter proxy has received comparatively little
attention from the research community. Certainly simple
analytical methods exist to study learning curves, as shown
in chapter 4. It is equally clear that health care providers
implicitly believe learning curves do exist for countless
varieties of procedures in health care. I can only comment
that this appears to be a fruitful area for research in the
future.
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observations about volume-outcome relationships in non-cardiac
organ transplantation.
VOLUME-OUTCOME STUDIES IN MEDICINE:
A REVIEW OF THE LITERATURE
Investigators have found inverse correlations between
procedure volume and procedure-specific mortality (the
classical, expected "volume-outcome" relationship) to exist
for a wide variety of surgical procedures. These include:
abdominal aortic aneurysm repair, vascular surgery, biliary
tract surgery, appendectomy, coronary artery bypass grafting,
total hip replacement, prostatectomy, gastric operations,
intestinal operations and hysterectomy. Similar correlations
have also been found for non-surgical conditions such as
cardiac catheterization and acute myocardial infarction
(although as discussed below, the findings are not as
compelling for non-surgical conditions-see reference 31)2.
The nature of this inverse relation varies by procedure.
For example, Luft (32) has shown that for coronary artery
bypass grafting, the relation is linear: centers that perform
low volumes of bypass have the highest mortality; as center
2 Luft and colleagues recently reviewed the entire
volume-outcome literature in detail. To obtain more detail,
the reader should refer to this superb review:
Luft HS, Garnick DW, Mark D, McPhee SJ; Evaluating
Research on the use of Volume of Services Performed in
Hospitals or by Physicians as an Indicator of Quality;
Contractor Document: Office of Technology Assessment;
U.S. Congress; Washington, D. C.; 1987.
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volume increases, mortality decreases steadily over the entire
range of center volumes. For other procedures such as
appendectomy, the relation is curvilinear (35): as center
volumes increase from very low to low levels, the above
inverse relation between volume and mortality is apparent;
however, as appendectomy volumes increase from moderate to
high levels, no further mortality reductions can be
demonstrated.
In characterizing procedures for which a linear volume-
outcome relation can be demonstrated, Luft and others (32-37)
point out that the slope of this line is procedure dependent.
For vascular surgery, eg, the slope is -0.00016
deaths/procedure: on average, a 100 procedure volume increment
results in a 1.6% mortality decrease. For transurethral
resection of the prostate, the slope of this line is -0.000015
deaths/procedure: the "volume effect" is less apparent.
In characterizing procedures for which curvilinear
relations can be demonstrated, investigators point out that
the inflection point varies by procedure. For abdominal aortic
aneurysm repair, eg, centers performing an annual volume of
50 procedures have roughly the same mortality as centers
performing any number greater than this, but an inverse
volume-outcome relation is apparent below 50 procedures. For
pyloroplasty, this inflection is reached at a procedure volume
of about five.
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Interestingly, these studies also suggest that:
1) Procedure complexity does not predict the
relation between volume and outcome. Thus on one hand,
complex operations such as coronary artery bypass graft
surgery and vascular procedures and simple operations
such as prostatectomy are characterized by a linear
relation. On the other hand, other operations-both simple
and complex-are associated with curvilinear relations.
2) The type of surgery also does not predict the
form of the volume-outcome relation. Thus, coronary
artery bypass grafting and abdominal aortic aneurysm
repair are both vascular procedures, but the former
displays a linear relation, and the latter displays a
curvilinear relation.
Perhaps overshadowing these observations, investigators
using different data sets have not been able to replicate all
the findings mentioned above. Consider coronary artery bypass
grafting, the procedure examined most commonly in volume-
outcome studies. Most investigators have demonstrated a linear
volume-outcome relation for this procedure. However, three
studies have demonstrated a curvilinear relation, two have
demonstrated a parabolic relation (in which mortality
declined, then increased as volume increased) and two were
unable to demonstrate any relation between volume and outcome
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(31). Equally important, there remain some surgical procedures
(repair of femoral fractures and herniorrhaphy, for example)
for which investigators have failed more often than not to
demonstrate any volume-outcome relation (31).
Volume-Outcome Relations and the Regionalization of Medical
Care-Health care planners and policymakers are particularly
interested in the results of volume-outcome studies. If these
studies had demonstrated consistent, reproducible patterns,
then policymakers would have a strong rationale to regionalize
care and so increase volume at specified centers.
Unfortunately the above inconsistencies in the literature
have to date prevented policymakers from generating an
airtight case-at least as it relates to the quality of care-
for regionalization. Another rationale for regionalizing
certain medical procedures (and simultaneously increasing
procedure volume at the designated centers) is that this would
result in cost savings due to economies of scale. However
despite its obvious appeal, there is little empirical evidence
in health care to support this rationale.
But whatever the rationale for regionalization, proponents
of the regionalization of health care technologies face
several important implementation challenges. First, existing
volume-outcome studies have not enabled investigators to
determine whether these relationships are due to increased
experience ("practice makes perfect") or whether the existing
referral system directs patients to providers proven to have
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better outcomes (31, 37-39).
This unanswered question carries enormous implications for
health care policymakers, and particularly those who have
struggled to formulate heart transplant policy3 . Had
investigators demonstrated that "practice made perfect", then
regionalization strategies should include a process for
selecting centers on a geographical basis and then assuring
that they perform large numbers of procedures. Had
investigators demonstrated selective referral patterns, then
regionalization strategies should simply identify the most
proficient centers and designate them (2,31).
The second major challenge facing regionalization
strategies (that maximize the "volume benefit") is that
procedure volume simply does not tell the whole story about
health care outcomes. Not all high-volume centers have good
outcomes, and not all low volume centers have poor outcomes
(see for example, figure 2.2, chapter 2). The phenomenon in
which a cohort of centers having similar procedure volumes
displays considerable variation in outcomes is particularly
evident among cohorts having low procedure volumes (see figure
2.2).
The explanation for this effect is that there is inherent
variability across patients-even with similar diagnoses and
treatments-and when this inherent variability is coupled with
I provide details of heart transplant policy in the
Introduction and in chapter 9.
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the relatively low rate of adverse outcomes, it becomes
statistically difficult (at the level of the individual
center) to separate poor performance from random noise in the
data. Thus while large data sets and advanced statistical
methods can be used to identify the correlation between volume
and outcome, they in many cases do not explain performance at
the individual center4
Yet a third issue on the subject of implementing region-
alization policies: it is unclear that centers could cope with
the relatively sudden increases in procedure volume that would
follow the implementation of such policies. Centers that have
achieved excellent results have done so precisely because they
have implemented processes that can be executed flawlessly
given a certain procedure volume. Stepwise increases in volume
could place pressures on these processes that they were not
designed to handle.
Policymakers would also require answers to several
additional questions before they could effectively use the
volume-outcome literature as a basis to formulate
regionalization policy. For example, what is the mechanism by
which volume-related outcome benefits are mediated? Do high
volumes improve performance of the surgeon, the
anesthesiologist, recovery room staff, or other personnel in
A thorough explanation of this issue appears in:
Luft HS, & Hunt SS; Evaluating Individual Hospital
Quality Through Outcome Statistics; Journal of the
American Medical Association; (255)2780-84.
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the hospital (31)? Do they simply justify the purchase of
specially designed equipment and materials, the recruitment
of specialized or highly trained personnel? Or do they
encourage hospital personnel to spend time analyzing and
improving the processes by which care plans are executed?
The Volume-Outcome Relationship in Heart Transplantation:
More Unanswered Questions-The above literature leaves two more
questions unanswered, and these questions are particularly
relevant to heart transplantation. The first question is,
"What is the relation between volume and outcome in 'medical'
(i.e. non-surgical) patients?"
The volume-outcome literature is nearly devoid of articles
that demonstrate such relations for medical patients. For
example, there are only four published articles concerning
volume-outcome relations in acute myocardial infarction. Two
of these show that high volume centers do better, one shows
that high volume centers do worse, and the final one shows no
correlation at all (31).
One explanation for the inability to demonstrate volume-
outcome relations in medical conditions is that methodological
problems prevent them from being detected. It is far more
difficult to code the medical records of non-surgical patients
than it is to do so for surgical patients. This makes it hard
for investigators to develop the precise classification
systems required to carry out volume-outcome research. Coding
difficulties arise because "medical" patients have more
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complex and less predictable courses in the hospital. In
addition, they are characterized by multiple diagnoses,
coexisting conditions, and reasons for admission to the
hospital.
Another explanation is that the confounding features of
"medical" conditions and the intricate, highly individualized
medical care processes they engender, fundamentally change the
relation between experience and outcome such that the expected
volume-outcome relations simply do not exist.
The reason why this is important is that the management of
heart transplant recipients is dominated after the first
several days by non-surgical issues. Recall for example that
such patients require lifetime therapy with toxic
immunosuppressive drugs, and that the major causes of death
following heart transplantation are infection and rejection-
conditions which are treated medically5
The second question is, "What is the effect of experiences
that are acquired during the performance of technically
similar procedures?" Recall that most "heart transplant
surgeons" perform many more coronary artery bypass operations
each year than they do heart transplants. Bypass procedures
are technically similar to the heart transplant procedure (and
An obvious place to look for insights regarding this
question is the volume-outcome literature for non-cardiac
organ transplantation. In fact, there is a rather well-
developed volume-outcome literature for kidney
transplantation. I have chosen to review this (at the end of
this chapter) following a review of this study's results.
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most cardiovascular surgeons believe the former are actually
more demanding than the latter). It is extremely likely that
"transplant surgeons" generate knowledge and/or skills as a
result of performing bypass operations that can be generalized
to the transplant procedure. This certainly could affect the
relation between heart transplant volume and mortality
following the transplant procedure. It is with these ideas and
concepts in mind that I now present the findings of this
study.
THE VOLUME-OUTCOME RELATIONSHIP IN HEART TRANSPLANTATION:
RESULTS OF THIS STUDY
During the years 1984-1986, United States heart transplant
centers displayed wide variation in transplant volume-the
total number of transplants performed per center (figure 5.1).
Specifically, transplant volume per center ranged from 207,
at the University of Pittsburgh, to one at several centers.
As shown in figure 2.2 (chapter 2), center-specific
transplant volume during the three year study period is not
correlated with mortality (r=-.04; t(df60)=.276; p=.78[NS]).
This finding is extremely important in that it is not
consistent with the majority of findings in the literature,
and that it does not support Medicare guidelines for the
certification of heart transplant centers. Therefore, I will
explore this finding in some detail, and in particular I will
explore the possibility that a true volume-outcome relation
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may somehow be hidden in this broad analysis.
It is possible, for example, that the effects of cumulative
experience (discussed in chapter 4) may have biased this
analysis. This is because low volume centers will have a
higher proportion of recipients that have undergone
transplantation before the centers have accumulated skills and
knowledge pertaining to the transplant procedure. I explore
this possibility by omitting the results from the first 10
transplants at all centers, and then repeating the above
analysis. The resulting scatter diagram (figure 5.2) also
shows no clear relation between total transplant volume and
mortality, and the correlation coefficient remains extremely
low and not significant6
It is also possible that a valid volume-outcome relation
could be present in certain subsets of the data set, but not
in others. I explore this possibility by performing separate
analyses for several representative subsets, and the results
again show no demonstrable volume-outcome relationship. I will
review these results in detail presently.
6 NOTE: The remaining scatter diagrams in this chapter
include all patients, not just those beyond transplant number
10. However in all cases, I did run similar analyses in which
I omitted these first 10 transplants. In no case did this
technique expose a volume-outcome relation when it was not
present in the analysis of the complete data set. In one case,
discussed below, omitting the first 10 transplants from the
analysis actually obliterated a strong trend towards a
significant volume-outcome relation.
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Figures 5.3 and 5.4 show separate analyses for centers that
began performing heart transplants in 1984 and 1985,
respectively. There is no volume-outcome correlation in either
subset. Interestingly, there is a strong trend in the expected
direction (low volumes, high mortality) in the 1985 data set
(r=-.36; t(df=27)= 1.99; p=.06[NS]). However, when I eliminate
transplant numbers 1-10 and repeat the analysis, the strong
trend disappears to a large degree (r=-.29; t(df=12)=l.44;
p=.21[NS]).
As discussed earlier, the technique of removing from the
analysis all transplants that were performed early in each
center's sequence has the effect of eliminating the
confounding effects of the learning curve phenomenon. As
demonstrated in this particular case, it also reduces sample
size by eliminating all centers that performed less than ten
transplants in total. It is worth repeating that at these low
volume centers, it is statistically difficult to separate poor
performance from random noise in the data and this provides
another reason to run parallel analyses (such as this one)
that specifically eliminate this "end effect".
Figures 5.5 and 5.6 are scatter diagrams displaying once
again a lack of correlation between heart transplant volume
and mortality. In this case, the subsets are males and
females, respectively. Interestingly, there is a strong trend
towards a direct relation (high volume, high mortality) in the
female subgroup (r=.25; t(df=53)=l.85; p=.07[NS], see figure
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5.6). However, it is apparent that this "trend" is largely
driven by one aberrant observation. When I eliminate this
observation and repeat the analysis, the "trend" vanishes
completely (r=.06; t(df=52)=.49 ; p=.63[NS]).
This aberrant observation comes from the University of
Pittsburgh, which had the highest total transplant volume
during the study period. I doubt this represents a coding
error, but I can think of no plausible explanation for high
mortality among females at this particular center.
Figures 5.7 to 5.13 provide additional proof that there is
no relation between heart transplant volume and mortality.
These figures represent further subset analyses, including
patients treated with and without triple drug
immunosuppressive therapy, patients having and not having
comorbid conditions, and patients with a low, moderate and
high burden of illness. Analyses of other patient subsets also
show no relationship, and these are available on request.
As a final test of the relation between total transplant
volume and mortality, I reaggregate the center-specific data
into three larger groups: high volume centers, moderate volume
centers, and low volume centers. This technique minimizes the
statistical difficulties (described earlier) associated with
the assessment of quality at low volume centers.
In the "high volume" category, I include the top five
centers in terms of transplant volume during the study period
(see figure 5.1). These five centers performed between 91-207
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transplants per center over the study period (for a total of
643), and all had completed at least 20 transplants prior to
1984. In the "low volume" category, I include the 40 centers
that performed the fewest transplants per center over the
study period. No center in this category performed more than
25 transplants in total, and 24 of them performed less than
10 transplants in total. This group transplanted a total of
410 patients during the study period. The remaining 25 centers
constitute the "moderate volume" category. This group
performed 952 transplants between 1984-1986.
The results are as follows:
MORTALITY FOLLOWING HEART TRANSPLANTATION (%):
HIGH, MODERATE AND LOW VOLUME CENTERS
OVERALL MORTALITY:
High Volume 15 (643)
Moderate Volume 12 (952)
Low Volume 19 (410)
VOLUME CATEGORY MALE FEMALE
High 13 (558) 28 (85)
Moderate 12 (818) 20 (134)
Low 19 (346) 22 (64)
USE 3 DRUG NOT USED
High 11 (266) 19 (377)
Moderate 10 (576) 20 (376)
Low 15 (230) 25 (180)
-CONTINUED ON NEXT PAGE-
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NO COMORBIDITIES COMORBIDITIES
High 15 (572) 17 (371)
Moderate 13 (678) 24 (274)
Low 17 (362) 29 (48)
LOW BURDEN MODERATE BURDEN H I G H
BURDEN
High 13 (94) 12 (147) 19 (156)
Moderate 14 (144) 15 (119) 18 (130)
Low 11 (92) 17 (94) 25 (147)
As one can see, overall mortality is 15% in the high volume
centers, 12% in the moderate volume centers and 19% in the low
volume centers. There are no significant differences between
the mortality rates in these groups, and the absence of a
trend toward decreasing mortality with increasing transplant
volume is yet another piece of evidence mitigating against a
significant volume-outcome relation in heart transplantation.
Upon closer inspection, one notes that low volume center
mortality rates are highest in all but two of the
subcategories shown (females, and low burden of illness).
However, based on previous analyses, it is reasonable to
attribute this effect to learning curve phenomena. And of
great importance, these subgroup analyses reveal no consistent
relation between mortality rates at moderate and high volume
centers, respectively. Once again, there is no evidence to
support the existence of a volume-outcome relation in heart
transplantation.
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PICKING UP THE PIECES:
THE VOLUME-OUTCOME RELATION IN NON-CARDIAC ORGAN
TRANSPLANTATION
In sum, there is little doubt that volume-outcome relations
do not exist in this data set. This finding is to some extent
unexpected, as most studies of surgical procedures suggest
that such relations are present. It carries important
implications for Medicare heart transplant center designation
policies, because they are based on an apparently invalid
assumption that such relations do exist. Should this finding
have come as such a surprise? Perhaps not!
It turns out that there is a relatively well-developed
volume-outcome literature covering the field of non-cardiac
organ trans-plantation (primarily kidney transplantation), and
not one study in this literature could demonstrate significant
correlations. (In fairness to Medicare policymakers, several
of the most important articles in this field became available
after they formulated their policies)7
For example Opelz et. al. (9a) in an early study, found no
evidence that one-year graft survival rates were lower in low
volume kidney transplant centers. Many centers in this study
7 A detailed review of this literature is provided in:
Sloan FA, Shayne MW, Doyle MD; Is There a Rationale for
Regionalizing Organ Transplantation Services?; in
Blumstein JF, Sloan FA, eds.; Organ Transplantation
Policy; Duke University Press; Durham, 1989.
My review of this subject is largely based upon this
reference.
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was characterized by low transplant volumes and hence high
variations in outcomes. Opelz' group attributed these
variations to random fluctuations. The authors did not account
for other factors that could affect graft survival in this
study.
Krakauer et. al. (9b, 9c) used a Cox proportional hazards
model and found significant "center effects" existed and these
persisted after controlling for patient and donor
characteristics such as the use of cyclosporine, race,
recipient age, blood transfusions prior to transplantation and
tissue match. However, these effects could not be attributed
to volume differences between centers.
Cicciarelli (7) assessed graft survival at 80 centers that
had performed at least 100 kidney transplants. He classified
centers into three categories according to their graft
survival rates-excellent (>55%), good (45-55%), and fair
(<45%). He found that "excellent" centers utilized
pretransplant blood transfusions more frequently, tissue typed
at the DR locus in a higher percentage of their patients, and
matched HLA-A,B histocompatibility loci comparatively
frequently 8. These procedural differences were sufficient to
explain the "center effect" in this group of centers that was
8 In a parallel finding of great interest, Cicciarelli
found that cyclosporine therapy resulted in an increase in
graft survival in excellent centers, but had a neutral effect
in fair centers. This finding suggests that excellent centers
are characterized by learning curves with respect to the use
of cyclosporine.
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relatively homogenous with respect to volume.
Benlahrache et. al. (9d) applied methodologies similar to
Cicciarelli's, but they used a data set that was more recent
and that included more low volume centers. They were able to
confirm Cicciarelli's findings using this data set, and they
also showed that center-specific graft survival was not
affected by center-specific (first) transplant volume.
Finally, Held et. al. (9) very directly assessed the effect
of kidney transplant volume on patient and graft survival
after controlling for more than a dozen characteristics of
patient, donor and center. The authors used a set of binary
variables to represent the number of transplants performed per
year at each center. The parameter estimates for the volume
variables were small, and in all cases the standard errors
exceeded the parameter estimates.
With this literature in mind, the results of the present
study appear somewhat less surprising. In fact, given that:
1) heart transplant surgeons readily admit that these
procedures are technically simpler than the coronary bypass
procedures and that,
2) they perform the latter with far more regularity than
heart transplantation, and that
3) medical follow-up for heart transplant recipients is
complex and prolonged,
it might be reasonable to classify heart transplantation not
as an exception to the otherwise consistent volume-outcome
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literature for surgical procedures, but as another example of
a medical procedure for which volumes and outcomes do not
appear to be correlated. I will develop this discussion
further in chapter 9.
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figure 5.1
TRANSPLANT VOLUME VARIATIONS
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figure 5.2
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TRANSPLANT VOLUME AND MORTALITY
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TRANSPLANT VOLUME AND MORTALITY
(in patients not receiving triple drug immunosuppressive therapy)
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TRANSPLANT VOLUME AND MORTALITY
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TRANSPLANT VOLUME AND MORTALITY
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TRANSPLANT VOLUME AND MORTALITY
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CHAPTER 6
PROCEDURE FREOUENCY AND MORTALITY
FOLLOWING HEART TRANSPLANTATION
SUMMARY:
This chapter investigates the hypothesis that the rate
at which heart transplants are performed is associated
with mortality.
KEY POINTS:
- The rate at which centers perform heart transplants
accelerates with increasing transplant number.
- Over the range of observed transplant rates, there is
no relation between transplant rate and mortality.
Results presented in chapter 5 suggest there is no relation
between heart transplant volume (defined as the total number
of transplant procedures) and mortality. Transplant rate is
a measure of experience that is closely related to transplant
volume. It is defined as the number of transplants performed
per unit time. In this chapter, I explore the relation between
heart transplant rate and mortality following the procedure.
Many investigators have appropriately chosen not to
distinguish between these two indices of experience. It is not
necessary to make the distinction when studying technologies
for which indications have been well established, and for
which utilization does not change over time. When procedure
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volumes remain constant over time, one gleans no additional
information by using the rate proxy (volume/time) versus the
volume proxy alone1.
In a study of heart transplantation between the years 1984-
86 however, it is necessary to distinguish between these two
proxies. This is because utilization nearly doubled over this
three year period (figure 3.1) and as shown below, this
overall increase reflects in part an accelerating transplant
rate at existing centers2. In addition, there is reason to
believe that the rate at which centers perform heart
transplants can affect their ability to benefit from previous
experience. For example, high transplant rates may afford
providers the opportunity to practice transplant-specific
skills, and diminish the possibility that these skills will
extinguish over time. In addition, high rates may encourage
providers to experiment with new procedures and techniques
that could lead to improved outcomes. They may stimulate
1 Interestingly, Luft and colleagues actually utilized
a measure of procedure rate in their seminal article on the
"volume-outcome" relationship (4)! They compared "annual
procedure volume" with mortality.
2 From an analytical standpoint, technologies exhibiting
a changing procedure rate are difficult study because there
is no easy way to determine whether outcomes in a particular
period are referable to volumes in that period or to volumes
in an earlier period. This problem is, of course, eliminated
when procedure volume remains constant over time.
(Again one is struck by the excellent fit, at a conceptual
level, between the learning curve proxy and the dynamic events
surrounding heart transplant technology circa 1984-86.)
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providers to learn about the technology more quickly and more
thoroughly than they otherwise would have done. They may
provide justification for providers to purchase specially
designed equipment and materials. Finally, they may facilitate
the recruitment of specialized or highly trained personnel,
or the development of better protocols for the management of
transplant recipients.
On the other hand, high transplant rates may place
excessive demands on transplant team members and increase the
likelihood that miscommunications will occur and that critical
information will be overlooked or misinterpreted.
To investigate the relation between heart transplant
procedure rate and mortality, I calculate the MEAN
INTERTRANSPLANT INTERVAL for each center. This measure of
procedure rate is equal to the number of days between the
first and last transplant divided by the total number of
transplants performed during the study period. Short
intertransplant intervals reflect high transplant rates.
After determining the mean intertransplant interval for
each center in the data set, I find that indeed there is a
strong positive correlation between this interval and center-
specific mortality, as shown in figure 6.1 (r=.35; t(df=65)=2.98;
p<.005): mortality declines as procedure rate increases.
However, as was the case in chapter 5, I must generate
secondary analyses which control for the concurrent effects
of cumulative experience. This is because transplant rate and
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cumulative experience are almost certainly related to each
other3.
For these secondary analyses, I again limit study to "new"
transplant centers: those first offering the transplant
service during 1984-86. In this cohort, I generate subsets
having identical levels of cumulative experience. I then
divide each subset into quartiles according to their
transplant rates, and calculate mortality for each quartile.
I repeat this analysis of rate in subsets matched for the
experience gained through transplant numbers 6 , 11, and 21.
For example, a group of transplant centers can be thought
of as having achieved identical levels of cumulative
experience at the point when each has completed its sixth
transplant4 (regardless of the specific date when this occurs
and regardless of the date when each center began its
program). However, the centers in this group will differ in
the rate at which they achieved this level of experience. If
3 To understand why these variables are almost certainly
related, recall that many centers have patients awaiting heart
transplantation. When a donor organ becomes available, an
organ procurement agency determines which patient should
receive it. The agency selects the "proper" patient on the
basis of its careful review of the waiting lists from all
transplant centers affiliated with that agency. New transplant
centers have relatively few candidates on their waiting lists,
so a patient from these centers is not likely to be chosen.
As a consequence, new centers are likely to experience low
transplant rates. However as these new centers evaluate and
list more patients, someone from their lists is more likely
to be selected, and hence their transplant rate increases.
4 The equivalent of five intertransplant intervals.
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rate is an important determinant of mortality, then the mean
intertransplant interval should be correlated with mortality
in these centers that are matched for cumulative experience.
The results of this analysis are as follows:
1) Intertransplant intervals vary dramatically from center
to center. Figure 6.2, a sample of raw data from 1984 start-
up centers, shows this variation. Figure 6.3 summarizes the
results of this analysis for the entire set. The latter shows
for example, that over the period in which centers performed
their first six heart transplants (five intertransplant
intervals), 1984 start-up centers had a mean intertransplant
interval of 56 days, with a range of 23-83 days.
2) Despite this considerable variation, centers display a
significant decrease in the mean intertransplant interval over
the three periods mentioned above (transplant intervals 1-6,
6-11, 11-21, see figure 6.3) 5 . Further evidence in support of
this finding includes:
- Of the 19 centers for which intertransplant intervals
can be determined for all three periods, 12 exhibit a
pattern of continuing transplant rate acceleration over
these periods.
- All but 2 centers experience their longest intertran-
5 Z (U(1.6)-U 6.1 1 )) = 2.26; p<.05. Other comparisons of the
mean intertransp ant intervals presented in figure 6.3 also
show that the results are highly unlikely to have occurred by
chance.
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splant intervals in the first period (transplants 1-6).
- Of the 12 centers for which data is available only
through the second period, 9 exhibit accelerating
transplant rates from the first to the second period.
3) The relative rates at which centers perform transplants
do not remain fixed from period to period (figure 6.4). For
example, the intertransplant interval of center 30 is among
the shortest during the second period (transplant numbers 6-
11), but it is among the longest during the subsequent period
(transplant numbers 11-21).
4) There is no apparent relation between the
intertransplant interval (ie. transplant rate) and mortality
when the effects of cumulative experience are controlled. This
is seen most clearly in figure 6.4. This figure shows six
separate analyses of the relation between transplant rate and
mortality in subgroups having identical levels of cumulative
experience. If transplant rate did have an independent effect
on mortality, then one would expect a fairly consistent
pattern such that centers in the fastest quartile (those with
the fastest transplant rates) would have the lowest mortality.
This pattern is not present. In fact, in only one of the
six analyses (1985 start-up centers, transplants number 1-6)
do centers in the fastest quartile experience the lowest
mortality rates. In the remaining five analyses, centers in
the remaining three quartiles all share honors at least once
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for having the lowest mortality rates. At the other extreme,
centers having the longest intertransplant intervals did have
the highest mortality in three of the six analyses, but in
another, these centers exhibited the lowest mortality6
In conclusion, there is a correlation between transplant
rate and mortality (figure 6.1). This correlation is mediated
by cumulative transplant experience. There is no evidence to
suggest that transplant rate has an independent, causal effect
on mortality following heart transplantation. The evidence
suggests in contrast, that cumulative experience affects both
transplant rate and transplant mortality. The relations
between transplant number (the marker for cumulative
transplant experience), transplant rate and transplant
mortality are summarized in figure 6.5.
It remains possible that transplant rates faster or slower
than those registered between 1984-1986 might yet be
associated with transplant mortality, and this possibility
should be investigated using more recent data sets.
6 This inconsistent relation between transplant rate and
mortality is not clarified by simply selecting a different
range of transplants over which to measure the transplant
rate. For example, I performed the above analyses for
transplant intervals such as 1-11, 5-16, and 1-21 (these are
available on request). As expected from result #3 above, such
changes do scramble the quartiles in which centers fall.
However, the mortality figures for these newly defined
quartiles still do not suggest there is a consistent relation
between transplant rate and mortality.
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figure 6.1
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FIGURE 6.2
INTERTRANSPLANT INTERVALS:
A SAMPLE OF THE DATA
CENTER: INTERTRANSPLANT INTERVAL
(in days)
1-6
31: 83
32: 35
33: 31
34:
35:
6-11 11-21 <---transplant
number
41
25 18
71
16
36: 35
13 12
28
37: 56
38: 36
27
21
14
18
39: 43
* "---" Indicates that data is not available for this particular
transplant sequence. Missing data may indicate that a center that
has not completed the specified sequence. It may also result from
a center that has completed the sequence but has not sent updated
information to the Registry.
FIGURE 6.2
INTERTRANSPLANT INTERVALS
(summary statistics)
1984 1985
Transplant Number 1-6
Mean:
Median:
Range:
St. Dev.:
56
51
23-83
18
Mean:
Median:
Range:
St. Dev.:
50
48
15-136
24
Transplant Number 6-11
39
35
12-72
17
Mean:
Median:
Range:
St. Dev.:
Transplant Number 11-21
24
18
12-41
9
Mean:
Median:
Range:
St. Dev.:
160,
Mean:
Median:
Range:
St. Dev:
26
25
9-72
15
Mean:
Median:
Range:
St. Dev.:
14
13
8-19
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FIGURE 6.4
TRANSPLANT RATE AND MORTALITY
1984 Start-Up Centers
Transplant Number 1-6
Quartiles Center Number
1 (fastest): 21, 22, 30, 40
2 16, 18, 19, 25
3 20, 23, 26, 27
4 (slowest): 15, 17, 24, 43
90-day mortality %
(transplants 6-8)
9 (n=12)
0
15
22
Transplant Number
Quartiles
1 (fastest):
2
3
4 (slowest):
6-11
Center Number
16, 26, 27, 30
15, 18, 22, 40
20, 23, 25, 43
17, 21, 24,
90-day mortality %
(transplants 11-13)
27 (n=12)
8
9
11
Transplant Number 11-21
Quartiles Center Number
1 (fastest): 16, 24, 27,
2 20, 26, 40,
3 15, 18, 23,
4 (slowest): 22, 29, 30,
90-day mortality %
(transplants 21-25)
17 (n=12)
18
17
18
1985 Start-Up Centers
Transplant Number
Quartiles
1 (fastest):
2
3
4 (slowest):
Transplant Number
Quartiles
1 (fastest):
2
3
4 (slowest):
Transplant Number
Quartiles
1 (fastest):
2
3
4 (slowest):
1-6
Center Number
35, 49, 55, 56,
32, 33, 36, 38,
37, 39, 44, 46,
31, 34, 48, 50
6-11
Center Number
35, 44, 56, 65
33, 38, 49,
36, 37, 51, 55
32, 50, 61,
11-21
Center Number
56,
35, 55,
33, 49,
65,
90-day mortality %
(transplants 6-8)
65 7 (n=15)
61 8
51 15
54, 47 17
90-day mortality %
(transplants 11-13)
7 (n=12)
17
23
0
90-day mortality %
(transplants 21-25)
7 (n=8)
8
0
15
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Figure 6.5
RELATIONS BETWEEN CUMULATIVE EXPERIENCE,
TRANSPLANT RATE AND MORTALITY
TRANSPLANT NUMBER
(Reflects Cumulative Experience)
INTERTRANSPLANT INTERVAL -> TRANSPLANT MORTALITY
(Reflects Transplant Rate)
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CHAPTER 7
CENTER CHARACTERISTICS AND MORTALITY
FOLLOWING HEART TRANSPLANTATION
SUMMARY:
This chapter investigates the hypothesis that structural
characteristics of new transplant centers are related to
mortality following heart transplantation.
KEY POINTS:
- Structural characteristics of transplant centers vary
considerably.
- Of the 9 center characteristics tested in this study,
all but two are not related to mortality following heart
transplantation. The two characteristics of transplant
centers that are related to mortality are: prior training
of transplant cardiologists, and prior training of
transplant coordinators.
Modern medical quality science asserts that structural
elements of health care organizations have a direct bearing
on the outcomes of patient encounters with that organization1 .
In attempting to apply this logic to the field of heart
transplantation, one might reasonably expect that several
characteristics of transplant centers would affect outcomes
1 There is ample proof of this assertion. See for
example:
Donabedian A; Explorations in Quality Assessment and
Monitoring; Volumes I-III; Health Administration Press;
Ann Arbor, Mi.; 1980.
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from the transplant procedure. These characteristics might
include, among others, the presence of sophisticated
diagnostic equipment, broad-based consultative services,
expertise in transplant immunology, and large, active
catheterization laboratories and open heart surgical programs.
In fact, Medicare's designated center coverage policy,
which is designed to maximize outcomes from the scarce donor
organ supply, is based on the assumption that there is a
relation between certain such characteristics and mortality
following heart transplantation. For example, it contains
criteria regarding transplant team structure, interactions
with allied subspecialties, the volume of open heart surgery
and cardiac catheterization programs, and the presence of
certain laboratory facilities (10). Unfortunately, to date
there exists no empirical data to support these assumptions2
This set of circumstances (ample proof outside the field of
heart transplantation that there is a relation between the
structural characteristics of health care providers and their
outcomes, combined with federal policies based on the
assumption that such relations exist for heart
transplantation) is reminiscent of the volume-outcome
situation described in chapter 5. However, as I described in
that chapter, I found no empiric support for the putative
2 I discuss Federal heart transplant policies in the
introduction and in chapter 9.
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heart transplant volume-outcome relation. This underscores a
necessity to study the relation between the structural
characteristics of heart transplant centers and transplant
mortality, and this is indeed the goal of the present chapter.
I have chosen once again to focus my analyses on "new"
heart transplant centers-those that initiated their programs
during the study period (1984-86). I do so to test the
validity of the "gatekeeper" function of the aforementioned
federal regulations which require that new centers meet
certain criteria before they are designated for reimbursement
by Medicare.
Not surprisingly, the structural characteristics of these
new centers are strikingly variable (figure 7.1). Among the
notable findings:
1) 70% of these centers had preexisting kidney transplant
programs at the time their heart transplant programs began,
2) 63% were members of the Council of Teaching Hospitals,
3) Their annual open heart surgical volumes varied from 94-
3,700 cases,
4) Their annual cardiac catheterization volumes varied from
180-6,193 cases,
5) Hospital admissions in 1985 ranged from 9,376 to 47,779,
6) Surgeons managed transplant recipients'
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immunosuppressive therapy in 63% of new transplant programs3,
7) The percentage of transplant centers that began programs
with cardiologists, surgeons, or transplant coordinators
possessing prior transplant experience was 25%, 43%, and 22%,
respectively.
Interestingly, of the nine structural characteristics for
which data is available, univariate analyses reveal that only
one is significantly correlated with heart transplant
mortality: this variable is the presence or absence of prior
training on the part of transplant cardiologists (mortality
with prior training: 7%, without prior training: 16%, p<.001;
see figure 7.2).
A closely related variable, the presence of prior training
on the part of transplant coordinators, exhibits a strong
trend in the same direction, but it does not quite reach
conventional standards for statistical significance (mortality
with prior training: 11%, without prior training: 16%, p=.07)
in this univariate test4. The comparable analysis of prior
training among transplant surgeons reveals no significant
effect.
To confirm and extend these findings, I perform bivariate
3 It would be more precise to describe this as a
procedural (not a structural) characteristic of transplant
centers, much like the use or non-use of triple drug therapy.
However, I discuss it in this chapter because it is an
attribute that is clearly referable to transplant centers.
4 However, bivariate analyses described below do suggest
that prior training of transplant coordinators is significant.
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analyses in which I stratify each center characteristic by the
overall burden of illness, the year of transplant, cumulative
experience and (for the "prior training" variables) certain
patient characteristics (figures 7.3-7.11). These analyses
reveal that:
- PREEXISTING KIDNEY TRANSPLANT PROGRAMS do not confer
mortality benefits to new transplant centers, despite their
implied institutional knowledge of transplant immunology. In
this case, the univariate analysis (figure 7.2) fails to
reveal a relation, and the bivariate analyses (figure 7.3)
confirm this finding.
- OPEN HEART SURGICAL VOLUMES do not have a linear relation
with heart transplant mortality in new transplant centers.
However, the univariate analysis (figure 7.2) suggests that
centers having extremely high or extremely low volumes of open
heart surgical procedures have higher mortality rates. The
accompanying bivariate analyses (figure 7.4) lend considerable
support to this finding: they demonstrate the same U-shaped
relation in fully 5 of the 7 groups. The results are
particularly striking for subgroups characterized by advanced
levels of cumulative experience (transplant numbers 11-15 and
>21) and by a low burden of illness.
This U-shaped phenomenon is clinically plausible, albeit
slightly unexpected. Centers featuring extremely high volumes
of non-transplant open heart surgery have surely developed and
perfected a care process enabling them to deliver high quality
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care to their routine open heart surgical patients. However,
by necessity these programs must emphasize rapid patient
transfer out of intensive care settings, and a highly
standardized approach to patient care. These attributes may
not provide the best milieu for the management of heart
transplant recipients.
High volumes of routine cases may in addition place
excessive demands on laboratories and health care
professionals or at the very least prevent them from
identifying the care of transplant recipients as a priority.
Because of the unexpected nature of this finding and the fact
that Medicare certification guidelines do not account for it,
this issue should be investigated further.
- CARDIAC CATHETERIZATION VOLUMES are related to transplant
mortality by a U-shaped pattern similar to that for open heart
surgery. In this case, the univariate analysis (figure 7.2)
is very strongly confirmed by the bivariate analyses (figure
7.5) which reveal the expected U-shaped pattern in all 7
subgroups.
At first blush, the relation between cardiac
catheterization programs and heart transplant mortality seems
obtuse at best, especially when compared to the rather obvious
relation between open heart surgery programs and transplant
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mortality5. However, the explanation for these very striking
findings follows the exact same logic as that used to explain
the open heart surgery phenomenon. These findings suggest that
cardiologists are indeed critical to the success of heart
transplant programs. Evidence presented below lends further
credence to this observation.
- HOSPITAL ADMISSIONS are not related to heart transplant
mortality in univariate (figure 7.2) or in bivariate analyses
(figure 7.6).
- AFFILIATION WITH THE COUNCIL OF TEACHING HOSPITALS
appears to offer a mild reduction in heart transplant
mortality, but this trend does not reach statistical
significance (univariate analysis-figure 7.2-mortality=13% vs.
18%; Z=1.68; p=NS). Bivariate analyses (figure 7.7) support
the conclusion that this characteristic is not an important
determinant of mortality following heart transplantation.
- CARDIOLOGIST/INTERNIST MANAGEMENT OF IMMUNOSUPPRESSIVE
THERAPY confers an insignificant mortality reduction compared
to situations in which surgeons manage these medications (12%
vs. 15%, Z=1.15; p=NS). Of considerable interest however,
bivariate analyses (figure 7.8) reveal a significant reduction
in transplant mortality when cardiologists or internists
manage immunosuppressive therapy in the group of patients who
5 The most palpable relation is that cardiac biopsies,
required frequently in the post-operative period to diagnose
and manage transplant rejection, require cardiac
catheterization.
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are among the first to undergo heart transplantation
(transplants number 1-5). This significant difference
disappears with increasing cumulative experience6. There is a
similar trend favoring cardiologists in 1984 (but it does not
achieve significance) and this trend is also eradicated by
1986.
The most likely explanation for these findings is that,
when compared with transplant surgeons, the cardiologists
associated with new transplant programs tend to with bring
with them slightly higher levels of skills and/or knowledge
in the management of immunosuppressive drugs. However,
surgeons catch up quickly as a result of direct, hands on
experience with their initial transplant recipients. This
explanation seems reasonable from a clinical standpoint. Prior
direct training in immunosuppressive management aside,
cardiologists do tend to use these drugs more frequently7.
- As mentioned above, univariate analysis reveals that
centers featuring CARDIOLOGISTS WITH PRIOR HANDS-ON TRAINING
IN HEART TRANSPLANTATION have significantly lower mortality
rates than centers not featuring cardiologists so trained
6 See transplants 11-15, and 21 (figure 7.8).
7 Cardiologists are first trained as internists.
Internists use prednisone to manage collagen vascular
diseases, asthma and certain allergic phenomena. They use
azathioprine (Imuran) to treat certain malignancies. And
although they have no direct exposure to cyclosporine, they
are exposed to patients with reversible, drug-induced
nephropathy, the major side-effect of cyclosporine.
170
(figure 7.2). Bivariate analyses (figure 7.9) strongly confirm
this phenomenon, as one observes the expected relationship in
all 7 subgroups.
The effect is particularly significant for transplants
performed in 1984 (Z>4.0; p<.001). However, the expected
ordinal relationship is maintained even as centers achieve
high levels of cumulative experience (see the analysis of
transplant number, figure 7.9). In the latter circumstance,
the subgroups characterized by prior cardiologist training
have relatively small sample sizes, and this makes
interpretation difficult. This is indeed unfortunate because
one would like to know how much "on site" experience is
required to offset the effect of prior training.
Of note, when I stratify the effect of prior cardiologist
training by various patient subsets, I can demonstrate the
expected ordinal relationship in both high and low risk groups
(figure 7.9). Interestingly, this effect achieves statistical
significance consistently in the low risk groups (males, no
comorbidities, no mechanical support, triple drug therapy
used), but never in the high risk groups.
The obvious problem in interpreting these positive findings
is that my supplementary survey provides no details concerning
the prior training of cardiologists. Therefore it is not clear
which feature of this prior training is responsible for the
improvements in subsequent outcomes. Many features could prove
critical, including the duration of training, the activities
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performed and responsibilities maintained during training, and
even the particular site of training. Now that this study has
documented the importance of prior hands-on training for
transplant cardiologists, further studies are needed to
maximize its beneficial effects8.
- In stark contrast to the above positive findings, PRIOR
HANDS-ON HEART TRANSPLANT TRAINING FOR THORACIC SURGEONS does
not confer mortality reductions in new transplant centers.
Thus, when I use a univariate analysis (figure 7.2) to compare
centers featuring such previously trained surgeons with
centers not having this feature, I find no significant
difference in mortality (12% vs. 15%; p=NS). This finding is
supported by bivariate analyses, which show no consistent
relationship between surgical training and outcomes in new
transplant centers (figure 7.10).
Thus to summarize, heart transplant mortality reductions
are associated with prior training of cardiologists but not
transplant surgeons. This finding may surprise some given that
long term survival following heart transplantation involves,
first and foremost, major cardiovascular surgery. However it
is relatively easy to explain and in fact consistent with
modern clinical experience.
The explanation for the lack of an association between
prior surgical training and transplant mortality is that the
8 This subject is covered in more detail in chapter 9.
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"transplant" surgeons have already mastered the performance
of closely allied procedures such as coronary artery bypass
and valve replacement. In terms of manipulative skills and
intra- and post-operative decisionmaking skills, the heart
transplant procedure is quite similar to these routine
procedures, and many believe it is actually simpler in terms
of the physical, manipulative aspects. Therefore, above noted
lack of association occurs because surgeons have successfully
generalized their skills to the heart transplant procedure.
The explanation for an association between mortality and
prior cardiologist training then becomes straightforward. Once
"surgical" mortality is reduced to a minimum, the overall
success with heart transplantation becomes dependent on
medical issues such as the management of rejection and
infection. These issues are handled in the majority of
transplant centers by cardiologists, coordinators, and other
non-surgeons.
- In a related finding of interest, the univariate analysis
presented earlier showed a strong trend towards reduced
mortality among centers featuring TRANSPLANT COORDINATORS WITH
PRIOR TRAINING (figure 7.2). Because this trend did not quite
achieve statistical significance (p=.07), it is particularly
important to review the relevant bivariate analyses (figure
7.11) in this case. These reveal the expected ordinal relation
in 13 of the 15 subgroups, and the results achieve statistical
significance for patients with a high burden of illness, for
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patients who have transplant numbers 1-5, and for patients
requiring preoperative mechanical support. Taken together,
the weight of evidence from univariate and bivariate analyses
suggests that prior training of transplant coordinators is
associated with mortality reductions in new transplant
centers. Again, this is consistent with clinical experience.
Transplant coordinators have an enormously complex job, and
unlike the above case of the transplant surgeon, few things
other than direct training would prepare a coordinator to
perform this job effectively.
Transplant coordinators orchestrate many or most of the
complex processes associated with the management of patients
pre-and post-transplant. They coordinate the flow of
information between physicians affiliated with the transplant
program and specialists consulting to it. They directly
participate in the evaluation of candidates for
transplantation. They are actively engaged in the diagnosis
and treatment of recipients' medical conditions, especially
on an outpatient basis. And they perform the absolutely
critical follow-up function, in which details of lab values,
diagnostic tests, and biopsy results-along with clinical
recommendations for action-are communicated to patients.
In summary, as was the case with the putative volume-
outcome relation, this study fails to provide strong empiric
support for the belief that mortality following heart
transplantation is a function of the structural
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characteristics of heart transplant centers. As a result, this
study does not support existing federal heart transplant
policies, which are based on the assumption that such
relations exist. The notable exception is the finding in this
study of a strong relation between mortality and the prior
training of cardiologists and/or transplant coordinators. This
latter finding has important implications for federal heart
transplant policy, and I will discuss it further in chapter
9.
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I (jtij 7 
CHARACTERISTICS OF
NEW TRANSPLANT CENTERS
Fields
Established kidney
transplant programs
Open heart surgery
Annual volume
Cardiac Catherization
Annual Volume
Hospital Admissions
Member Council of
Teaching Hospitals
Who Manages
Immunosuppressive
Therapy?
Pnor Training:
Cardiologists
Prior Training:
Surgeons
Prior Training:
Transplant Coordinators
# Centers
yes
no
94-236
240-436
467-744
755-3,700
180-900
900-1,569
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29,084-47,779
yes
no
Cardiologists/
Internists
Surgeons
yes
no
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no
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10
10
10
10
10
10
10
10
10
10
25
15
14
24
10
30
17
23
9
31
Total Heart Transplants
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CHARACTERISTICS OF NEW TRANSPLANT CENTERS
AND MORTALITY %
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Figure 7.7
COUNCIL OF TEACHING HOSPITALS AFFILIATION AND
MORTALITY % FOLLOWING HEART TRANSPLANTATION
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CHAPTER 8
EVIDENCE FROM THE LOGISTIC REGRESSION
SUMMARY:
This chapter uses logistic regression to study relations
between characteristics of the patient, donor and center,
various measures of experience, and heart transplant
mortality.
KEY POINTS:
- Findings from this analysis support the findings of
previous analyses.
This study's data set contains many variables that could
reasonably be expected to impact mortality following heart
transplantation. In chapters 2-7, I study these putative
relationships using standard univariate and bivariate
techniques. These analyses do in fact suggest that certain
variables are associated with heart transplant mortality, and
that others are not. Unfortunately, the above techniques are
limited by their capacity to assess these relations for at
most a few variables at a time. Yet just as it is reasonable
to assume that many variables impact heart transplant
mortality, so it is reasonable to assume that these variables
produce their effects via complex interactions with each
other.
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Clearly therefore, it is desirable to reexamine this data
set using statistical methods that have the capacity to assess
correlations between the variables themselves, and between
these variables and heart transplant mortality per se. I use
logistic regression analysis for this purpose.
As with other multiple regression techniques, the logistic
regression assigns weights to each independent variable
(predictor) and produces an equation that most closely
replicates variations in the dependent variable. Like some but
not all regression techniques, logistic regression is
applicable when the dependent variable is binary, and so for
this analysis I use 90-day mortality status (dead or alive)
as the dependent variable.
Theoretical and empirical observations both suggest that
the response function (the relation between dependent and
independent variables) is frequently curvilinear when the
dependent variable is binaryl, and to be sure logistic
regression is first and foremost a curve-fitting technique.
The response function for the "tilted S" shaped logistic
function is given as:
Y = exp(B + B1 X1 + B2X2 +...BnXn)/[1 + exp(B + B 1 X + B 2 X 2
+...BnXn ) ]
1 For a further discussion of these issues, see:
Neter J, Wasserman W, Kutner MH; Applied Linear
Statistical Models; Richard Irwin, Inc; Homewood,
Illinois; 2nd ed; 1985; 357-67.
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Of course, the fundamental assertion that a curvilinear
response function best describes the relation between 90-day
mortality and the relevant independent variables is difficult
to prove. More importantly, the myriad assumptions made during
routine computerized calculations of the response function may
not be defensible from a clinical standpoint. And of great
importance, the iterative, model-building process (by which
one reduces the original list of independent variables to a
relatively small number that in combination predict a
relatively high percentage of the variation in outcomes)
inevitably requires judgement and clinical experience. These
considerations inject a certain degree of subjectivity into
the logistic regression analysis. Therefore, interpretation
of its results requires caution just as does interpretation
of the uni- and bivariate analyses mentioned above.
Nevertheless, it is apparent from the previous discussion
that the logistic regression technique and the analyses found
in chapters 2-7 effectively complement each other. The
strengths of one approach correspond to the weaknesses of the
other. When one utilizes both methodologies to analyze the
same data set, the combination provides a balanced approach
and a prudent means to confirm and support conclusions.
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I use PROC CATMOD from Version 5.0 of SAS to perform
logistic regression analysis2. I study the combined effects of
the following variables on 90-day heart transplant mortality:
2 PROC CATMOD is a procedure for categorical data
modeling. It fits linear models to functions of response
frequencies, and it can easily be used for logistic regression
(as well as linear modeling, log-linear modeling and repeated
measurement analysis). CATMOD uses maximum-likelihood
estimation of parameters for log-linear models and for the
analysis of generalized logits. For more information about
PROC CATMOD, please refer to:
SAS User's Guide: Statistics: Version 5 Edition; SAS
Institute, Inc.; Box 8000; Cary, N.C. 27511-8000; pp171-
253.
(Note: The text in this footnote is excerpted from the SAS
Guide)
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PATIENT CHARACTERISTICS
Gender
Age
Coronary Artery Disease
Cardiomyopathy
Comorbid Conditions
Preoperative Mechanical Support
Left Ventricular Ejection Fraction
SEX
AGE
CAD
CRDMPY
COMORBID
DEVICE
LVEF
DONOR CHARACTERISTICS
Ischemic Time ITIME
PROCEDURAL CHARACTERISTICS
Triple Drug Therapy TRPDRG
CENTER CHARACTERISTICS
Kidney Transplant Program
Annual Volume-Coronary Bypass
Annual Volume-Cardiac Catheterization
Who Manages Immunosuppressive Therapy
Prior Transplant Experience-Surgeons
Prior Transplant Experience-Cardiologists
Prior Transplant Experience-Coordinators
Total Admissions, 1985
Council of Teaching Hospital Affiliation
HTKT
BYPASS
CATH
DRUGMD
EXPSUR
EXPCRD
EXPTC
ADMIT
COTH
CHARACTERISTICS OF EXPERIENCE
Year of Transplant
Total Number (volume)
Cumulative Experience (learning curve)
YOT
VOL
LC
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VARIABLE NAME
Preparing To Perform Logistic Regression-Before I began to
assemble the model, I chose to eliminate the variable coding
for the use or non-use of cyclosporine. Cyclosporine use is
obviously correlated to the use of triple drug therapy, as the
latter regimen includes cyclosporine. But whereas the use of
cyclosporine remains steady and extremely high throughout the
study period (figure 3.2), the use of triple drug therapy
increases steadily. Because cyclosporine use per se is so
consistently high, it is unlikely to have contributed to the
changing mortality during the study period. In addition,
because its use is correlated with the use of triple drug
therapy, a decision to include a variable coding for it might
reduce the apparent mortality impact of triple drug therapy.
I also chose at this point to eliminate the variable coding
for transplant rate. I did so because earlier analyses had
shown that: a) cumulative experience is strongly correlated
with transplant rate, and that, b) when transplant rate can
be adequately distinguished from cumulative experience, it
does not affect transplant mortality (see especially figure
6.5). Once again I felt that it would be wise to exclude a
variable that is known to be correlated with another variable,
and that appears to have little impact on its own; a decision
to include such a variable might impair the capacity of the
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model to assess the effects of that second variable3
Thirdly, to simplify the analysis, I chose dichotomous
variables to represent the learning curve, ischemic time and
transplant volume. The definitions for these variables and my
rationale for doing so are as follows:
- The learning curve variable divides patients according to
whether or not they are among the first five to receive
transplants at a particular center. The split at transplant
number five is consistent with previous analyses (see for
example figures 4.3, 4.5 and 4.9-4.23) and is also based on
visual inspection of the data (see figure 4.2) which suggests
that the learning curve is most easily documented through
about the fifth transplant4.
- The ischemic time variable divides patients according to
whether or not their donor ischemic times are greater than two
hours. The most important reason for so doing is that most
transplant coordinators report their ischemic time data with
3 Interestingly, after I built the final model
(described below), I ran two additional iterations. In the
first iteration, I substituted the cyclosporine marker for
the triple drug therapy marker. The results in fact suggested
that use or non use of cyclosporine was not a significant
predictor of 90-day mortality. Similarly, transplant rate,
when it was substituted for the learning curve, did not
contribute in significant fashion to the predictive capacity
of the model.
As described below, I do rerun the final model using
different "splits" for the learning curve variable (ie. at
transplant #6, #7, etc.) to assess the length of the
transplant sequence over which the effect is still
significant.
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this degree of specificity. They tend not to indicate ischemic
times down to the minute.
- The transplant volume variable divides patients into two
groups according to their center's transplant volume. I have
already used categorical-type variables in certain analyses
to represent the volume proxy (see chapter 5). In this case,
after visual inspection of the data (figure 2.2), I initially
define the split to occur at a volume of 50 transplants.
However, I recognize that this is a somewhat arbitrary cutoff
point, so I have chosen to rerun the analysis using several
different cutoffs before reaching any conclusions about its
effect (see footnote 5).
Beginning Logistic Regression Analysis-The first iteration
of the logistic regression model reveals the following
results:
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LOGISTIC REGRESSION: MODEL 1
VARIABLE ESTIMATE ST. ERROR CHI-SQUARE
PROB.
INTERCEPT 2.056 .978 4.41 .035
SEX - .585 .221 6.99 .008
AGE - .201 .207 0.02 .892
CAD - .620 .279 4.47 .035
CRDMPY - .132 .280 0.22 .647
COMORBID - .619 .201 9.45 .002
DEVICE - .358 .228 2.46 .117
LVEF - .160 .184 0.76 .384
ITIME - .003 .001 4.05 .044
TRIPDRG 1.088 .389 7.80 .005
HTKT - .075 .277 0.07 .785
BYPASS .054 .378 0.02 .885
CATH .446 .395 1.28 .258
DRUGMD 1.008 .250 0.35 .555
EXPSUR .361 .277 1.69 .193
EXPCRD -1.126 .451 6.23 .013
EXPTC - .906 .360 6.32 .012
ADMIT .201 .288 0.49 .485
COTH .270 .318 0.72 .397
YOT .203 .229 0.79 .374
VOL .067 .089 0.67 .413
LC .751 .357 4.44 .035
I repeat this iteration of the model several times
using center volume cutoffs of 10, 30 and 70 transplants. In
no case does this variable have a significant impact on 90-
day mortality.
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This first model suggests that eight variables have a
significant impact on mortality. These are:
VARIABLE STATE THAT
INCREASES MORTALITY
Gender Female
Coronary Artery Disease Present
Comorbid Conditions Present
Ischemic Time >2 hours
Triple Drug Therapy Not Used
Prior Experience-Cardiologists Not Present
Prior Experience-Coordinators Not Present
Learning Curves Transplant # >5
Refining the Model-Then as is routinely done, I proceed to
make successive refinements of this first model based on
clinical judgement, analysis of correlations, and a review of
coefficients and their associated standard errors. I now
review the major aspects of this iterative process. I give
special attention to my decisionmaking process as it relates
to the generation of the second model. This provides an
excellent example of the thinking I use in subsequent
iterations.
Several features of the first model require closer
investigation. These are:
- The "large center" effect: Several of this study's center
characteristics seem to reflect center size. There is reason
to suspect they are correlated with each other. If so, then
including all of them in the model might diminish the model's
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capacity to detect an effect of any one. The relevant
variables are: the presence of a kidney transplant program,
annual volume of coronary bypass, annual volume of cardiac
catheterization, total 1985 admissions, and affiliation with
the Council of Teaching Hospitals.
In fact, the relevant correlation matrix confirms that
strong correlations exist between catheterization volume and
bypass volume, and between the presence of kidney transplant
programs and council of Teaching Hospital Affiliation. It also
suggests a mild correlation between catheterization volume and
the presence of kidney transplant programs:
"LARGE CENTER" EFFECT: CORRELATION MATRIX
HTKT BYPASS CATH ADMIT COTH
HTKT ---- .04 .20 .07 .54
BYPASS .04 ---- .52 .13 .12
CATH .20 .52 ---- .04 .02
ADMIT .07 .13 .04 ---- .04
COTH .54 .12 .02 .04
Because they are correlated with other "large center"
variables, I choose to eliminate the cardiac catheterization
and kidney transplant variables from the model's next
iteration. And, because the 1985 admissions variable is both
not correlated with other variables and not shown to be a
significant predictor of 90-day mortality, I choose to
eliminate this variable as well.
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- The "Professional Training" effect: It is reasonable to
suppose that centers choosing to train one member of their
transplant team (prior to initiating their program) might
choose to train other members of the team as well. Therefore,
the variables representing training of the cardiologist,
coordinator and surgeon might be expected to be correlated.
If they were, a decision to include them all might interfere
with the capacity of this analysis to detect an effect of
training per se6.
In fact, the relevant correlation matrix confirms that
strong correlations exist between the training of the surgeon
and the training of both the cardiologist and the coordinator.
It also displays a mild correlation between the training of
the cardiologist and the coordinator:
"PROFESSIONAL TRAINING" EFFECT: CORRELATION MATRIX
EXPSUR EXPCRD EXPTC
EXPSUR ---- .41 .41
EXPCRD .41 ---- .17
EXPTC .41 .17 ----
Based on these findings, I choose to run a series of models
for the next iteration: each version includes only one of the
6 Of course, the first model found that two of these
variables-training of cardiologists and coordinators-are
significant regardless of any correlations between them. Thus,
this analysis boils down to my attempt to unmask any possible
effect of transplant surgeon training.
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training variables. I do this in an attempt to isolate the
training effect for each individual. (My presentation of the
second model, below, will reflect this).
The "Hemodynamic" Effect-Clinical experience suggests that
the variables representing left ventricular ejection fraction
and the use or non use of mechanical support should be
correlated. Clinicians are aware that mechanical circulatory
support devices are associated with frequent, often severe
complications, so they reserve them for cases of severely
decompensated left ventricular function. In fact, the
correlation coefficient for these two variables is .18.
Although this is a rather modest correlation, I choose in any
case to eliminate-for the time being-the LVEF variable from
further iterations of the model.
I do so because I: a)have a strong, persistent clinical
suspicion that the two variables are correlated, b)recognize
that measurements of left ventricular function have a large
margin of error, c)recognize there are many methods for
measuring left ventricular function, so data from different
centers may not be comparable, d)recall that nearly 25% of
patients in the data set do not have available data on LVEF,
as compared to superb reporting of the DEVICE variable in the
data set7.
7 And as above, once I generated the final model, I
reinserted the LVEF variable. It did not significantly
contribute to the model's predictive power. This is an
important finding in that it conflicts with the results of
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The "Indication" effect: The presence of one indication for
heart transplantation would be expected to be inversely
correlated to the presence of other indications (occasionally
people have more than one indication, but this is rare).
Therefore I suspect that the presence of coronary artery
disease and cardiomyopathy would be correlated. In fact, the
correlation coefficient for these variables is -. 78. I choose
to eliminate the cardiomyopathy variable from further
iterations of the model.
To summarize the above decisions, the model's second
iteration omits 5 variables that were present in the first
iteration. In addition, it actually consists of three separate
analyses, each containing only one of the training variables.
Of great interest, the results of this second model (see
below) are remarkably similar to those of the first. The same
eight variables remain significant, and no new variables
achieve significance.
prior univariate analyses. I discuss this below.
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LOGISTIC REGRESSION: MODEL 2
VARIABLE ESTIMATE ST. ERROR CHI-SQUARE
PROB.
INTERCEPT 2.081 .825 6.36 .012
SEX - .424 .221 3.98 .046
AGE - .007 .007 1.05 .306
CAD - .490 .171 4.95 .004
COMORBID - .642 .198 9.51 .001
DEVICE - .169 .190 1.48 .373
ITIME - .003 .001 5.35 .020
TRIPDRG .743 .299 6.20 .013
BYPASS .285 .270 1.12 .291
DRUGMD .152 .177 0.74 .391
EXPSUR .209 .216 0.95 .331
EXPCRD -1.164 .418 7.74 .005
EXPTC - .723 .293 6.11 .013
COTH .252 .256 0.97 .325
YOT .293 .220 1.77 .183
VOL .312 .346 2.09 .170
LC .783 .350 5.01 .025
It is particularly important that the following variables
do not achieve statistical significance, as this model is
designed to maximize their potential impact: prior training
of surgeons, volume of bypass surgery, affiliation with the
Council of Teaching Hospitals, and mechanical support devices.
Approaching Final Form-To achieve the final form of the
model, I run more than twenty subsequent iterations. The
8As I describe above, I ran three separate analyses in
this, the second iteration. For each of the three analyses,
I included one, and only one, of the training variables (prior
training of surgeons, cardiologists and coordinators). I did
this to isolate the effects of training for each of the three
professions.
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highlights of this process include:
- None of the so-called "large center" variables contribute
importantly to 90-day mortality. I say this with confidence
because none achieve significance in any of the iterations
despite my continual efforts to substitute one for the other,
and to isolate them from each other.
- Year of transplant also does not contribute to 90-day
mortality. Certainly this variable never achieves significance
when it is maintained in the analysis along with the triple
drug therapy variable. However, recall that earlier analyses
(figure 3.4) showed that triple drug therapy usage was
correlated with year of transplant. To further resolve this
issue, I stratify the entire data set according to the use or
non-use of triple drug therapy, and then reassess whether year
of transplant is significant in either of these subsets. It
is not.
- Transplant volume does not contribute to 90-day
mortality. This variable does not achieve significance even
after I change the cutpoint definition from 50 transplants to
10, or 30, or 70 transplants (see footnote 5).
- Patient age and "who manages the immunosuppressives?" are
also not important predictors of 90-day mortality. These
variables do exhibit occasional correlations with other
variables, but these correlations do not make sense from a
clinical standpoint. Nevertheless, attempts to isolate these
variables from these with which they are correlated fails to
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reveal that these variables are them-selves important.
- Prior training of transplant surgeons never does achieve
a statistically significant impact on 90-day mortality. In
contrast, models including both prior training among
cardiologists and coordinators consistently show that both
variables are significant, despite the fact that these two
variables are moderately correlated with each other. I have
decided to include both predictors in the final model, because
the skills and responsibilities of these professionals differ.
However, because these variables are correlated, the final
model probably somewhat underestimates the magnitude of their
individual impact9
- The logistic regression analysis detects a significant
effect of cumulative experience through the ninth transplant.
As I mentioned above, the learning curve variable initially
divides patients according to whether they are among the first
five transplants at each center. This variable is consistently
an important predictor of 90-day mortality. Once the final
model is in hand, I experiment with different definitions of
this learning curve variable. This experimentation shows that
the learning curve variable remains a significant predictor
up to a cut point of transplant number 9: When the first 9
A strategy I chose not to use is to create a single
variable representing training of either the cardiologist or
the coordinator. This would increase the apparent significance
of the training variable, but the meaning of this variable is
less clear from a clinical standpoint.
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transplants are separated from the remainder, this variable
has significant predictive effects. When the first 10
transplants are separated from the remainder, it loses these
effects.
In sum, the final model (below) suggests that the following
attributes are associated with significantly higher heart
transplant mortality: female sex, transplant indication:
coronary artery disease, comorbidities present, non-use of
triple drug immunosuppressive therapy, prolonged ischemic
times, no prior training among cardiologists, no prior
training among coordinators, and a lack of cumulative
experience. In all cases, this evidence is consistent with
earlier findings.
LOGISTIC REGRESSION: FINAL MODEL
VARIABLE ESTIMATE ST. ERROR CHI-SQUARE
PROB.
INTERCEPT 2.069 .741 7.80 .005
SEX 
- .515 .212 5.87 .015
CAD 
- .503 .168 8.90 .003
COMORBID 
- .683 .191 12.78 .001
ITIME 
- .003 .001 5.11 .023
TRIPDRG .941 .296 6.94 .002
EXPCRD 
- .929 .400 5.38 .020
EXPTC 
- .578 .282 4.20 .040
LC .830 .340 5.94 .015
A useful attribute of the logistic regression analysis is
that it is possible to use the final model's coefficient
estimates and their standard errors to calculate the relative
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risk of death at 90 days. This is accomplished by using the
following formulae:
Relative Risk
95% Confidence Limits
= eB
= eB+(l.96 *SE)
The results of these calculations are:
RELATIVE RISK 95% CONFIDENCE LIMITS
FEMALE
CORONARY ARTERY
DISEASE
COMORBID CONDITIONS
TRANSPLANT #1-5
(Vs. >#5)
TRIPLE DRUG THERAPY
ISCHEMIC TIME
PRIOR EXPERIENCE:
TRANSPLANT COORD.
PRIOR EXPERIENCE:
CARDIOLOGIST
The final model also suggests that several notable
variables are not related to transplant mortality. These
include:
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1.6
1.6
1.1-2.4
1.2-2.2
2.1
2.2
2.0
1.2
1.4-3.0
1.6-3.4
1.5-2.8
1.1-1.4
2.0
2.7
1.1-3.4
1.3-5.9
1) Total transplant volume. This is consistent with earlier
findings.
2) Program start-up year. Improved mortality over the three
year study period is more appropriately attributed to
increasing use of triple drug immunosuppressive therapy and
to decreasing proportions of patients transplanted at new
transplant centers.
Again, these findings are consistent with earlier analyses.
3) Use of preoperative mechanical support. Earlier
univariate and bivariate analyses (chapter 2) had suggested
that patients requiring such support did experience higher
mortality rates. This minor lack of congruence in the findings
of the two statistical methods may reflect physicians ability
to select patients who are otherwise at low risk for the
procedure (and that at least some of the cues used by
physicians are not captured as effectively in the univariate
and bivariate analyses as they are in the multivariate
analysis).
In considering this minor discrepancy, it is also worth
recalling that the existing literature (19,20) on the relation
between preoperative mechanical support and transplant
mortality is inconclusive (see chapter 2 for a discussion of
this subject). All previously published studies of this
subject have used simple univariate analyses, but despite
similar statistical methods, the above studies reached
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opposite conclusions. My study is the first to analyze
preoperative mechanical support using multivariate techniques.
Clearly the putative relation between preoperative mechanical
support and post-transplant mortality requires further
investigation.
In my opinion, such investigations would be greatly
enhanced by efforts to distinguish between the various forms
of mechanical support and to use multivariate analyses. My
clinical experience suggests that patients requiring support
via intraaortic balloon counterpulsation have different
characteristics from patients requiring left or biventricular
support devices. For example, they are less likely to be
female and less likely to have peripheral vascular disease.
These differences may affect the relation between preoperative
mechanical support and transplant mortality. My study has the
benefit of multivariate analysis, but I am unable to
differentiate patients according to the particular form of
preoperative mechanical support.
4) Pre-operative left ventricular function. As with the use
of preoperative mechanical support, univariate and bivariate
analyses had suggested that patients with preoperative left
ventricular ejection fractions less than 11% had a worse
prognosis. In this case, the incongruence between the results
of the two statistical methods probably reflects inaccuracy
in the measurement of left ventricular function. The ejection
fraction can be calculated using at least four different
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technologies. Each one is imperfect to some extent, and their
results are not strictly comparable. Undoubtedly, contributing
transplant centers used different technologies to make this
calculation (I did not collect data on the technique used to
make it). Variation in technique across centers considerably
reduces the value of the data collected on left ventricular
function, and considerably reduces my ability to rigorously
analyzed its effects on transplant mortality.
It is remarkable that these latter two cases are the only
instances in which there is a lack of agreement between the
results of this logistic regression and the results of the
conventional univariate and bivariate analyses of chapters 2-
7. The vast majority of the findings are the same regardless
of the analytical method used. This lends great strength to
the findings themselves. In chapter 9, I discuss the results
of this study and its implications for heart transplant
policy.
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CHAPTER 9
DISCUSSION
SUMMARY:
This chapter reviews theoretical, methodological and data
reliability issues associated with the present study. It
then discusses this study's implications for transplant
policy and makes recommendations for future research.
KEY POINTS:
- Prior to this study, no one had attempted to analyze
the relation between mortality following heart transplan-
tation and:
* the characteristics of transplant centers, or
* experience with the procedure.
In addition, data linking mortality with recipient and
donor characteristics was not conclusive.
- This study shows that several patient and donor
attributes are related to mortality following heart
transplantation. Other study results appear below:
- Among center characteristics, prior transplant
experience in cardiologists and coordinators confers
substantial mortality reductions in new transplant
centers.
- There is a learning curve for heart transplantation:
As centers perform each of their first 5-10 transplants,
mortality risk decreases for subsequent transplants.
- There is no relation between transplant mortality and
transplant volume, rate or year.
- The results of this study should be considered in the
context of several methodological issues.
- The results of this study have several policy
implications, discussed below.
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INTRODUCTION
Long before heart transplantation was demonstrated to be a
viable therapy for patients with end-stage heart failure, it
was apparent that this technology would be extraordinarily
expensive and that its success would depend on teams of highly
skilled individuals that could deliver intensive, meticulous,
and comprehensive care to each recipient. By the mid-1980s,
many centers had demonstrated that heart transplantation was
indeed efficacious, and in fact that it was a lifesaving
therapy for a small group of individuals who were otherwise
certain to die within months. It had also become clear that
the scarce donor organ supply would limit the availability of
the transplant procedure to a number substantially less than
the number of patients who could benefit from the procedure.
Thus by mid-decade, policymakers were compelled to address
several key issues regarding heart transplantation. How could
they assure equitable access to the technology? How could they
maximize the benefits derived from the scarce donor supply?
How could they control the costs of this procedure?
The challenge facing policymakers was that strategies
designed to address any one of the above issues appeared to
conflict with strategies designed to address the others. For
example, third parties recognized that a decision to cover
heart transplantation was necessary to assure access, but such
a decision would result in enormous program costs. In this
case, public pressure forced them to do so, and in any event
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the conflict was not overly daunting because third parties
could simply pass on the program costs in the setting of such
strong public sentiment.
The conflict raised between strategies designed to increase
access and those designed to maximize benefits from the scarce
donor supply was more pointed, however. On one hand, attempts
to enhance access required that more centers be certified to
perform it. This was the case because there was a clear
relation between geographic proximity to a transplant center
and the probability that a patient in need could actually
receive a transplant. Transplant centers and their patients
could simply not manage the complex care process in instances
where patients lived far from transplant centers.
On the other hand, maximizing social benefits from the
scarce donor organ supply meant-to some-that only a few
centers could be designated to perform heart transplantation.
The strategy of limiting heart transplant center diffusion was
designed to accelerate learning about the procedure,
centralize and coordinate what limited expertise there was,
and to increase the volume of procedures at these few centers.
Volume increases, the logic went, would likely lead to
mortality and cost reductions, as had been shown for other
medical procedures.
Unfortunately, policymakers were forced to face this
pointed conflict in the absence of data that could have
informed their strategies. Specifically, no one had studied
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the relation between experience and outcomes in heart
transplantation. Did centers with high transplant volumes
enjoy better outcomes from the procedure? Is volume in fact
the proper proxy for experience with new or rapidly emerging
technologies? What constitutes adequate transplant experience
for physicians or centers that wish to initiate programs?
Should experience be vested in the transplant surgeon, the
cardiologist or the coordinator, or in fact is it the center
as a whole that accumulates experience? No one knew.
Policymakers did their best in the absence of such data.
Medicare, which was also concerned about program costs, heeded
the advice of an expert panel and chose to limit diffusion
through a designated center strategy. UNOS, the United Network
for Organ Sharing, adopted personnel-based experience criteria
that effectively facilitated the establishment of transplant
programs in geographic areas of need1.
This dissertation has informed the above debate.
Specifically, by exploring and characterizing the relations
between heart transplant experience and outcomes, it has
provided an empirical basis for the study and refinement of
current heart transplant policy.
I present the major findings of this dissertation in
chapters 2-8. In this chapter, I summarize, compile and
analyze these findings, address methodological issues raised
1 These issues are discussed in more detail in the
Introduction.
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by the study and conclude by reviewing the policy implications
of this study.
EXPERIENCE IN HEART TRANSPLANTATION:
DEFINITIONS AND CHARACTERISTICS
The major goal of this dissertation is to explore and
characterize the relation between experience and outcome
following heart transplantation. "Experience" is defined in
Webster's New Collegiate Dictionary as "the fact or state of
having been affected by or gained knowledge through direct
observation or participation (30)." Experience increases
through repetition of a particular function or task. In health
care, both professionals and patients value experience highly.
For example, experience forms the most important criterion in
deciding whether to promote health care professionals to
positions of authority. Patients routinely seek care from
professionals who are felt to have gained "experience"
treating their particular medical condition.
People value the experience of providers because they
assume it is correlated with improved results. However, this
is not always the case. First, if perfection or near
perfection in performance can be achieved vicariously, then
repetition of that activity will not result in further
improvement. Many simple activities associated with management
of transplant recipients fit this description. Consider the
standard evaluation received by transplant recipients who
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present with fever. A transplant physician learns how to
perform this evaluation by reading a "fever work-up" protocol.
Once the physician reads that protocol, he or she gains little
knowledge about the protocol through subsequent repetitions
of the fever work-up2.
Another mechanism by which experience may not lead to
improved outcomes is if the operator misinterprets or fails
to learn from his experiences. A third mechanism for a
disconnect between experience and improved outcomes occurs
when knowledge or skill gained through experience plays an
insignificant role in determining the outcomes of a particular
activity. This is the case in Percutaneous Transluminal
Coronary Angioplasty (see chapter 4) where innovations in
catheter design overshadow the importance of operator
experience.
It is therefore possible to conceive of situations in which
the relation between experience and outcome is direct,
indirect or nonexistent. In heart transplantation, any of
these relations could plausibly exist.3 Hence it is necessary
2 Of course, the interpretation of these diagnostic
tests depends heavily on experience.
3 Positive relation: A physician becomes more skilled
managing rejection he sees more episodes of it. Negative
relation: Errors increase because the coordinator cannot keep
up with the flow of data generated by an increasing recipient
pool. No relation: A new immunosuppressive drug is introduced.
This drug has no kidney toxicity. This obviates prior
experience balancing the renal side-effects of
immunosuppressive drugs with the risk of rejection.
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to determine this relation empirically (for heart
transplantation).
The challenge is that the word, "experience" connotes
several different concepts: there is more than one proxy for
"experience". The two most widely recognized models-or
proxies-for experience are volume and the learning curve.
Volume is simply the total number, or amount of repetitions
of a particular function or task. Procedure volume would
appear to be an ideal descriptor of experience in
circumstances where individuals have already mastered a
particular skill or function; they have long since developed
a standard approach to that procedure. In such circumstances,
the increment learned by any single performance of that
procedure is a) small compared to the high skill levels that
have already been achieved, and b) about the same as the
increment learned by the next, or the preceding performance.
These conditions are met for the mature, long accepted
surgical procedures that have been studied in the medical
volume-outcome literature (reviewed in chapter 5).
In contrast, procedure volume does not capture the dynamic,
accelerated process by which individuals gain proficiency as
they attempt a procedure for the first several times. In these
circum-stances, individuals actively experiment each time they
perform the procedure: they vary their approach, practice
manipulative or cognitive skills, and integrate current
experiences with those of the past and those of colleagues.
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Of course with each repetition, the individual faces fewer
unfamiliar situations or decisions, and performs activities
which become less and less unique. Therefore, individuals gain
considerably more skill per repetition as a result of their
first attempts than they do from subsequent repetitions.
Eventually they reach a "steady state" proficiency; they have
mastered that procedure.
To review, when individuals first attempt a procedure, each
isolated performance results in an increment of learning that
is, a) relatively large compared to existing skills, and b)
greater than the increment gained through subsequent
repetitions. This type of learning, more dynamic than the
volume proxy has the capacity to describe, holds true whether
the procedure itself is new (heart transplantation, using VCR
machines, etc.) or whether individuals first try to perform
an established procedure (obtaining blood specimens, driving
a car). TO THE EXTENT THE SKILLS AND KNOWLEDGE ACQUIRED DURING
EARLY REPETITIONS OF THE PROCEDURE ARE TRANSLATED INTO
IMPROVED OUTCOMES OR REDUCED COSTS, A LEARNING CURVE IS
GENERATED.
When compared with the volume proxy, it would appear that
the learning curve proxy describes more precisely the events
surrounding heart transplant technology circa 1984-86 (the
period of the present study). During this period, a very
substantial proportion of transplants were performed at
centers where few or none had previously been performed. These
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new transplant centers are implementing many unique care
processes, and their professional staff is gaining skill in
many new areas.
Nevertheless empirical studies, such as this dissertation,
are required not only to identify the proper proxy for
experience but to determine the key factors that modulate, or
influence the relation between experience and outcome. These
factors include, for example prior training of key
individuals, preexisting attributes of the transplant centers,
and the transplant community's ever deepening understanding
of the requirements for successful heart transplantation.
THE RESULTS OF THIS STUDY
I now review the findings of this study. I begin by
reviewing the relations between "traditional" determinants-
characteristics of patients, donors and centers-and transplant
mortality. I then review relations between experience and
transplant mortality.
TRADITIONAL DETERMINANTS
As first presented in chapters 3 and 7, this study confirms
that several patient, donor and center characteristics are
related to mortality following heart transplantation, and that
several others are not. I discuss the following attributes:
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Gender
Type of Preexisting Heart Disease
Age
Preoperative Mechanical Support
Preoperative Left Ventricular Function
Comorbid Conditions
Donor Ischemic Time
Immunosuppressive Regimens
Prior Experience among Coordinators
Prior Experience among Cardiologists
Prior Experience among Surgeons
Volume of Allied Procedures
Who Manages Immunosuppressive Therapy?
FEMALES HAVE A 60% GREATER RISK OF DEATH FOLLOWING HEART
4TRANSPLANTATION THAN MALES . One other study (25) reached a
similar conclusion. Another study (23) found no relation
between gender and survival, but noted that females had higher
rates of transplant rejection. One theory to explain these
findings is that females are exposed to their spouse's gene
pool during childbirth, and this modulates their future immune
responsiveness. It would be easy to test this theory because
NOTE: I derive the estimate of 60% from the logistic
regression analysis (described in detail in chapter 8). The
results of univariate analyses (figure 2.12) suggest nearly
a 70% mortality reduction in females. In the following
discussion, I continue to provide estimates from the logistic
regression only for the sake of simplicity and consistency
(the reader may refer to figure 2.12 in order to calculate
mortality reductions based on univariate analyses). By doing
so, I do not intend to suggest that the logistic regression
is more reliable or compelling than the other statistical
analyses in this document. As I discussed in chapter 8, all
of the available tests have strengths and weaknesses, and so
their results should be considered to complement each other.
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clinicians routinely obtain antigen sensitivity panels during
routine pretransplant evaluation. Testing the above theory
would involve studying the effects of parity on antigen
sensitivity, rejection rates and mortality.
PATIENTS WHO HAVE CORONARY ARTERY DISEASE AND REQUIRE
TRANSPLANTATION HAVE A 60% HIGHER RISK OF DEATH than those
with other indications for the procedure. One earlier study
(26) reported similar findings. Patients having coronary
artery disease frequently have had bypass surgery at an
earlier stage of their disease. Prior thoracic surgery
increases the technical difficulty of the heart transplant
procedure, and this may lead to higher mortality rates. It is
also possible that transplant recipients with coronary artery
disease have a higher incidence of other conditions (such as
peripheral vascular disease, chronic cigarette smoking, or
chronic pulmonary disease) that affect mortality following
transplantation. A third possibility is that the multiple
blood transfusions associated with bypass surgery expose
recipients to foreign antigens and so alter immune
responsiveness. If the data were available (it is not,
currently, in the Registry) one could test the latter
hypothesis by stratifying transplant recipients with coronary
artery disease into two groups according to the presence or
absence of prior bypass surgery. Similarly, it would be useful
to stratify all recipients according to the presence of a
prior history of blood transfusion.
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Another group of findings that carries major implications
for the patient selection process are that RECIPIENT AGE DOES
NOT CONFER INCREASED RISK, whereas the presence of COMORBID
CONDITIONS5 CONFERS A MORTALITY RISK EQUAL TO TWICE THAT OF
PATIENTS WITHOUT SUCH CONDITIONS.
These findings are grouped together because clinicians
commonly use them to assess whether an individual should be
accepted as a candidate for heart transplantation. Clinicians
are certainly aware that there is a profound shortage of donor
organs. As a result, they screen patients using the above (and
other) criteria to assure that the donor organ will be given
to patients having a reasonable chance for long term survival.
They all recognize such measures are imperfect, however, and
inevitably they must rely on clinical judgement and a
consensus-development process in which teams of experts assess
risks and the probability of long-term survival.
The fact that age is not correlated with post-transplant
mortality has been reported before (11-15). However in
previous studies, small sample sizes made it difficult to
determine whether age was truly not correlated or whether
clinicians could effectively counter a real "age-effect" by
selecting patients who were otherwise at low risk for the
procedure. In this study, the large sample size permits
5 This is a proxy that combines the presence of any one
of the following into one category: preexisting diabetes,
chronic obstructive pulmonary disease, primary renal
dysfunction or primary liver dysfunction.
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multivariate analysis with sufficient analytic power to
address this question. The results indeed show that age is not
correlated with post-transplant mortality.
The fact that comorbid conditions is associated with
increased mortality risk will come as no surprise to
clinicians. It provides strong empiric support for current
screening practices, which rely heavily on evaluations to
exclude the presence of these conditions.
As discussed in chapter 8, this study is somewhat
inconclusive with respect to the impact of MECHANICAL
CIRCULATORY SUPPORT and LEFT VENTRICULAR EJECTION FRACTION on
mortality post-transplant. Specifically, univariate and
bivariate analyses suggest that these two variables are
predictive of mortality, whereas the logistic regression does
not suggest they are predictive.
In the former case, the inconclusive findings probably
reflect the fact that patients requiring different levels of
mechanical support (ie: intraaortic balloon pumps versus left
and biventricular assist devices) are lumped into one
variable. These patients almost certainly have different
characteristics (different gender, incidence of peripheral
vascular disease) and these differences themselves have large
potential effects on transplant mortality. As a result, the
patients captured in the "mechanical support present" category
represent an unacceptably heterogeneous group.
In the latter case, the lack of concordance probably
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reflects the fact that left ventricular ejection fraction is
simply not a sensitive, accurate measure of cardiac
performance: the signal-to-noise ratio in this data is so low
as to render it largely useless (see chapter 8 for a further
discussion of these issues).
DONOR ISCHEMIC TIME HAS A SMALL BUT SIGNIFICANT EFFECT ON
TRANSPLANT MORTALITY. Patients for whom the donor ischemic
time is greater than 2 hours have 20% higher mortality risk
than patients with shorter ischemic times. Thus, previously
noted ultrastructural and functional derangements associated
with prolonged ischemic times (27) can now be linked with
increased mortality.
In addition to the above results correlating patient and
donor attributes with transplant mortality, this study reveals
several interesting correlations between (the characteristics
of) transplant centers and mortality following heart
transplantation. I review these presently:
PATIENTS NOT RECEIVING TRIPLE DRUG IMMUNOSUPPRESSIVE
THERAPY HAVE A MORTALITY RISK EQUAL TO TWICE THAT OF PATIENTS
WHO ARE RECEIVING IT. Immunosuppressive therapy is a
relatively fixed characteristic of transplant programs.
Typically, transplant programs develop a single
immunosuppressive protocol and use it for all recipients.
Protocols can be modified to meet the needs of individual
patients, but this is rare. When centers do modify their
protocol, the change is generally implemented for all
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recipients. Between 1984 and 1986, transplant centers
increasingly adopted triple drug therapy protocols, this had
a major impact on transplant mortality. In fact, this
procedural modification is the principal reason for the
improved transplant survival seen during these years. This
point is illustrated by data from this study showing that 1984
transplant recipients who did not receive triple drug therapy
experienced the same probability of survival as similarly
treated patients who underwent transplantation in 1986 (see
chapter 3).
When compared to older regimens involving high dose cyclo-
sporine, or first generation immunosuppressive drugs in the
absence of cyclosporine, triple drug therapy is associated
with fewer rejection episodes and with a decreased
susceptibility to infection (13-22). These are certainly
responsible for the improved survival associated with triple
drug therapy.
PRIOR HANDS ON TRAINING OF CARDIOLOGISTS OR TRANSPLANT
COORDINATORS are characteristics of new transplant centers
that confer a major positive impact on outcomes. CENTERS THAT
BEGIN TRANSPLANT PROGRAMS WITH NEITHER OF THESE FEATURES HAVE
MORTALITY RISK APPROXIMATELY 2.5 TIMES GREATER THAN CENTERS
THAT BEGIN WITH AT LEAST ONE. These findings persist in all
subgroup analyses, and are particularly striking in patients
having the worst prognosis.
Except perhaps for the magnitude of their effect, these
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findings will not surprise cardiologists or coordinators. In
many centers, these individuals orchestrate all aspects of
pre- and post-transplant management. They decide who to list
for transplant, diagnose and treat recipients' medical
conditions, coordinate input from other transplant team
members, and follow-up the details of lab values, diagnostic
tests, and biopsy results.
In striking contrast, TRANSPLANT PROGRAMS THAT BEGIN
WITHOUT PRIOR TRAINING OF THE TRANSPLANT SURGEON HAVE RESULTS
THAT ARE NO DIFFERENT FROM THOSE THAT BEGIN WITH THIS FEATURE.
This finding is somewhat counterintuitive given that the field
was pioneered by surgeons and that it obviously features
cardiovascular surgery of mythical proportion. However it is
in fact consistent with modern clinical experience. The likely
explanation is twofold:
1) Surgeons that attempt heart transplantation have already
mastered the intraoperative and postoperative skills
associated with routine open heart surgery (coronary artery
bypass, valve replacement), and they generalize these skills
to the heart transplant procedure6
2) The component of intra- and post-operative mortality
that is due to the technical skills of the surgeon has already
6 In fact, most surgeons believe that the heart
transplan-tation is technically less demanding than coronary
bypass surgery, because the latter involves suturing together
diseased vessels, whereas the former involves a pristine (sic)
surgical field.
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been reduced to a minimum as a result of the above, so overall
success with heart transplantation becomes dependent on
medical issues such as the management of rejection and
infection. These issues are handled in the majority of
transplant centers by cardiologists, coordinators, and other
non-surgeons.
The relations between two other center characteristics and
mortality should be mentioned:
1) Centers with relatively low AND relatively high VOLUMES
OF OPEN HEART SURGICAL PROCEDURES have HIGHER mortality
following heart transplantation. A similar U-shaped relation
exists between CARDIAC CATHETERIZATION VOLUME and transplant
mortality. This finding is of interest because Medicare has
set as one of its designation criteria minimally (but not
maximally) acceptable volumes for these allied procedures
(10). The rationale for this Medicare criterion is that
transplant programs will need support from individuals and
delivery systems that produce these services. The finding that
LOW allied procedure volume is associated with high transplant
mortality appears to justify such requirements. However, the
finding that HIGH allied procedure volume is associated with
high transplant mortality raises speculation that the delivery
systems and communication patterns designed to produce high
volumes of allied procedures cannot adapt to the unique and
intensive needs of a transplant program.
2) Centers in which CARDIOLOGISTS OR INTERNISTS MANAGE
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IMMUNOSUPPRESSIVE THERAPY have insignificantly lower (12% vs.
15%) transplant mortality when compared with centers in which
surgeons do this. Interestingly however, the former group does
significantly better in caring for patients who are among the
first to under go heart transplantation (transplants 1-5),
although this difference disappears completely as surgeons
manage more patients (figure 7.8).
Because of the previously described results showing that
prior transplant experience makes a difference for
cardiologists and coordinators but not surgeons, these
findings require further discussion. It is important to
recognize that most cardiology and cardiovascular surgery
fellowship programs do not prepare individuals to prescribe
immunosuppressive drugs. On the other hand, most of these
fellows have received some relevant training during their
residencies. Internal medicine residents in fact get extensive
opportunities to manage patients with prednisone (for asthma,
allergic reactions, immune system diseases, etc.), and this
drug is responsible for many of the immunosuppressive-related
complications following heart transplantation. They also get
reasonable exposure to patients taking azathioprine for the
treatment of solid tumors, and to patients experiencing drug-
induced renal toxicity as is commonly seen with cyclosporine.
On balance, cardiologists probably do have more extensive
prior experience with these drugs than surgeons, but the data
suggests that surgeons catch up quickly.
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It is also important to recognize that in this study, all
but one of the transplant centers in which surgeons manage
immunosuppressive therapy also feature a KIDNEY TRANSPLANT
PROGRAM. This latter feature does not independently impact
mortality following heart transplantation, but it is likely
that surgeons utilize this on-site expertise as they began to
manage immunocompromised patients.
EXPERIENCE AS A DETERMINANT
The results of this study suggest there is a heart
transplant LEARNING CURVE. That is, in centers initiating
heart transplant programs between 1984-86, recipients who are
among the very first to undergo the procedure have higher
mortality risk than those who subsequently undergo
transplantation. This phenomenon is detectable through (about)
the ninth transplant. Beyond (about) the ninth transplant, it
is not possible to demonstrate further reductions in
transplant mortality as a function of increasing repetitions
of the transplant procedure. The heart transplant learning
curve has several features:
1- The relation is consistently present in patients who are
at high risk from the procedure. It is not consistently
present in low risk patients.
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2- The exact shape of the curve depends on the subgroup
analyzed7. However as a general rule, patients who are among
the first five transplants at a particular center have twice
the mortality risk of those who are transplanted after the
10th procedure.
3- The relation is readily apparent in centers beginning
programs in 1984 and 1985. The data set contains very small
numbers of patients who underwent heart transplantation at
centers beginning programs in 1986. It is thus not possible
to demonstrate learning curves for these centers (see chapter
4 for a detailed discussion of this issue).
4- Knowledge and skills gained through the management of
low risk patients are transferable to the management of high
risk patients. For example, center A transplants a high risk
patient after several low risk patients. That high risk
patient has a lower mortality risk than he would have, had
center A transplanted him without the benefits accrued through
its prior experience with low risk patients.
5- The learning curve is visible in centers regardless of
whether their cardiologists, coordinators or surgeons have
obtained prior experience.
It is by no means a complete surprise that this study has
identified a heart transplant learning curve. After all, the
Shape includes, a)the slope of the line correlating
transplant number with mortality, and b)the number of
transplants over which this correlation can be demonstrated.
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successful performance of heart transplantation requires that
centers implement many new care processes, and that many pro-
fessionals gain skill in new areas. It is nevertheless of
great interest that a learning curve can be demonstrated using
an outcome measure as insensitive to the quality of care as
90-day mortality.
From the information in this study, it is not possible to
identify which of the many patient care processes are affected
by early experience and hence mediate the learning curve.
Nevertheless, as a basis for speculation and future research,
it is useful to divide the overall care process into the
following phases 8
1) Before Transplantation: With practice, transplant
centers might reasonably improve their skills in the
evaluation of the underlying heart failure and the coexisting
conditions which may well dominate the post-transplant course.
They may become more adept at evaluating the needs for social
support post-transplant, and making arrangements for these
needs in a timely fashion. In addition, they may well learn
how to make better decisions about whether and when listed
8 Sloan, et. al., developed the following analytic
framework to support their review of the volume-outcome
relation in organ transplantation. It first appeared in:
"Is There a Rationale for Regionalizing Organ Trans-
plantation Services?"; Organ Transplant Policy; Blum-
stein, Sloan eds.; Duke University Press; 1989.
The framework applies equally well to a discussion of learning
curves.
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patients should be hospitalized for inotropic or mechanical
support.
2) Immediate Post-Transplant Period (hospital stay): This
period is initially characterized by major physiologic and
hemodynamic abnormalities, and later by intense patient
rehabilitation and education. There is undoubtedly
considerable opportunity to improve care through practice in
this phase. Many unique diagnostic and therapeutic procedures
must be executed and their results interpreted. New conditions
must be diagnosed and responded to appropriately. In these
instances, both the reaction time and judgement might benefit
from experience. Even the decision to discharge the patient
can have a major impact on outcomes, at least in the short
term.
3) Post Discharge Management of the Patient-As mentioned
earlier, transplant recipients must take immunosuppressive
medications for the rest of their lives to prevent or reduce
the severity of rejection. These medications place patients
at high risk for serious infection. In addition, they can
cause osteoporosis, renal failure, diabetes and hypertension.
Therefore the supreme challenge in modern transplant
management is to taper the doses of these medications so as
to minimize adverse side effects while not allowing the risk
of rejection to become too high. Physicians unquestionably can
improve their abilities through practice in immunosuppressive
management.
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Less obvious but equally important in this phase are the
processes for scheduling the frequent outpatient visits and
biopsies, processing the accumulated laboratory data, and
informing patients about medication changes. And no less
important are processes for supporting patients and families
through the emotional highs and lows that routinely accompany
convalescence from this life-saving procedure. Here too, there
is little doubt that early experiences can allow transplant
centers to improve their performance.
While this study does not elucidate the specific care
processes which are characterized by learning curves, it does
suggest that the mechanism underlying the phenomenon includes
at least two of the variables discussed earlier (see chapter
4). First of all, learning curves are more easy to demonstrate
in patients with high pretransplant burdens of illness. The
likely explanation is that the marginal skills obtained from
managing an initial cohort of recipients are critical for high
risk patients, but not as important in managing uncomplicated
patients.
Interestingly, the marginal skills required to improve
outcome in the high risk patients can be gleaned from the
management of low risk patients (see figures 4.24-25). This
suggests that improved outcomes in high risk patients depend
more on mastery of the basic care processes encountered during
treatment of routine recipients (rejection management, the
response to abnormal kidney function tests, etc.) than on
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familiarity with the unique situations encountered during the
management of critically ill patients. The correct execution
of routine care processes, accomplished through repetition,
appears to be the key determinant of survival in high risk
transplant recipients.
Second, the heart transplant learning curve is influenced
by the advent of triple-drug therapy. A learning curve is easy
to demonstrate in patients treated without this innovation
(figure 4.17), but it is not present in those that did receive
triple-drug therapy. Thus, as advances in catheter design
simplified the task of PTCA, so has an immunosuppressive drug
innovation reduced the importance of learning in heart
transplantation.
This finding is of critical importance, because the trend
towards the use of triple drug immunosuppressive therapy has
clearly continued beyond 1986, the end of the study period.
This suggests that the results of this study (as they apply
to the learning curve) may not easily be applied to heart
transplant practice in 1990. It is absolutely essential to
restudy this learning curve phenomenon using more recent data
sets9
9 Of course as described below, an offsetting phenomenon
here is that mortality, this study's outcome measure, is
extremely insensitive. It is quite possible that other studies
using more sensitive indices of outcome (such as post-
transplant renal function, hospital days, functional status
or the frequency of rejection) will detect learning phenomena
even in patients receiving triple drug therapy.
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Other measures of experience do not have an impact on
transplant mortality. For example, mortality declines with
each successive YEAR OF TRANSPLANT, but the decline is due to
increasing use of triple drug therapy10and to an increasing
proportion of patients transplanted at centers that had
already achieved benefits attributable to the heart transplant
learning curve.
TRANSPLANT VOLUME, the total number of transplants
performed at a particular center, also has no effect on
mortality. This is an extremely important finding because
Medicare maintains a volume criterion in its certification
process: it requires that a center perform at least 36
procedures before it will designate that center to receive
reimbursement for transplant-related services.
As reviewed in chapter 5, this study is the first of its
kind to analyze the volume-outcome relation in heart
transplantation.
Interestingly, investigators have demonstrated such relations
for a wide variety of surgical procedures (see review in
chapter 5), but no investigator has been able to demonstrate
them in kidney transplantation1 .
10 1984 transplant recipients who were treated with
triple drug therapy had mortality rates equal to 1986
transplant recipients who were treated similarly.
11 As noted in chapter 5, much of the volume-outcome
literature in kidney transplantation became available after
Medicare set the above policies.
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In fact, this study's findings can be thought of as
confirming and extending the findings referable to kidney
transplantation. Both involve the implementation of highly
unique care processes and an unusual degree of cooperation
between allied professionals-especially surgeons and medical
specialists. Both are characterized by relatively simple
surgical procedures followed by lifelong, complex medical
follow-up.
Perhaps this last feature suggests an explanation for the
lack of a demonstrable volume-outcome relation in organ
transplantation. Surgical expertise in organ transplantation
has been perfected to the point that survival following a
transplant has come to depend primarily on the medical follow-
up received by the patient. And although the volume-outcome
relation has not been extensively studied in non-surgical
conditions, it has turned out to be far more difficult to
document such relations when they have been sought after (see
chapter 5).
TRANSPLANT RATE also has no effect on mortality, at least
over the range of rates noted during this study. Transplant
rates are thus high enough to let individuals maintain skills
and familiarity with the complex processes by which transplant
care is delivered. These rates also do not occur with a
frequency that would overwhelm caretakers or the intricate
transplant care processes. It is important to reexamine the
relation between rate and outcome using more recent data,
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since many transplant centers now perform transplants at rates
below the lowest rates recorded in this data set.
RELIABILITY AND VALIDITY OF THE RESULTS
The results of this study should be interpreted in light of
the following facts:
RELIABILITY OF THE DATA
The principal source of data for this study is the Registry
of the International Society for Heart Transplantation. During
the mid-1980s, this Registry was personally maintained on an
IBM XT personal computer by Dr. Michael Kaye at the Minnesota
Heart Institute. Until recently, heart transplant centers were
not required to submit data to the Registry. However, during
the period of this study approximately 95% of all US
transplant centers, including the 20 most active centers,
voluntarily contributed data to the Registry. There is no
reason to suspect that data from the remaining centers would
have changed the results of this study.
At most transplant centers, the responsibility for
preparing and mailing data to the Registry falls to the
transplant coordinators. This task is time-consuming and
frequently interferes with the coordinator's routine patient
care responsibilities. Furthermore, coordinators are not paid
to prepare Registry forms. Thus, variation in the frequency
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with which files are updated and in the completeness of
reports is to be expected. However, there is no reason to
suspect that certain types of centers systematically
underreport or omit data from the forms. Therefore there is
no reason to suspect a reporting bias in the data. In any
event, the selection of a 90-day mortality endpoint for this
study (as opposed to a one year endpoint, which has been used
by many centers in reporting their own findings) minimizes the
potential for reporting bias by decreasing the interval over
which follow-up is required.
The supplementary survey contributed important data on
patient and center characteristics. 80% of the Registry
centers responded to requests for the supplemental
information. They provided data on a total of 85% of all
recipients. Supplemental information was available for the top
ten centers by volume (although it was necessary for the
author to make site visits to Stanford, the University of
Pittsburgh, and the University of Minnesota to accomplish
this) and all but two of the top 20 centers. Contributing
centers did not differ from non-contributors with respect to
90-day mortality or other parameters. Similarly, patients for
whom supplemental information was available had outcomes that
were no different from those for whom supplemental data was
available.
As with the original Registry forms, transplant
coordinators were responsible for completing supplemental
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surveys. However, as above, there is no reason to suspect a
reporting bias with respect to data collected via the
supplemental survey.
A second issue referable to data reliability is the fact
that information contained in certain variables is imprecise.
The variables in question concern the management of
immunosuppressive therapy, prior experience and comorbid
conditions.
WHO MANAGES IMMUNOSUPPRESSIVE AGENTS?-The supplemental
survey requested that centers respond to this question by
circling one of the following: surgeons, cardiologists or
other internists. In some centers, this question cannot be
answered so simply. For example at Brigham and Women's
Hospital, surgeons write the orders on patients who are in the
immediate post-operative period, although they frequently
solicit advice from cardiologists. After the immediate post-
operative period and for all outpatients, cardiologists manage
immunosuppressive therapy. In other centers, interdisciplinary
teams make treatment decisions, and in many instances,
transplant coordinators are allowed to manipulate certain
agents with supervision (!).
Nevertheless, a)most centers do delegate this
responsibility to one of the above groups, and b)it is likely
that centers featuring non-traditional approaches to
immunosuppressive management would distribute themselves
between the three possible answers to this question. This
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would minimize the risk of bias, but of course the larger
issue is that the present study cannot examine whether teams
of physicians can more effectively manage immunosuppressive
therapy than can individuals.
PRIOR HANDS-ON EXPERIENCE-This study's supplemental survey
allows one to determine whether cardiologists, coordinators
and/or surgeons had obtained prior experience before
initiating new transplant programs. Unfortunately the survey
provides no room for respondents to characterize their prior
experiences. Obviously, some detail concerning the duration
of prior training, the degree of involvement in direct patient
care, and the types of patients treated would be desirable.
This study has shown that learning curves are present at
new heart transplant centers. It cannot be inferred from this
study that individual learning curves (presumably manifesting
themselves during the period of prior training) would follow
the same pattern, although clinical experience suggests that
individual learning curves would be related to the degree of
involvement in direct patient care.
COMORBID CONDITIONS-The supplemental survey did not provide
precise definitions for each comorbid condition, so
coordinators had to use personal judgement in answering this
question. This may have introduced biased overreporting of
comorbid conditions among recipients who died. However, it is
just as possible that respondents would overreport these
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conditions for surviving recipients. In fact, the overall
incidence of reported comorbidities (7%) is clinically
believable, and the magnitude of their negative effects are
consistent with clinical expectations.
MISSING DATA
Information regarding several areas of interest is captured
by neither the Registry nor the supplemental survey. Among the
uncaptured information that would be most interesting, there
are:
Traditional Determinants of Mortality
Unfortunately, the Registry collects no data from the
routine preoperative right heart catheterization. This pre-
transplant catheterization contains many objective parameters
of preoperative hemodynamic function such as the cardiac
output, right heart filling pressures, and the pulmonary
capillary wedge pressure. All transplant centers routinely
collect this information during their pre-transplant
evaluations, and it would not be difficult for the Registry
to gather this data. These measures would provide far more
insight into preoperative hemodynamic status than currently
collected information (listing status, presence of
preoperative mechanical support) because the latter can be
influenced by physician discretion or variations in the use
of mechanical support devices.
In particular, such data would enable the Registry to
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assess the effects of elevated pulmonary vascular resistance
(PVR) on mortality following heart transplantation. Elevated
PVR is a common sequelae of advanced cardiac disease. It has
been known for 15 years that elevated PVR can cause right
heart failure in the donor heart shortly after transplantation
(16). Irreversible and severely elevated PVR is therefore an
absolute contraindication to heart transplantation. However,
there is considerable controversy about the risks of cardiac
transplantation in patients who have reversible elevations or
who have mild to moderate elevations. For the record, the most
common practice is to interdict heart transplantation for
patients who have fixed PVR measurements greater than 6-8 wood
units (3-4 times the upper limit of normal) (17).
Details of Immunosuppressive Therapy
Registry data banks contain minimal information regarding
immunosuppressive therapy. The data collected is simply a list
of the agents used for rejection prophylaxis in each patient.
There is no information regarding the dosages used, the
parameters used to adjust dosages, or even the times at which
each drug is initiated and/or discontinued. In the transplant
community, it is widely accepted that recipient mortality and
morbidity are affected by the above decisions, and so this
represents a major failing of the current study. Two other
aspects of immunosuppressive therapy should also be mentioned:
A) OTHER IMMUNOSUPPRESSIVE DRUGS-In 1987, many centers
began to use OKT3, a monoclonal antibody, for the prophylaxis
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and acute treatment of rejection. Antithymocyte Globulin is
also used at certain centers. Other centers are experimenting
with vincristine, cytoxan, total lymphoid irradiation and
other approaches. The Registry data banks do not permit
evaluation of these new approaches.
C) THE TREATMENT OF REJECTION-Once rejection occurs, it
requires immediate therapy. As with rejection prophylaxis,
centers have developed unique approaches that could have major
effects on transplant mortality. Variations in the drugs of
choice, routes of administration, duration of therapy and the
approach to recurrent rejection are among the more important
elements in rejection treatment, but unfortunately the
Registry contains no information on this subject.
Details of the Care Process
The data sets used in this study contain no information
regarding diagnostic and treatment protocols, communication
patterns and teamwork. The present study suggests that such
details are important determinants of transplant mortality.
For example, learning curves are present even at centers that
feature prior training of key transplant personnel. Thus,
there is a component of "institutional learning" (ie getting
the above care processes right) that cannot be avoided by
simply training key personnel. Among the most interesting
processes to study are: the diagnosis and treatment of
rejection, transplant biopsy protocols, patient education and
rehabilitation protocols. Others include the quantity and
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quality of communication between patient and transplant team,
between team and consultants, and between team members
themselves.
Miscellaneous Data
The study does not include transplants in children,
heterotopic transplants or retransplants, and so results may
not apply to these groups. Patient characteristics such as the
presence of peripheral vascular disease, a history of tobacco,
drug or alcohol abuse, or socioeconomic status may impact
outcomes, but they are also not studied. And of course, the
study is based on transplants between 1984 and 1986. It is
remotely possible that the findings of this study might not
be applicable to heart transplant technology in 1990.
POLICY IMPLICATIONS
As outlined above, the heart transplant policies of the
United Network for Organ Sharing (UNOS), Medicare and other
groups were formulated in the context of a paradox. The
paradox was that policies aimed at increasing access to the
procedure (such as those which stimulated the proliferation
of transplant centers) appeared to conflict with policies
aimed at maximizing social benefit from the scarce donor pool
(such as those which designated a small number of centers for
reimbursement).
Policymakers found it difficult to approach this paradox
logically because there existed no data to inform the debate.
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On one hand, there was no data to support the belief that
transplant center proliferation improved access to the
technology. On the other hand, there was no data to support
the belief that designating centers and hence increasing
procedure volumes at the designated centers would improve
outcomes.
In the absence of such data, heart transplant policy has
been inconsistent. Medicare has chosen to designate a small
number of centers for reimbursement; one of its principal
reasons for doing so has been to increase transplant volume
and centralize expertise at these designated centers. UNOS has
chosen to adopt policies that encourage the proliferation of
heart transplant centers.
This study provides data that for the first time can inform
the heart transplant policymaking process as it relates to the
above paradox. It demonstrates that patient, donor and center
characteristics, as well as learning curve phenomena, all
affect mortality following heart transplantation. And
critically, it shows that there is no relation between
transplant volume and mortality. The implications of these
findings for current and future heart transplant policy
include the following:
IMPLICATIONS FOR UNOS-In 1990, heart transplant centers are
required by federal law to comply with UNOS membership
criteria. The UNOS criteria focus on the experience of the
transplant surgeon and transplant cardiologist. They do not
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require prior institutional experience nor do they specify
any structural criteria1 2 for institutions to qualify. In
effect, UNOS criteria encourage physicians to become trained
and then to establish new transplant programs (hopefully in
geographic areas of need).
This study provides strong support for the UNOS personnel-
based criteria, because it shows that prior training at the
individual level is an important predictor of survival
following heart transplantation. However, this study shows
specifically that it is the prior experience of cardiologists
and transplant coordinators that affects outcomes; prior
experience of transplant surgeons does not affect outcomes.
UNOS criteria emphasize prior experience on the part of
cardiologists and transplant surgeons. UNOS should
certainly not delete the criteria for surgeons on the basis
of this study alone, but it might consider relaxing them,
especially for surgeons who wish to initiate programs in
geographic areas of need. In addition, UNOS should maintain
current standards for cardiologists and it should develop
criteria for the prior training and experience of transplant
coordinators.
The UNOS policy not to require that institutions maintain
certain features (such as kidney transplant programs,
12 These might include the presence of a kidney
transplant program or written protocols for the management of
transplant recipients.
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affiliation with medical schools, or a high volume open heart
surgical program) is also supported by this study. None of
these features was found to have an impact on mortality
following heart transplantation. Of course it remains possible
that other structural features are important determinants of
survival, and it would appear reasonable to study these if
questions persist.
IMPLICATIONS FOR MEDICARE-Heart transplant centers wishing
to be designated by Medicare must meet its criteria which, as
opposed to those of UNOS, focus on institutional experience
and other structural characteristics of institutions. Medicare
criteria do not include guidelines for prior professional
experience with the procedure.
The results of this study suggest that Medicare should
revise its heart transplant policy in many important aspects.
Most importantly, this study was unable to demonstrate a
volume-outcome relation in heart transplantation, but a
cornerstone of Medicare policy is based on the assumption
that one exists. Medicare's premise is that reimbursing for
the procedure only when it is performed at high volume centers
would redirect patients towards those centers and hence
improve the survival of Medicare beneficiaries from the
procedure. This premise is not valid.
Interestingly, Medicare was correct in assuming there would
be a relation between experience and outcome in heart
transplantation; it simply chose the wrong model for
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experience! As described above, the proper descriptor for
experience in heart transplantation is the learning curve.
As Medicare considers how it should revise its
institutional-based experience criterion, it might well
consider this study's finding that the benefits of experience
have peaked after approximately the 9th transplant, and they
are at most minimally important in low risk patients. Medicare
should therefore revise its experience criterion from the
present minimum of 36 transplants to at most, 10 to 15 cases1 3
Furthermore, it should require that the first several heart
transplants performed at any center should be performed on low
risk patients.
Other results of this study have implications for Medicare
heart transplant policy. Specifically, this study shows that
transplant center characteristics have no impact on survival.
Medicare's designated center policy includes several of these
characteristics, including the annual open heart surgical
volume and the annual volume of cardiac catheterizations. It
would appear reasonable to drop these criteria from the
designation process and to study the remaining criteria that
have not been addressed in this study.
THE LEARNING CURVE AND TRANSPLANT POLICY-One of the most
important contributions of this study is its documentation and
13 In addition, UNOS should abandon its plans to review
centers that fail to perform 12 transplants per year, so long
as their survival rates conform with standards.
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characterization of the heart transplant learning curve. In
effect, this study shows that transplant centers "learn by
doing" up to about the 9th transplant, but this phenomenon is
far more apparent for high risk patients than it is for low
risk patients. First and foremost, this finding must be
reexamined using more recent data sets (for the reasons
mentioned above and in chapter 4) If these learning curves
continue to be demonstrable, then both Medicare and UNOS
should incorporate guidelines that:
1-Assure that the new centers transplant low risk patients
exclusively in their initial 7-10 experiences, and,
2-Recognize that poor outcomes are more likely to occur
initially1 4,perhaps by establishing survival standards for the
first 7-10 transplants which are lower than standards for any
subsequent transplants.
14 But as above, these poor outcomes may not be
inevitable. One can reasonably expect to see important
mortality reductions to the extent that new centers transplant
only low risk patients during their initial 10 transplant
sequence.
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RECOMMENDATIONS FOR FUTURE RESEARCH
Confirming and Extending the Results
This study utilized Registry data from 1984-1986. Heart
transplant technology has progressed in the four subsequent
years (though not with the blinding speed that characterized
the mid-1980s), so it is necessary to reconfirm the relations
between mortality and all measures of experience. Even without
updated supplementary surveys, the Registry contains enough
data to confirm this study's major findings.
In addition, it would be useful to study relations between
experience and other outcomes besides mortality. Mortality is
an insensitive outcome measure. Measures of functional status,
quality of life, number of hospital-days per year, frequency
of rejection, complication rates and the functioning of
critical organs (including the transplanted heart) are likely
to provide additional insight. Possibly, the variables in this
study would exhibit different relations with other outcome
measures (for example, the learning curve might be
demonstrable over the first 20 transplants when serum
creatinine is the outcome measure. As another example, perhaps
there is a relation between center volume and complication
rates). Most centers already collect data regarding multiple
outcomes (13), and it may not require unreasonable effort to
collate this centrally.
A third area that merits investigation is the relation
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between experience at the level of the individual physician
and outcomes (31). Center experience does not necessarily
correlate with physician experience. In many transplant
centers, several physicians share responsibilities, so center
experience proceeds more rapidly. In contrast, physicians
occasionally care for transplant recipients at different
centers. It is plausible (and many findings in this study
suggest) that individual experience is a more important
determinant of outcomes than center experience.
The fourth and perhaps most publicly visible issue is the
relation between experience and costs of heart
transplantation. Cost control has rightfully been at or near
the top of third parties' heart transplant agenda, and it is
a principal rationale for the Medicare designated center
strategy. There is extensive evidence to suggest a relation
between volume and cost in industrial settings (40), but it
has been difficult to document similar savings in health care
due to methodological difficulties in the quantification of
health care costs (49)1 5. Although no empirical proof is
available, it is certainly true that the capital costs of
transplant programs are low because they use the facilities
already in place for open heart surgical programs.
15No one doubts that heart transplantation is expensive.
However, its cost per year of life saved is comparable to
other generally accepted medical technologies such as renal
transplantation and dialysis.
245
Beyond Center Characteristics: The Heart Transplant Care
Process
Most heart transplant centers have modern diagnostic and
therapeutic equipment, and they have subspecialists that can
lend expertise when necessary. This study suggests that
transplant mortality depends not on their mere presence, but
upon the communication patterns, handoffs and protocols by
which these structural elements are integrated. These care
processes are extremely diverse, and they mature and change
in response to learning, increasing volume, or changes in
transplant rate. Analysis of these care processes may provide
insights that could enhance results at new and established
programs.
Consider the following example, which illustrates the
complex processes by which transplant centers care for
recipients:
Patient X is 3 months status-post heart transplantation.
He develops a fever of 102 degrees. He notifies a
transplant coordinator who in turn notifies a transplant
staff physician. The physician instructs the coordinator
to tell the patient to come to the EW for evaluation. The
EW physician who sees the patient suspects he has a viral
pneumonia. He notifies the transplant physician. The
latter calls an infectious disease expert to inquire
about proper viral titers and the appropriateness of
246
starting empiric antiviral therapy.
In this case, certain attributes of the transplant center
enable it to provide optimal care for the patient. These
include an EW physician and an infectious disease expert who
are skilled in the evaluation of immunocompromised patients,
a laboratory with the capacity to perform sophisticated viral
studies, and a pharmacy that stocks rarely used antiviral
drugs. Regulators can easily determine whether a transplant
center possesses such characteristics.
Far more difficult to ascertain, but equally vital to the
quality of patient care is the skill with which the center
coordinates these features; the accuracy and efficiency with
which the above process is executed. The complex interactions,
information handoffs and nuances of protocol become apparent
when one considers the errors that could occur as this
relatively simple process is executed:
The patient might not know that he should call when he
develops a fever. He might not know who to call, or how to
contact that person. The coordinator might be unreachable as
a result of a broken beeper or a missed communication with the
page operator. The same is true of the transplant physician
and the infectious disease expert. The transplant physician
might forget to alert the EW that the patient is
immunocompromized. The pharmacy might be temporarily out of
the antiviral drugs. The laboratory that routinely runs
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antiviral titers might be closed when the specimen arrives,
or might forget to tell EW personnel that special protocols
must be followed in order to assure proper handling of the
blood specimen, etc.
In this analysis of care processes, two phenomena require
investigation in particular:
PROGRAM GROWTH AND CARE PROCESSES: The care of each
transplant recipient requires meticulous follow-up and the
full cooperation of several services beyond the core
transplant team. This is relatively easy when the number of
recipients is small and a degree of novelty still surrounds
the program. However, as programs grow to even moderate size,
they place a surprisingly large burden on the cardiac
catheterization laboratory, the pathology department and
various consultative services. The possibility for
miscommunication and incomplete follow-up increases rapidly,
and this may indeed explain why this study did not find a
relation between volume and outcome. The transplant team must
find ways to prevent this1 6. Unfortunately, we know little
about how transplant teams manage growth and even less about
optimal strategies to do so. Enumeration of optimal strategies
may well enhance performance at our largest transplant
16At Brigham and Women's Hospital for example, we added
a second coordinator to handle inpatient issues, and solicited
assistance from interested 2nd year cardiology fellows around
the 80th transplant. We also updated all protocols and renewed
in-service training sessions for nurses.
248
centers.
TRANSLATING EXPERIENCE INTO IMPROVED CARE PROCESSES: This
study has documented a learning curve for heart
transplantation, but it has not elucidated its mechanism. Do
physicians modify their patient selection strategy? Do they
become more vigilant observers for complications, or do they
treat them differently? Do they modify rejection prophylaxis
strategies or strategies for the management of acute
rejection? Is it the surgeon, cardiologist or coordinator that
is most critical?
Similarly, this study has documented that prior experience
(on the part of cardiologists and coordinators) is strongly
associated with improved results from heart transplantation.
What features of this prior experience confer survival
benefits? How long must the training period be? What "parent"
programs provide the most effective training? A deeper
understanding of the mechanisms underlying experience might
well lead to enhanced performance at our newest transplant
centers.
Related Topics of Interest to Policymakers
The transplant policymakers' dilemma has long been that
policies designed to improve access may compromise outcomes
from the scarce donor supply. By documenting and
characterizing the relations between experience and outcomes,
this study has provided approximately half the data that the
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policymakers need in order to set truly rational transplant
policy.
It remains for researchers to study the relation between
transplant center proliferation and access to the procedure.
Empirical studies are required because it is not immediately
clear that policies designed to stimulate transplant center
proliferation would enhance access. For example, access might
be determined primarily by the extent to which physicians
caring for patients with end stage congestive heart failure
were aware of the transplant opportunity or were willing to
refer such patients.
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